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1.1.1. Background 
The kidneys are located in the retroperitoneal space, usually one on each side of the spinal 
column. They normally are bean shaped, and have the size of a fist. 
The kidneys have several important functions in the homeostasis of the body. Most 
importantly, they regulate the water balance. The kidneys also purify the blood from water 
soluble metabolites and waste products, by eliminating them in the urine. They also have a 
hormonal function. The secretion of erythropoietin stimulates the bone marrow to make red 
blood cells preventing anaemia, and renin regulates blood pressure via the renin angiotensin 
aldosterone axis. The production of 1.25 dihydroxyvitamin D, the active form of vitamin D, 
regulates the calcium and phosphorus homeostasis and the production of parathyroid 
hormone. Vitamin D essentially affects bone metabolism but has an impact on many other 
organ systems as well, e.g. immunomodulation. 
A persistent decrement in kidney function is named “chronic kidney disease (CKD)”, as 
suggested by the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines from the 
US National Kidney Foundation (NKF), to represent the entire spectrum of disease that 
occurs following the initiation of kidney damage. In 2002, the guidelines defined CKD as 
either presence of kidney damage, or an estimated glomerular filtration rate (eGFR) below 60 
ml/min/1.73m² for at least 3 months1. Kidney damage is defined as the presence of pathologic 
abnormalities, or markers of damage, including abnormalities in blood or urine or at imaging 
studies. According to the KDOQI guidelines, CKD was initially classified into five stages 
based on the level of GFR and on proteinuria for the first two stages, and on GFR for the 
other 3. In 2009, the Kidney Disease: Improving Global Outcomes (KDIGO) agreed to retain 
the current definition of CKD based on GFR levels or presence of kidney damage, but they 
modified the CKD classification (table 1) by adding albuminuria stages in addition to GFR 
stages, by subdividing stage 3 in subgroups a and b depending on severity of renal failure, and 
by emphasising clinical diagnosis2. Patients with CKD 5 (eGFR < 15 ml/min/1.73m2
Of note, this classification also incorporates subjects whose decrease in eGFR is attributable 
to the natural and physiological decline of renal function with age, and as such the 
terminology “kidney disease” can be confusing.
) require 
renal replacement therapy (RRT) such as kidney transplantation or dialysis to survive when 
their eGFR further declines.  
3 
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The gold standard to determine Glomerular filtration rate (GFR) is inulin clearance. Other 
exogenous compounds used in a similar way to determine GFR are radiolabelled isotopes 
such as Iodine-125 iothalamate and Chromium-51 ethylenediamine tetraacetic acid. These 
determination methods are however costly, labour intensive, and cumbersome. In practice 
GFR is most often estimated (eGFR) by equations that take into account serum creatinine, age 
and gender. Body weight is additionally implemented in the Cockcroft-Gault equation and 
race in the Modification of Diet in Renal Disease (MDRD) study equation2;4;5
 
.  
 
 
Table 1: Revised Chronic Kidney Disease (CKD) classification (KDIGO 2009) 
     Stage eGFR Description   Albuminuria 
  (ml/min/1.73 m2   )   (ACR, mg/g) 
1 > 90 
 
Kidney damage with normal or ↑ eGFR 
 
  
2 60-89 Kidney damage with mild ↓ eGFR  
  
3 a 45-59 Mild - Moderate ↓ eGFR 
 
< 30 (optimal and high-normal) 
3 b 30-44 Moderate - Severe ↓ eGFR 
 
30-299 (high) 
4 15-29 Severe ↓ eGFR 
 
> 300 (very high) 
5 < 15, dialysis or Kidney failure 
  
 
transplantation 
             
Abbreviations: ACR: albumin-to-creatinine, eGFR: estimated glomerular filtration rate   
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1.1.2. Uraemic retention solutes 
Uraemic retention solutes are those compounds that are retained in the body when kidney 
function declines. Under normal conditions, the glomerular filter clears water soluble 
molecules with a molecular weight (MW) up to 58 kDa. The decline in clearance of these 
solutes in renal failure results in a progressive accumulation of these molecules. Partial 
metabolic transformation and elimination by other than renal pathways (e.g. hepatic or gastro-
intestinal elimination) may compensate for this loss of renal clearance.  
During the last few years, an immense progress has been made in the identification and 
quantification of uraemic solutes.6 Nevertheless, a substantial number of retention molecules 
still remains unidentified. In a number of publications by the European Uraemic Toxin work 
group (EUTox), the toxicity of a number of retention solutes was described with special 
attention for their potential for cardiovascular damage.7-17
The uraemic molecules are preferentially classified into three major groups according to their 
physico-chemical characteristics
 
6;18
Only the solutes which are studied in this thesis will be discussed in more detail below. 
 which have a subsequent impact on their clearance during 
dialysis. The small water soluble compounds (MW<500 Da), the middle molecules (MM) 
(MW>500 Da) and the protein bound compounds. For all retained solutes, the concentration 
depends on the interplay between removal, which in most cases is decreased, and the degree 
of generation. 
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1.1.2.1. Small water-soluble compounds 
Prototypes for this group are urea and creatinine. In fact, creatinine belongs to the larger 
group of guanidines.  
Guanidino compounds are structural metabolites of arginine. Increased guanidine levels have 
been determined in serum, urine, cerebrospinal fluid, and brains of uraemic patients.19 The 
neurotoxicity of several guanidines is extensively described.20 Guanidino compounds have 
also been shown to enhance baseline immune function and lipopolysaccharide (LPS)-
stimulated intracellular TNF-α by normal monocytes.21 Their potential cardiovascular impact 
was, until recently, mainly attributed to asymmetric dimethylarginine (ADMA), which 
inhibits nitric oxide synthase (NOS).22 A holistic and standardized evaluation of ten guanidino 
compounds in different in vitro models showed that especially symmetric dimethylarginine 
(SDMA), the structural counterpart of ADMA formerly considered biologically inert, 
contributes to biological effects related to cardiovascular complications in uraemia.13;14;23;24 
These effects may be involved in altering the prevalence of cardiovascular disease in CKD, as 
confirmed by clinical data pointing to an in vivo association of SDMA with IL-6 and TNF-α 
in CKD at different stages.14 Both ADMA and SDMA are only weakly correlated to eGFR25
In general, the water-soluble compounds are easily removed by any dialysis strategy. 
Although guanidine compounds are water-soluble, they have a different kinetic behavior from 
urea because of their large distribution volume which makes them more difficult to 
remove.
. 
26;27 A two-compartmental kinetic model demonstrated that prolonged dialysis and 
increased dialysis frequency are effective in significantly reducing the concentrations of the 
guanidino compounds compared to standard haemodialysis.28
 
  
1.1.2.2. Middle Molecules 
The prototype molecule for this group is β2-microglobulin. Middle molecules are presently 
considered as solutes in the large MW range (500-60,000 Da). This range incorporates many 
toxins, which were only identified after the formulation of the original middle molecule 
hypothesis, in which the upper MW limit was 2,000 Da. Most currently known uraemic 
retention solutes are low molecular weight peptides and proteins (LMWPs). Up till now, at 
least 40 middle molecules or groups of middle molecules have been identified.29 Many of 
these solutes have been linked with inflammation, endothelial cell damage, smooth muscle 
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cell proliferation and thrombocyte activation, all processes associated with enhanced 
cardiovascular (CV) damage. Apart from these effects associated with CV damage, middle 
molecules have a toxic impact on other cell and organ systems as well. However, these 
compounds will not be discussed further, since they are not part of this thesis. 
 
1.1.2.3. Protein-bound compounds 
Protein-bound uraemic retention solutes constitute a heterogeneous group of compounds 
which are retained in patients with kidney failure. Although most of these compounds are 
molecules with low MW, they behave like high MW substances as a result of their binding to 
albumin (MW 68 kDa) or another protein(s). This large group of uraemic solutes should not 
be considered as a homogenous entity, as retention pattern, and the removal during dialysis 
depend upon the degree and strength of protein binding, and the number and type of protein 
binding sites, which are different for all of them, so that each subgroup should be considered 
separately. Prototypes of this group are the phenols and indoles. As a substantial part of the 
generation of these products is regulated in the intestine, the option to decrease tissue 
concentrations by manipulating intestinal generation by dietary intervention or intestinal 
absorption has insufficiently been explored, although it is of major importance especially 
when considering phenolic and indolic compounds. 
P-cresylsulfate and p-cresylglucuronide 
Intestinal fermentation of the amino acid tyrosine generates 4-hydroxyphenylacetic acid 
which is decarboxylated to p–cresol or demethylated to phenol30 and very likely also 
phenylacetic acid as well as other phenols are generated.31;32 Over the last twenty years, it has 
generally been conceived that after its generation, p-cresol was absorbed as such by the 
intestine and then distributed over the body, since upon analysis the molecule was found in 
serum of subjects with normal and disturbed renal function.33 In reality, after its absorption 
and passage through the intestinal mucosa, p-cresol is metabolized by a cytosolic 
sulfotransferase to p–cresylsulfate, its main conjugate, as well as to p–cresylglucuronide by a 
glucuronosyltransferase. (figure 1) What might remain of p-cresol after transfer into the portal 
vein is further on conjugated in the liver.34;35 In addition, the lung mucosa also contains 
sulfotransferase and glucuronosyltransferase activity, conjugating the toxic phenolic 
compounds that might enter the body via inhalation.  
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The reason why p-cresol was considered for a long time as a major phenolic compound in the 
body is attributable to an artefact created during sample preparation. Until a few years ago, 
virtually all analytical methods used deproteinisation by acidification as a first step, causing 
hydrolysis of the p-cresol conjugates. Deproteinisation without acidification left p-
cresylsulfate (and although this was not measured, probably also p-cresylglucronide) intact, 
with virtually no detectable p-cresol.36 P-cresylsulfate concentration is increased in patients 
with renal failure and has a protein binding of ± 94%. In contrast, p-cresylglucuronide, the 
other p-cresol conjugate, shows virtually no substantial protein binding.
In contrast to the mother compound p-cresol which is a strong inhibitor of leukocyte 
response
  
37;38, p-cresylsulfate has a proinflammatory impact on monocytes and lymphocytes.37 
P-cresylsulfate has also been linked to endothelial microparticle release, an indicator of 
endothelial and vascular damage.39 Clinical studies showed a relation between p-cresol 
(acting as a surrogate for p-cresylsulfate) and clinical outcomes.40;41 Recent studies confirmed 
that also p-cresylsulfate levels were predictive for mortality at different stages of CKD42 and 
for cardiovascular and all-cause mortality in haemodialysis patients.43 The relation between p-
cresylsulfate and coronary artery disease in patients with no or only moderate degrees of 
CKD44 extends the association of this compound with cardiovascular outcomes beyond the 
scope of pronounced uraemia.45
 
  
 
 
 
 
 
 
 
 
 
 
 Figure 1: Organs and enzymatic pathways involved in the generation of p-cresyl conjugates 
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Indoxylsulfate 
Indoxylsulfate is produced by the metabolism of dietary tryptophan. Briefly, tryptophan is 
metabolized to indole by intestinal bacteria. After intestinal absorption, indole is metabolized 
in the liver to indoxyl and then to indoxylsulfate.  
As excretion of this compound depends mainly on proximal tubular secretion, indoxylsulfate 
levels, mainly as its albumin-bound form (± 90 % bound), are markedly increased in patients 
with renal failure.6 Indoxylsulfate enhances drug toxicity by competition with acidic drugs at 
the protein binding sites. Indoxylsulfate inhibits the active tubular secretion of acidic drugs 
and anionic solutes. A host of in vitro and in vivo animal studies associate indoxylsulfate with 
inflammation46, endothelial dysfunction47, vascular smooth muscle cell proliferation48, cardiac 
fibrosis49 and disturbances of bone metabolism.50 In addition, it has repeatedly been 
associated with loss of residual renal function51, by itself a factor with strong impact on 
outcome52
Inhibition of intestinal absorption of indoxylsulfate by the absorbant AST-120 (Kremezin)
.  
® 
has been associated with a delay in the initiation of dialysis53, a delay in the progression of 
renal failure as estimated by eGFR decline54 and, if applied before the start of dialysis, with 
better prognosis once dialysis was started.55 Although controlled, these studies have been 
performed in small populations and thus need confirmation. Recently, serum indoxylsulfate 
has also been associated with vascular disease and mortality in CKD patients.56
 
 
Other strategies to remove protein-bound solutes are discussed more in dept in chapter 4.1. 
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1.1.3. Cardiovascular disease and inflammation in CKD 
Cardiovascular disease (CVD) remains a major cause of morbidity and mortality in CKD 
patients, either treated by haemodialysis, peritoneal dialysis or renal transplantation, as well as 
in earlier stages of CKD not requiring renal replacement therapy. 
Lindner et al were the first authors pointing out that dialysis patients are exposed to 
cardiovascular problems and suffer from accelerated and severe atherosclerosis57. Two 
decades later, Foley et al observed a far greater risk of CVD in haemodialysis (HD) patients 
compared to the general population58; similar problems were registered as well in the pre-
dialytic stage (from CKD 3 on)59. Recently, it was shown that even in mild renal failure, from 
a GFR of 60 ml/min/1.73 m2 on or even earlier, the cardiovascular risk starts to increase60;61. 
This has led to the concept that renal disease is a model of accelerated vascular ageing where 
vascular changes can already be observed at young age.  
Figure 2: Schematic presentation of traditional and novel (or uraemia-specific) 
cardiovascular risk factors  in chronic kidney disease. (From 62) 
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Traditional risk factors for CVD like age, gender, smoking, diabetes, dyslipidemia and 
hypertension, which predict cardiovascular mortality in the general population, are present in 
CKD, but can only partially explain the high cardiovascular risk in this population. So-called 
novel risk factors for CVD, such as inflammation, endothelial dysfunction, oxidative stress, 
malnutrition, uraemia and vascular calcification are highly prevalent in CKD patients and 
seem to play a far more important role in vascular disease than in the general population62-68. 
(figure 2) In particular, research has focused on factors specific to the uraemic condition 
leading to the identification of an increasing number of uraemic solutes with direct 
vasculotoxic effects.7
Atherosclerosis is the most important underlying cause of CVD, both in the general as well as 
in the CKD population. It is a disease of the arterial intima characterized by the presence of 
plaques and occlusive lesions, in which the above mentioned risk factors contribute.
 
69 
Initially, atherosclerosis was previously considered to be a degenerative disease, but it is 
currently recognized as an inflammatory disorder.70
The other type of vascular lesion is arteriosclerosis, characterized by diffuse dilatation and 
hypertrophy of large arteries with loss of arterial elasticity.
 A key role in this process is played by 
leukocyte-endothelial interactions, causing vascular damage by products of inflammation 
such as free radicals. Atherogenesis, the process leading to atherosclerosis is accelerated from 
even minor decerements of renal function, long before renal replacement therapy is needed. 
Clinically, atherosclerosis causes ischaemic problems such as angina pectoris, myocardioal 
infarction, stroke and peripheral vascular disease.  
71 The main adverse effects of 
arterial stiffening are an increased systolic blood pressure with a normal or decreased diastolic 
blood pressure, left ventricular hypertrophy and diminished coronary perfusion.72 This arterial 
stiffening is a normal ageing process, but in CKD, arterial enlargement and increased stiffness 
are already observed in the early stages.73;74 It is predictive for CVD75;76, but is also associated 
with inflammation and endothelial dysfunction.77;78
In chronic renal failure, inflammation and CVD are linked to each other. CKD is 
characterized by a state of chronic micro-inflammation, as evidenced by increased levels of 
inflammatory markers, such as C-reactive protein (CRP), IL-6 and white blood cell count.
  
79 
This baseline inflammatory status is associated with oxidative stress, endothelial dysfunction, 
vascular calcification and wasting and thus with atherosclerosis.80 In contrast, the blunted 
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immune response upon activation results in an increased susceptibility for infection and a 
higher risk of malignancy.81;82
This duality in immune response in CKD patients originates at different levels. Some uraemic 
retention solutes exert pro-inflammatory effects (e.g. guanides, advanced oxidation protein 
products (AOPP)), whereas others are anti-inflammatory (e.g. purines). In this way, uraemic 
retention solutes can contribute to both CVD and the propensity to infection of uraemic 
patients.
  
21;47;83;84  
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1.1.4. Renal Replacement Therapy (RRT) for CKD 5 
Once CKD is diagnosed, patients need to be evaluated to determine the type of kidney 
disease, the stage of CKD, the complications related to the level of kidney function, the risk 
for further loss of kidney function and the risk to develop CVD. Based on this information, 
treatment can be started. Initially, drug therapy will be instituted, which will mainly focus on 
slowing down the progression of kidney failure and preventing and treating CVD and other 
complications of reduced kidney function. At more developed stages of CKD,  the patient will 
be prepared to start renal replacement therapy, which will be considered when eGFR 
decreases to approximately 15 ml/min/1.73 m2 (European Renal Best Practice85
1.1.4.1. Renal Transplantation 
). This renal 
replacement therapy can either be dialysis or renal transplantation. 
While transplantation at first sight is the preferred therapy for kidney failure, there is a 
shortage of donor kidneys, transplants may fail and the majority of end stage renal disease 
(ESRD) patients is not suitable for transplantation; as a consequence, the majority of the CKD 
stage 5 patients will be treated with either haemodialysis or peritoneal dialysis, while awaiting 
transplantation or because they are no valid candidates for a graft.  
1.1.4.2. Haemodialysis 
Haemodialysis (HD) is an extracorporeal technique. The blood is purified through an artificial 
kidney, which contains two chambers separated by a membrane. The blood flows in one 
compartment and dialysate in the other, in opposite directions. Waste products are cleared 
from the blood by diffusion induced by a concentration gradient across a semi-permeable 
membrane, and convective clearance and fluid removal are achieved by ultrafiltration induced 
by hydrostatic transmembrane pressure.  
1.1.4.3. Peritoneal Dialysis 
In this form of dialysis, the peritoneum, which surrounds the abdominal cavity and envelopes 
the intestine, serves as a semi-permeable membrane across which dialysis can occur. In 
peritoneal dialysis (PD), dialysis fluid is instilled into the peritoneal cavity via a permanent 
catheter, placed in the lower part of the abdomen. At regular intervals, the fluid is drained and 
replaced. (figure 3) 
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PD is based on the principles of diffusion and osmosis. Uraemic toxins and solutes move 
across the membrane, by diffusion, from the blood stream to the dialysis fluid, or vice versa, 
depending on the concentration gradient. Fluid removal from the body is induced by osmosis, 
due to the addition of an osmotic agent, usually glucose, to the dialysate. Other osmotic 
agents can also be used, such as icodextrin, a glucose polymer, or amino acids. The pores in 
the peritoneal membrane are large enough to allow the waste products to pass into the 
abdominal cavity, but small enough to only allow the passage of larger proteins to a limited 
extent.  
There are two types of PD: continuous ambulatory peritoneal dialysis (CAPD) and automated 
peritoneal dialysis (APD). With CAPD, dialysate is instilled into and drained from the 
peritoneal cavity by gravity. No machine is needed. There is almost continuously dialysate 
fluid present in the peritoneal cavity and during the day, the fluid is changed on regular 
relatively short intervals, with a longer dwell time overnight. In APD, a cycler performs 
several exchanges overnight, whereas in the morning a dwell time starts that can last longer. 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3: Schematic representation of peritoneal  dialysis 
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Continuous removal of waste products achieved using PD results in improved well-being of 
the patients, partly as a result of stabilization of the amount of waste products in the body. 
This in contrast with haemodialysis (HD), where waste products accumulate in-between two 
dialysis treatments. Patients on PD have increased flexibility compared to HD, since PD can 
be done by the patient himself at home. In addition, PD is less expensive for the society.  
Currently, there are more than 190,000 patients on PD worldwide, representing approximately 
10% of the total patient population receiving dialysis.86 It is expected that the number of PD 
patients will increase during the next decade, especially in developing countries.87
 
 
  
 
  
 
  
 
 
 
 
 
 
 
 
 
 
1.2. PERITONEAL MEMBRANE BIOLOGY 
 
 
 
 
 
 
  
1.2. Peritoneal membrane biology 
35 
In 1730, James Douglas made the first modern description of the peritoneum. He observed 
that it was smooth and flat, and lubricated by a fluid to preserve it from the inconveniences of 
continuous friction.88
For efficient peritoneal dialysis, the peritoneum must function as a dialyzing membrane, 
although this is not its primary purpose.
 As observed by Douglas, the main function of the peritoneum and other 
serous membranes was to reduce friction between moving organs. 
89 The peritoneum is the most extensive serous 
membrane in the body; it covers the visceral organs (visceral peritoneum) and lines the 
abdominal cavity (parietal peritoneum). Due to the arrangement of peritoneal folds, its surface 
area is equivalent to that of the skin (2 m2). Specialized regions of the peritoneum include the 
omentum and the mesentery. Normally the peritoneum is very thin, 20-40 µm in the greater 
omentum and somewhat thicker in the parietal and visceral peritoneums.90
 
 
 
 
 
 
 
 
 
 
 
The peritoneal membrane is composed of a monolayer of flat mesothelial cells that rest on a 
continuous basement membrane, and a submesothelial layer of connective tissue with variable 
thickness and structure, containing blood and lymphatic vessels, nerve fibres and different cell 
types (macrophages, fibroblasts, mast cells, leukocytes, adipocytes) immersed in an 
extracellular matrix.89 (Figure 4) Adipocytes can be seen in all peritoneal preparations, as they 
form fat deposits and constitute the majority of cells in the mesentery and great omentum.91
Figure 4: Peritoneal membrane structure 
 
However, their role in the peritoneal pathophysiology remains unclear.  
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The mesothelium 
The mesothelium consists of a continuous monolayer of mesothelial cells of mesenchymal 
origin, joined by various intercellular junctions. The luminal surface of mesothelial cells has 
numerous microvilli that markedly increase the functional mesothelial surface area, up to 40 
m2, for exchange between mesothelial cells and the peritoneal cavity.92 The number of 
microvilli expressed on each cell varies under different physiological and pathological 
conditions.93 Microvilli protect the delicate mesothelial surface from frictional injury by 
entrapping water and serous exudates, which act as lubricants for the cells. Mesothelial cells 
also possess cilia on their apical surface that are typically five times longer than adjacent 
microvilli. The quantity increases with increasing cell density, which suggests they play an 
essential role in mesothelial cell polarity and cell-cell adhesion. Although the mesothelium 
offers little resistance as a biological barrier, it contains abundant anionic sites and 
intercellular junctions that potentially allow it to act as a selective barrier to the passage of 
plasma molecules.92
Furthermore, mesothelial cells provide the first line of defense in peritoneal protection during 
long-term or repeated exposure to unphysiologic PD solutions and against micro-organisms 
during infection.
  
92 Mesothelial cells are active cells that can synthesize a plethora of pro-, 
anti-, and immunomodulatory mediators including growth factors, cytokines, hyaluronan, 
nitric oxide, components of the RAAS system and prostaglandins. These mediators are 
released in response to bacterial infection or chemical/surgical injury to initiate the reparative 
processes and restoring the homeostatis in the peritoneum. Repeated insult triggers chronic 
inflammatory responses that often result in the induction of peritoneal fibrosis. Mesothelial 
cells are able to secrete chemotactic peptides following activation with proinflammatory 
cytokines and live bacteria or active metabolites secreted by bacteria, and hence contribute to 
the intraperitoneal recruitment of leukocytes during peritoneal inflammation. Phagocytosis of 
a foreign agent by mesothelial cells induces cell activation and the release of proinflammatory 
cytokines and chemokines, that further amplify the inflammatory response and induce 
effective endothelial activation, essential for migration of leukocytes into the peritoneal 
cavity.94 It has been postulated that chronic irritation of mesothelial cells results in 
dedifferentiation, a process called epithelial-to-mesenchymal transition (EMT).95 (figure 5) 
During this process, mesothelial cells lose expression of several genes, such as cytokeratins 
and E-cadherin and gain others, such as alpha smooth muscle actin  (α-SMA) and snail.  
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Trans-differentiated mesothelial cells are able to migrate from the superficial cell layer into 
the interstitial space, where they become active as myofibroblasts, which are probably 
responsible for the increased submesothelial thickness and fibrosis observed in long term PD 
patients.  
 
 
 
 
 
 
Figure 5: Epithelial-to-mesenchymal transition (EMT) (From {Aguilera, 2005 127 /id}) 
Glucose, advanced glycation end products (AGEs), glucose degradation products (GDPs), low pH 
and inflammatory mediators (peritonitis) stimulate epithelial-mesenchymal transition (EMT) of 
mesothelial cells (MCs). MCs loose expression of several genes, such as E-cadherin and 
cytokeratins, and gain others, such as snail and smooth-muscle actin (αSMA). Trans-
differentiated MCs are able to invade the peritoneal sub-mesothelium and produce a high 
quantity of extracellular matrix (ECM) and vascular endothelial growth factor (VEGF), a pro-
angiogenic factor associated with peritoneal membrane failure. Intercellular adhesion molecule 1 
(ICAM-1), interleukin 1 (IL-1), matrix metalloprotease (MMP), plasminogen activator inhibitor 1 
(PAI-1), transforming growth factor β (TGF-β). 
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The basement membrane 
The basement membrane, underlying the mesothelial cells, is a thin (±40 nm) laminar network 
composed of mainly type IV collagen, laminin, fibronectin and proteoglycans. It functions as 
a support for the mesothelium and as a selective cellular barrier, allowing macrophages and 
lymphocytes to pass through it, but preventing fibroblasts from the underlying connective 
tissue to contact the mesothelial cells.96
 
 
The submesothelial layer 
The submesothelial interstitial tissue is a complex network of collagen fibres (type I and III), 
elastic fibres and a gel containing macromolecules. The main component is hyaluronan, a 
non-sulfated glycosaminoglycan, which can bind enormous quantities of water and forms 
together with proteoglycans a gel-like substance that behaves like a filter. Thus, the interstitial 
matrix probably plays a major role in the transport of solutes and solvents. This extracellular 
matrix (ECM) provides mechanical strength to the tissue and acts as a framework for cell 
attachment and migration.91
Under normal circumstances, fibroblasts produce the macromolecules that constitute the ECM 
(collagens, elastic fibres, GAGs), but when stimulated, they can, like mesothelial cells, 
generate chemotactic and proinflammatory factors, which contribute to the recruitment of 
leukocytes.
  
97;98
Resident macrophages, underneath the basement membrane and around the blood vessels, are 
activated by invading microorganisms or their secreted products and subsequently produce 
and/or secrete a broad variety of proinflammatory cytokines. In addition, interaction of 
macrophages with microorganisms also causes an increased secretion of chemoattractive 
agents, resulting in migration of leukocytes from the bloodstream to the site of inflammation.  
  
Next to macrophages, mast cells further increase the peritoneal response to injury by releasing 
a large amount of inflammatory mediators and chemoattractive agents.99
Other important structures are blood and lymph vessels. Peritoneal blood vessels, especially 
capillaries and post-capillary venules, take care of nutrient transport and waste removal from 
tissues and organs within the peritoneal cavity. Lymphatic vessels represent a drainage 
system, which helps to maintain the normal level of intraperitoneal fluid, by returning 
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excessive fluid and proteins to the systemic circulation. Furthermore, they can also participate 
in host defence by removing leukocytes carrying foreign bodies, from the peritoneal cavity.96
 
 
The peritoneal microcirculation 
The large vessels supplying blood to the visceral peritoneum function primarily as conduits to 
supply blood to the visceral organs. The arterioles and capillaries are organised as a network 
(figure 6), with redundant capacity and bypass circuits, which can lead to a substantial 
recruitment of normally closed loops when needed, e.g during inflammation. This capillary 
recruitment, which involves already existing capillaries, should be clearly distinguished from 
neo-angiogenesis, where neoformation of capillaries takes place. 
 
 
 
 
 
 
 
 
 
 
 
 
arteriole 
capillaries 
postcapillary venule 
Figure 6: Intravital micrsocopy of the rat peritoneal microcirculation. (Adapted from 100) 
Arterioles divide into a thin capillary network that forms postcapillary venules and venules. 
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The arterioles are the major sites of microvascular resistance and regulate flow to capillary 
beds. They are lined by endothelial cells resting on a basal lamina surrounded by a layer of 
smooth muscle cells. Terminal arterioles may participate in the exchange process as they have 
a discontinuous muscle layer. However, the relative contribution to overall peritoneal 
transport is minimal since the surface area and permeability of these vessels are much less 
than that of capillaries and postcapillary venules.  
Capillaries are the principal sites for solute and fluid exchange. The wall of the capillary is 
composed of an endothelium and a basal lamina. Capillary size is approximately 5-8 µm, 
which is large enough to let red blood cells (average diameter 7.5 µm) through, usually one at 
a time and with some deformity. 
Small venules that are located just distal to the capillaries are often termed postcapillary 
venules. They participate in fluid and solute exchange, are an important site for microvascular 
leukocyte adhesion, and may demonstrate dramatic changes in permeability during 
inflammatory conditions. Postcapillary venules are generally 10-40 µm in diameter and are 
composed of endothelial cells resting on a basal lamina surrounded by pericytes. Larger 
venules are enclosed by muscular media.  
 
The peritoneal microcirculation plays a critical role in inflammatory responses associated with 
peritoneal dialysis. An important aspect of this response is the interaction of leukocytes with 
the vascular endothelium.  
Intravital microscopic studies have demonstrated that the attachment and migration of 
leukocytes from the vascular space to the extravascular space (leukocyte recruitment) is 
localized primarily to postcapillary venules.101
 
 (Figure 7) 
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Leukocyte recruitment occurs within postcapillary venules and is dependent on a cascade of 
events involving the selectins as the primary molecules that induce and support rolling. As the 
inflammatory process proceeds, the number of rolling leukocytes increases and the velocity of 
the rolling decreases. The adhesive interaction between the leukocytes and the endothelium is 
mediated by a complex, highly coordinated dynamic interplay between adhesion molecules 
expressed on the surface of both the leukocytes and the endothelium.  
 
The selectin-family and their carbohydrate-containing ligands mediate leukocyte rolling. This 
brings the leukocyte into transient, but close contact with the endothelial cells. If the 
appropriate stimuli are present, the leukocyte prepares for firm adhesion and transendothelial 
migration by activation of a second family of adhesion molecules, the integrins, which 
interact with Ig-like molecules. 
 
 
 
Figure 7: Leukocyte recruitment 
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Molecular compounds of the peritoneal microcirculation 
 
The capillary endothelium constitutes one of the barriers for water and small solute transport 
during PD. Transport rate across the peritoneal membrane depends on the intrinsic 
permeability to each solute and the effective peritoneal surface area (EPSA), reflecting the 
number of perfused capillaries within the peritoneum in contact with the peritoneal dialysis 
solution. 102
The permeability for water and solutes across the endothelium is best described by the three-
pore model, which includes transcellular, ultrasmall pores (radius: 3 to 5 Å) called aquaporins 
(AQP), and which are exclusively permeable to water, small pores (radius: 40 to 50 Å) 
permeable to water and small solutes, and large pores (radius > 150 Å) permeable to 
macromolecules.
  
103 The water channel AQP1 is the molecular counterpart of the ultrasmall 
pore, involved in the free water permeability explaining the sodium sieving during the first 30 
min of a hypertonic dwell.102;104
Histopathological studies have shown that long-term PD is associated with modifications of 
the peritoneal membrane (see chapter 1.3), including perivascular and submesothelial fibrosis, 
alterations of the mesothelium, and replication of capillary basement membrane.
 
105;106 In 
particular, vascular proliferation and increased endothelial area within the peritoneal 
membrane have been documented in long-term PD patients.105;107
 
 Thus, vascular proliferation 
and, possibly, vasodilatation of peritoneal vessels, might represent the structural basis for 
increased EPSA in long-term PD. 
Nitric oxide (NO) plays a role in the regulation of vascular tone and permeability,108 and 
interacts with angiogenic growth factors.109 It might thus regulate EPSA and ultrafiltration 
(UF) during PD.110
NO is synthesized from L-arginine by three nitric oxide synthase (NOS) isoforms: the 
neuronal NOS (nNOS), the endothelial NOS (eNOS), and the inducible NOS (iNOS). In long-
term PD, peritoneal NOS activity increased fivefold above levels observed in controls and 
uraemic subjects prior to the onset of PD.
 
107 Furthermore, the increased NOS activity 
correlated positively with PD duration and was solely attributable to the upregulation of 
eNOS – itself reflecting the increase in endothelial area.107 Thus, the release of NO, secondary 
to NOS upregulation, might be a major regulator of UF in PD patients.  
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Vascular endothelial growth factor (VEGF) is a potent regulator of angiogenesis and vascular 
permeability.109 VEGF is expressed in the human peritoneal membrane and is located in the 
endothelium lining peritoneal capillaries. Its expression is clearly upregulated in long-term 
PD patients.107 VEGF has also been detected in the dialysate, where its abundance correlates 
with the permeability for small solutes and the loss of ultrafiltration.44 The synthesis of VEGF 
by cultured mesothelial and endothelial cells isolated from the peritoneum has been 
demonstrated.111 Thus, by analogy with other angiogenic diseases, upregulation of VEGF may 
trigger vascular proliferation in the peritoneal membrane in long-term PD. The putative 
stimuli involved in the regulation of VEGF in the peritoneal membrane include other growth 
factors, local ischaemia, or inflammatory cytokines, or even direct glucose mediated 
effects.109;112
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: A model for the different molecular mechanisms involved in peritoneal membrane 
dysfunction in long term peritoneal dialysis. (Adapted from {Devuyst, 2002 416 /id}) 
Abbreviations: PD, peritoneal dialysis; AGEs, advanced glycation end products; GDPs, glucose 
degradation products; TGF-β1, transforming growth factor beta 1; VEGF, vascular endothelial 
growth factor; eNOS, endothelial nitric oxide; NO, nitric oxide; EPSA, effective peritoneal 
surface area; UF, ultrafiltration 
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Multiple interactions between NO, eNOS and VEGF occur within endothelial cells. Both NO 
and eNOS are required for VEGF-driven angiogenesis and vascular permeability.113 On the 
other hand, VEGF is known to upregulate eNOS and NO production.114 In turn, NO 
modulates and even suppresses the hypoxic induction of VEGF, which creates a negative 
feed-back between NO and VEGF induction.109
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Long-term peritoneal dialysis (PD) is associated with functional and structural deterioration of 
the peritoneal membrane. Predominant causes for technique failure are ultrafiltration failure 
(UFF)115 and recurrent or severe peritonitis.116;117
The most consistent changes in peritoneal tissues of PD patients are 1) an increase in the 
submesothelial thickness, which is associated with peritoneal fibrosis; 2) angiogenesis; and 3) 
epithelial-to-mesenchymal transition (loss of mesothelial cell layer) (EMT).
 Dysfunction of the peritoneum as a dialysis 
organ is thought to be the result of structural changes that develop in the peritoneal membrane 
with time on PD.  
106;117;118 Fibrosis 
and angiogenesis mostly occur together 119, and interventions that reduce angiogenesis mostly 
reduce fibrosis and vice versa.120 Fibrosis and angiogenesis appear to be linked through 
upregulation of common initiating growth factors (TGF-β, VEGF), inflammatory cytokines, 
and the EMT process.121
 
 Factors that selectively inhibit these growth factors can protect the 
peritoneal membrane against deterioration.  
Causes of these peritoneal changes are multifactorial. Nevertheless, many of these factors are 
modifiable, and attention should be paid to them in the clinical practice to maintain peritoneal 
membrane integrity. 
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1.3.1. PD-related factors affecting peritoneal membrane quality 
 
1.3.1.1. Glucose & glucose degradation products 
Low pH, lactate buffer, the presence of glucose in the dialysate fluid, and the generation of 
glucose degradation products (GDPs) and advanced glycation end products (AGEs) out of 
glucose as a result of heat sterilization of the PD fluid122;123
Peritoneal dialysis solutions using glucose as osmotic agent have been used for more than two 
decades as effective treatment for patients with end-stage renal disease. Although alternative 
osmotic agents such as amino acids and macromolecular solutions, including polypeptides 
and glucose polymers, are now available, glucose is still the most widely used osmotic agent 
in PD. It has been shown to be safe, effective, readily metabolized, and inexpensive. On the 
other hand, it was assumed for years that exposure of the peritoneal membrane to high 
glucose concentrations contributes to both structural and functional changes in the dialyzed 
peritoneal membrane. However, comparing heat sterilized and filtered sterilized dialysis 
solutions, containing the same glucose content and having the same low pH,  pointed out that 
the latter two were of less importance than GDPs.
, have attracted most attention as 
culprits for the deterioration of the peritoneal membrane.  
124 Both in vitro 125-129 and in vivo130;131 
studies suggest a link between high concentrations of GDPs and AGEs in the dialysate, and 
induction of peritoneal fibrosis and angiogenesis through stimulation of TFG-β and VEGF 
production by mesothelial cells.132
This led finally to the development of solutions low in GDPs and with a physiological pH. 
Although these solutions perform clearly better in terms of biocompatibility in an in vitro 
setting
  
135-139 and in animal models140-144, their benefit in clinical conditions on preservation of 
peritoneal membrane integrity is not convincing so far145;146. This might be due to substantial 
differences in GDP content between the different brands of “low GDP, normal pH” solutions. 
It has been demonstrated for example that Physioneal® (Baxter, Illinois) contains nearly 
identical concentrations of 3,4-deoxyglucosone-3-ene, considered as being the most toxic 
GDP147, as its classic counterpart Dianeal®, which might explain the disappointing outcome of 
the study by Fan et al.146
The discrepancy can also be explained by the fact that, besides GDPs and low pH, many other 
factors impact on the properties of the peritoneal membrane. These factors are often neglected 
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in clinical studies, potentially leading to unnoticed differences in case-mix and blurring the 
interpretation of the potential impact of the novel solutions.  
 
1.3.1.2. Peritonitis 
Repetitive or protracted peritonitis episodes are associated with long-term peritoneal 
membrane changes, leading to increased solute transport and decreased ultrafiltration.148;149 
However, if promptly and efficiently treated, peritonitis does not cause any permanent change 
in small solute transport.150 Peritonitis induces inflammation and a subsequent fibrogenic 
response. Inflammatory cytokines, which are induced in the peritoneal cavity during 
peritonitis, may further promote chronic inflammation and fibrosis. However, it is likely that 
the inverse is true as well: patients with an already damaged peritoneal membrane with 
defective mesothelial and defensive functions, are more prone to infection, and have 
difficulties to clear the responsible germs. Relapsing peritonitis is thus most likely a sign of 
bad peritoneal viability, rather than a cause of it.151
 
  
1.3.1.3. Additives protecting the peritoneal membrane integrity during PD 
To date, interventions designed to preserve the peritoneum by means of pharmacological 
manipulation (e.g. benfotiamine152, pyrodoxamine153-155, Glycosaminoglycans - GAGs156-166
Hyaluronan (HA) is a GAG composed of repeated dimers of N-acetylglucosamine and 
glucuronic acid. High-molecular weight HA added to dialysis fluid exerts anti-inflammatory 
and antifibrotic actions on in vitro cultured mesothelial cells.
) 
are promising, but clinical relevance is disappointing. Of all substances used as additives, 
GAGs have been investigated most extensively, but with inconsistent and even conflicting 
results. 
161 Animal studies indicated that 
intraperitoneal administration of HA results in improved ultrafiltration166 and solute 
clearances 164;165 and can protect the peritoneal membrane during peritonitis or after repeated 
infusion of dialysis solutions.166 A clinical study by Wang et al confirmed a decreasing 
peritoneal fluid absorption, leading to a better ultrafiltration rate. Moberly et al reported a 
trend for higher solute clearance and net ultrafiltration and supported the acute safety of HA 
when administered intraperitoneally in the dialysis solutions of a small series of PD 
patients.162;163 
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Heparin is a GAG with well-known anticoagulant activity161;167, a property used in peritoneal 
dialysis to maintain catheter patency and to prevent the development of peritoneal 
adhesions.161;168 However, heparin also has a host of other biological actions beyond its role 
as an anticoagulant, including immunomodulating, anti-inflammatory and antiproliferative 
effects, and effects on the extracellular matrix, and angiogenesis.167;169;170 Low-molecular 
weight heparins can inhibit the effects of fibroblast growth factor (FGF) and of vascular 
endothelial growth factor (VEGF)171, of which the latter has been linked to peritoneal 
membrane inflammation and angiogenesis during PD therapy.172-174 On the other hand, using 
a rat model of peritoneal perfusion, Schilte et al failed to demonstrate a beneficial impact of 
heparin.156 Moreover, heparin use is accompanied by serious side effects, such as bleeding 
tendency, and in addition, it can only be administered intraperitoneally or subcutaneously, 
limiting its everyday applicability.175-177
Therefore, it might be of interest to submit other GAGs to evaluation, preferentially with oral 
administration. 
 In theory, heparin can also be administered 
intravenously, but in the context of peritoneal dialysis, this is not a viable or relevant option. 
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Prevention of PD-induced ultrafiltration failure and peritoneal membrane changes has been a 
very important research topic over the last few years. Using angiogenesis inhibitors may lead 
to reduced vessel formation, resulting in sustained ultrafiltration (UF) and improved well-
being of patients due to a more continuous removal of waste products. Until today, several 
protocols have been developed to reduce angiogenesis in PD. 
Cyclooxygenase (COX) enzymes are involved in prostaglandin synthesis. COX-2 is known to 
be an angiogenesis stimulator by upregulating the mRNA transcription and the production of 
VEGF.178 Studies have already shown a possible role for COX-2 inhibitors in the reduction of 
fibrosis and angiogenesis both in vitro and in vivo.179;180 Treatment with the COX-2 inhibitor 
celecoxib in a rat exposure model prevented PD-induced angiogenesis in both the omentum 
and parietal peritoneum, but VEGF levels were unaffected.181 However, ultrafiltration 
capacity was restored. Celecoxib may therefore be of interest in the prevention of 
ultrafiltration failure in PD patients. Unfortunately, the use of Cox-2 inhibitors is associated 
with an increased incidence of acute myocardial infarction and death from cardiovascular 
disease.182
Another interesting possibility to prevent angiogenesis is the use of tyrosine kinase inhibitors. 
Sunitinib, for example, is involved in the inhibition of VEGF and platelet-derived growth 
factor receptor signaling.  
  
A case study with a PD patient with metastatic renal cell carcinoma treated with sunitinib 
demonstrated a stabilization of the abdominal metastasis as well as the thickness of the 
peritoneal membrane and D/P creatinine. These observations suggest that sunitinib may have 
prevented peritoneal membrane angiogenesis.183 In addition, animal studies showed 
prevention of new vessel formation in the omentum as well as the mesentery by sunitinib at 
the end of a 5 week period of PD treatment.184 However, sunitinib treatment did not prevent 
an increase of PD-induced VEGF levels. Interestingly, a loss of mast cells in the mesentery 
was observed in the sunitinib-treated animals. Together with previous studies, in which mast-
cell-deficient rats also showed significantly reduced angiogenesis in the omentum, this 
suggests an important role for mast cells in new blood vessel formation upon PD.185
There are also studies focusing on the prevention of the onset of angiogenesis.  
  
Peroxisome proliferator-activated receptor-γ agonists are known to control glycaemia by 
improved insulin sensitivity and have anti-inflammatory, and therefore probably also 
antifibrotic, properties. Administration of a drug of this group, rosiglitazone, in a PD mice 
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exposure model led to reduced AGE formation and inflammation, a preserved mesothelial cell 
layer, and improved ultrafiltration.186 Nevertheless, although promising for inhibiting the 
alterations due to PD, rosiglitazone treatment of patients with type II diabetes has been linked 
to several severe side effects.187
Since epithelial-to-mesenchymal transition (EMT) also leads to angiogenesis, there has been 
recently a focus on the prevention of EMT in the context of PD.
  
188;189  In a rat PD exposure 
model, EMT as well as angiogenesis were inhibited after treatment with recombinant bone 
morphogenic protein-7 (BMP-7). BMP-7 antagonises TGF- β1 and as a consequence can 
block mesenchymal-to-epithelial transition.190
Administration of two TGF-β
 
1 blocking peptides (P17 or P144) to PD-fluid instilled mice 
significantly reduced fibrosis, but also angiogenesis.191
Inhibitors of angiotensin- converting enzyme (ACE) and Ang II receptor are shown to 
attenuate the production of VEGF in mesothelial cells in vitro.
  
192 Previously, administration 
of these inhibitors/blockers was already shown to attenuate structural and functional alteration 
of the peritoneal peritoneum in a PD rat model.193-196
Rapamycin, a commonly used immunosuppressive agent, has been demonstrated to prevent 
angiogenesis in the mesenteric tissue of portal hypertensive mice, at least in part through an 
anti-VEGF activity. 
  
197
 
 
Whether the above-mentioned positive interventions used in animal studies can be translated 
into clinical medicine remains to be elucidated. Currently, the COX-2 inhibitor celecoxib, the 
only COX-2 antagonist still in use in the USA, is under study in a clinical trial. Nevertheless, 
we have to be careful in using blocking agents. A lot of pathways leading to, for example, 
EMT are also involved in pathways necessary for a good functioning of the body. 
Agents directly blocking TGF-β cannot be easily used in the clinical practice of PD, at least 
for long-term treatments, because TGF-β has important modulating functions of the immune 
and inflammatory responses.198 Blocking TGF-β1
 
 could thus lead as a counterpart to chronic 
inflammation.  
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1.3.2. Non-PD related factors affecting peritoneal membrane quality 
 
1.3.2.1. Salt intake 
There is much debate about the potential benefit of a reduction in dietary salt intake in the 
normal population, but for patients with kidney disease, there seems to be a consensus that a 
too high salt intake should be avoided, although there is no agreement on the ideal daily dose 
of salt. In any case, it is evident that salt intake induces thirst, and will thus inevitably lead to 
a higher intake of fluids, which in its turn will enhance the need to increase ultrafiltration. The 
latter is in PD patients often pursued by using hypertonic glucose exchanges. In addition, salt 
intake will increase blood pressure quite rapidly, which might again lead to a need for more 
ultrafiltration by the introduction of hypertonic peritoneal dialysate bags. Since these 
hypertonic solutions are able to induce peritoneal damage, salt restriction should be advocated 
in PD patients, to indirectly preserve the peritoneal membrane integrity. 
In addition, there is evidence that dietary salt intake by itself, even without causing 
hypertension or volume overload, might be deleterious, resulting in cardiac remodelling, 
fibrosis and left ventricular hypertrophy.199;200 Also in the kidney, it has been demonstrated 
that salt intake leads to enhanced glomerulosclerosis and deterioration of residual renal 
function.201-203
 
 It has been postulated that upregulation of transforming growth factor beta 1 
(TGF-β1) might be one of the underlying mechanisms.  
1.3.2.2. Genetic factors 
As for many biological processes and structures, the integrity of the peritoneal membrane can 
be altered by genetic polymorphisms. Some polymorphisms with functional repercussions 
have been described, but it is very likely that many more exist, and that they partially explain 
differences in the propensity to develop peritoneal dialysis related complications such as 
encapsulating peritoneal sclerosis.  
The most important genetic polymorphism is probably the one for interleukin 6 (IL-6), of 
which a G and a C allele have been described. IL-6 has been associated with systemic 
inflammation, but has also been linked with peritoneal inflammation, and is most likely the 
link between the two phenomena. IL-6 was not only associated with increased small solute 
transport, but also with albumin leakage, and thus an increase of large pore flow, by itself a 
marker of inflammation.204  
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Patients with a GC or CC disposition have much higher IL-6 levels in serum and in the 
drained dialysate, while an upregulation of IL-6 mRNA in the peritoneal membrane was 
associated with much faster transport of small solutes.205 In the same study, also 
polymorphisms of VEGF and eNOS were evaluated, but no impact on peritoneal membrane 
was detected.205 Hwang et al described an IL-6 T15A SNP polymorphism, which was 
associated with baseline peritoneal membrane transport rate after adjustment for diabetes, 
comorbidity and CRP.206
Endothelial nitric oxide synthase (eNOS) is involved in the autoregulation of blood vessel 
tone. A gene polymorphism of the eNOS gene, with impact on the circulating NO levels, has 
been described. eNOS genotype "aa" or "ab", versus "bb", was an independent predictor of 
lower peritoneal membrane transport rate at initiation of PD, after adjustment for gender, 
body weight, and diabetes.
  
207
 
 
1.3.2.3. Medication 
Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) 
are used extensively in patients with renal diseases because of their beneficial effects on the 
cardiovascular system, and their ability to reduce proteinuria and to influence the progression 
of renal failure in patients with various types of glomerulopathies.208;209 The latter effect is 
likely due to the fact that angiotensin II (AII) has the properties of a growth factor.210 It has 
been shown that these effects are mediated through Ang II induction of transforming growth 
factor-β (TGF-β) synthesis and secretion.211 That explains an ability of AII inhibitors to 
attenuate development of renal fibrosis212, predominantly by suppressing the activity of TGF-
β.211
TGF-β
  
1 is a member of a family of cytokines and is involved in many wound healing 
processes.213 This profibrotic protein is believed to be a central mediator of fibrotic diseases in 
many tissues (liver, lung, kidney, central nervous system).214;215 More specifically, TGF-β1 
has been proposed to be a key molecule in PD fluid-induced peritoneal membrane 
deterioration.191;216-218 Blocking TGF-β1 has recently been shown to protect the peritoneal 
membrane from dialysate-induced damage.191 ACE inhibitors have also been shown to have a 
positive impact on the development of peritoneal membrane morphological alterations such as 
fibrosis and neoangiogenesis.195;219 AII inhibition prevents the increase in small solute 
transport193  and slows down the rate of decline in ultrafiltration219 in long-term PD. Thus, 
these drugs have a positive influence on PD technique survival. 
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1.3.3. Uraemia-related factors affecting peritoneal membrane quality 
There is evidence that the uraemic milieu is toxic for the peritoneal membrane. Both animal 
and human biopsy studies suggest that uraemia can induce fibrotic changes in the 
peritoneum.106;220
In a subtotal nephrectomy rat model, uraemia induced fast transport status. Further 
exploration indicated that in uraemia, there was peritoneal vascular proliferation and fibrosis, 
corresponding to upregulation of vascular endothelial growth factor (VEGF)  and fibroblast 
growth factor (FGF).
  
220 Similar observations were confirmed by Vrtovsnik et al in a uraemic 
rat model.221 In a Japanese cohort study including uraemic patients before the start of PD, the 
average peritoneal thickness was already increased and the lumen/vessel diameter ratio was 
decreased with an increase in thickness of the postcapillary venules.222 This is congruent with 
the findings of the peritoneal biopsy study group, based on a worldwide sampling of 
peritoneal membranes, showing that, even before initiation of dialysis, end-stage renal failure 
patients exhibit a peritoneum that is thickened and presents more vasculopathy as compared 
with peritoneum in healthy control subjects.106
The mechanism by which uraemia alone induces changes in the peritoneum is not clear, but 
these effects may be related to the chronic inflammation, observed in patients with end-stage 
renal disease. As mentioned earlier in this introduction, leukocyte function is altered in 
uraemic patients, who are characterized by a chronically stimulated baseline inflammatory 
state, but also by an impaired response upon stimulation. This can explain also the increased 
susceptibility for recurrent peritonitis in PD patients.  
 
Many alterations in important leukocyte functions are caused by the presence of uraemic 
retention solutes. The exact definition and classification of the individual retention products 
responsible for these effects in uraemic plasma is important, as identification of the 
responsible toxins would allow a tailored approach to removal by blood purification. 
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1.3.4. Animal models to study peritoneal membrane quality 
The development of peritoneal dialysis has been paralleled by a growing interest in 
establishing suitable experimental models to better understand the functional and structural 
processes operating in the peritoneal membrane. Visceral and parietal peritoneum from mice 
and rats is effectively undistinguishable from that described in humans.89
The majority of studies are performed in rat and rabbit models.
 
223-225 Rats are easy to handle 
and affordable. Rabbit models allow long periods of PD time and mimic certain aspects of the 
human situation (the ratio of peritoneal surface area and exchange volume in rabbits and 
humans is similar). However, rabbits are very sensitive animals and difficult to house.226
The possibility of using genetically modified mice cannot be underestimated as a tool to 
investigate the molecular aspects of peritoneal pathophysiology during PD and to pave the 
way for the development of novel, specifically targeted diagnostic and therapeutic 
strategies.
 
These animal models have provided significant insight into peritoneal membrane 
pathophysiology, but are limited in some cases by a lack of pathway specificity.  
227-229 Knockout mice have been used for example to demonstrate the importance of 
aquaporin-1 for fluid transport during the first hour of a PD-dwell.230  One of the 
disadvantages of mice is their small size, making manipulations difficult and more prone to 
deviations from the described standard approach. For example, a 25 g mouse has a plasma 
volume of only approximately 1.5 ml. Thus, sampling and injections should be downscaled to 
the microliter range. It is also not possible to cannulate more than a limited number of vessels 
in a mouse. In addition, mice are very sensitive to temperature changes, so a rigorous 
temperature control system is needed. Nevertheless, Ni et al were the first to show that a 
mouse model of PD is feasible for physiological experimentation.228
For all these reasons and because of the previous experience in our laboratory, we have opted 
to use the rat as an animal model to study PD-related interventions. 
  
However, it would be interesting to have eventually also experiments with larger animals, 
which have a longer life span and are probably more realistic in mimicking the situation of 
long-term PD in humans than are the short-term rat models we have at this moment.223 
Animal models using larger animals have however the disadvantage that they are far more 
expensive, in labor time and in cost of feeding, lodging and breeding. Larger animals will also 
necessitate longer time frames to set up and conduct new research projects, as the longer 
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lifecycle of larger animals is advantageous in relevance to the human long-term PD situation; 
however there is also the implication that it may take months before changes in the peritoneal 
membrane can be observed.  
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The condition of the peritoneal membrane is crucial to continue peritoneal dialysis (PD) as a 
renal replacement therapy. Morphological deterioration of the peritoneal membrane leads to 
the necessity to discontinue PD therapy. As described above, the causes of these peritoneal 
changes are multifactorial. The general objective of this thesis is to gain a better insight, by 
using chronic and acute rat models, in the mechanisms that alter peritoneal membrane 
function and to find strategies to prevent or attenuate these processes.  
The specific aims of this thesis are: 
1) To evaluate the potential protective effect of a specific additive, applied as an oral 
formulation, on peritoneal function and anatomy in a chronic rat model of peritoneal 
perfusion. 
2) To investigate the direct impact of dietary intervention on peritoneal morphology and 
function. 
3) To investigate the in vivo toxicity of specific uraemic retention solutes on leukocyte 
recruitment in the peritoneal microcirculation. 
Chapter 1 describes how chronic kidney disease progresses and what the treatment options 
are in chronic kidney disease stage 5. An overview of the uraemic retention solutes, which 
were evaluated in the scope of this thesis, is given. The peritoneal membrane morphology and 
changes during PD are described, together with their different causes.  
Chapter 2 describes the effects of oral sulodexide treatment on the development of functional 
and morphological changes of the peritoneal membrane using a standardized rat model of 
chronic peritoneal dialysate fluid (PDF) exposure. Sulodexide is a highly purified mixture of 
GAGs containing 80% low-molecular weight heparin and 20% dermatan sulphate. After 12 
weeks of PDF exposure, a functional peritoneal equilibration test (PET) was executed and 
(immuno)histological analyses of the peritoneum were performed. 
In chapter 3, the direct morphological impact of dietary salt loading on the peritoneal 
membrane of healthy rats was explored. 2% NaCl was given in the drinking water of normal 
Wistar rats. After 2 weeks, peritoneal samples were taken for histology and determination of 
gene expression. 
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In addition to its clinical importance for peritoneal dialysis patients, the peritoneum provides a 
unique and simple organ structure for in vivo microvascular research. In chapter 4, the acute 
effects of specific uraemic retention solutes on leukocyte recruitment in the peritoneal 
microcirculation are evaluated, using intravital microscopy. In contrast with in vitro models, 
this approach enabled us to evaluate directly this crosstalk, as intravital microscopy allows 
visualization of leukocyte recruitment in mesenteric postcapillary venules. 
Chapter 4.1. gives an update of the most important protein-bound uraemic retention solutes. 
An overview of in vitro and observational in vivo data is given and removal strategies are 
discussed. The effects of p-cresylsulfate, p-cresylglucuronide and indoxylsulfate on leukocyte 
recruitment, capillary leakage and hemodynamic parameters are described in chapter 4.2.  
The inflammatory properties of the small and water soluble guanidino compounds asymmetric 
dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) are evaluated in 
chapter 4.3. ADMA is generally accepted to be an inhibitor of nitric oxide synthase (NOS) 
and a marker of endothelial dysfunction. Furthermore, this molecule is linked with all cause 
mortality and cardiovascular events, both in the general as well as in the chronic kidney 
disease population. SDMA, the structural isomer of ADMA, was until recently considered 
biologically inert. In the present study, both ADMA and SDMA were compared for their 
impact on leukocyte recruitment, capillary leakage and hemodynamic parameters. 
In chapter 5, the general conclusions resulting from this thesis are summarized and discussed. 
Proposals on how future research could contribute to better preservation of the peritoneal 
membrane, resulting in a prolonged time in PD treatment are made. 
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2.1.1. Abstract 
Peritoneal dialysis (PD) is associated with functional and morphological alterations of the 
peritoneal membrane (PM). It is hypothesized that vascular endothelial growth factor (VEGF) 
plays a role in this process. Sulodexide is a glycosaminoglycan with effects on vascular 
biology. Therefore, the impact of oral sulodexide on PM function and morphology in a rat 
model of peritoneal perfusion was evaluated.  
Rats received 10 mL peritoneal dialysate fluid (PDF) twice daily via a tunnelled PD catheter. 
The test-PD group (Sul) received 15 mg/kg/day oral sulodexide versus none in the control–
PD group (Con). A third group received no PDF (Sham). After 12 weeks, a peritoneal 
equilibration test was performed and the PM was sampled. Neo-angiogenesis was evaluated 
using immunostaining with von Willebrand, and epithelial-to-mesenchymal transition (EMT) 
using co-localization of cytokeratin and a-smooth muscle actin. VEGF was determined in the 
dialysate by enzyme-linked immunosorbent assay.  
PD induced loss of ultrafiltration, also in the sulodexide group. Creatinine and glucose 
transport were better preserved, and sodium dip was more pronounced in the sulodexide 
group versus control. Submesothelial thickness, neo-angiogenesis and EMT were more 
pronounced in the Con versus Sul versus Sham group. VEGF in the dialysate, corrected for 
diffusion was higher in Con and Sul versus Sham. 
Oral sulodexide administration diminishes neo-vascularization, submesothelial thickening 
and EMT induced by exposure to PDF in a rat model. As there was no difference in VEGF at 
the protein level in the dialysate, we hypothesize that oral sulodexide inhibits VEGF locally 
by binding. 
 
2.1.2. Introduction 
Peritoneal dialysis (PD) is an accepted and established renal replacement modality [1, 2]. 
Whereas it is advocated as a first line technique, the most important limiting factor for its 
long-term use is the progressive reduction in dialytic efficacy and ultrafiltration. This 
decrease is due to a progressive degradation of structure and function of the peritoneal 
membrane (PM) [3–5]. The changes are highly comparable to those observed in diabetes and 
mainly consist of two distinct but concurrent processes: fibrosis with submesothelial 
thickening and neo-angiogenesis [6], leading to increased small solute clearance and 
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ultrafiltration loss, and finally to technique efficacy failure. Conceivably, these 
pathophysiologic similarities have been related to the presence of high concentrations of 
glucose and its degradation products [7, 8]. The non-physiology of dialysis solutions and the 
subsequent peritoneal failure have prompted the search for preventive options, one of these 
being the use of glycosaminoglycans (GAGs).  
Heparin is a GAG with a well-known anticoagulant activity [9], a property used in animal 
models of PD to maintain catheter patency and to prevent the development of peritoneal 
adhesions [10]. Heparin has a host of biologic actions beyond its role as an anticoagulant, 
including immunomodulating effects, antiproliferative effects, effects on the extracellular 
matrix, effects on angiogenesis and anti-inflammatory effects [9, 11, 12]. Low-molecular 
weight heparins can inhibit fibroblast growth factor (FGF) and vascular endothelial growth 
factor (VEGF) activity [13]. The PM is specifically subjected to inflammation, fibrosis and 
angiogenesis during the course of PD therapy, and some of these processes have been linked 
to VEGF [14–16]. All this provides ample rationale for the study of GAGs in PD.  
Heparin use is accompanied by serious side effects, such as bleeding tendency and can only 
be administered intraperitoneally or subcutaneously (s.c.), limiting its everyday use [17–19]. 
Therefore, alternative GAGs should be evaluated.  
Sulodexide is a highly purified mixture of GAG containing 80% low-molecular weight 
heparin and 20% dermatan sulphate [18–20]. The pharmacological behaviour of sulodexide 
differs substantially from unfractionated heparin and is mainly characterized by a prolonged 
half-life and a reduced effect on global coagulation and bleeding parameters. Sulodexide has 
been approved for human use and has been related to improvement of proteinuria and 
cardiovascular disease in diabetes [21–23]. Experiments using an intraperitoneal formulation 
in humans [24] or an s.c. formulation in rats [25] demonstrated a beneficial impact of 
sulodexide on the, respectively, functional and morphological properties of the PM. 
Sulodexide administration can thus potentially have a beneficial impact on PD patients 
through conservation of the integrity of the PM.  
As intraperitoneal or s.c. administration are both labour intensive and prone to generating side 
effects, such as peritonitis or local bleeding, it is important to test whether oral 
supplementation with sulodexide might be effective. The low-molecular weight of both 
sulodexide fractions allows for better oral absorption compared to heparin [19]. After oral 
administration of sulodexide in rats, pharmacodynamic effects are observed within hours, and 
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fluorescent sulodexide was observed in tissues of kidney and liver and in the endothelium of 
veins and arteries [26]. Several clinical studies demonstrated the safety and good tolerance of 
the drug in humans [27] and in animals [28]. Fracasso et al. [29] orally administered 
sulodexide to patients, showing a beneficial functional effect but without morphological 
exploration.  
For all these reasons, sulodexide appears to be a good candidate for an oral drug to protect the 
PM during PD. Therefore, this study analyses the effect of oral sulodexide on peritoneal 
function and anatomy in a rat model of peritoneal perfusion. 
 
2.1.3. Materials and methods 
 
Laboratory animals 
Forty-nine female Wistar rats (Iffa Credo, Brussels, Belgium) with a mean body weight of 
237 ± 11 g at the beginning of the experiment were investigated. They were kept under 
constant temperature and humidity in a 12 h controlled dark/light cycle and were allowed 1 
week of acclimatization before the start of the experiment. During the experiment, rats were 
housed in groups of four per cage. The ethical committee of experimental animals at the 
Faculty of Medicine and Health Sciences, Ghent University, Belgium, approved the protocol. 
 
Rat model  
A subcutaneous mini access port (PMINA-CBAS-C30 Soloport; Instech Solomon, Almere, 
The Netherlands) was implanted in a sterile manner in the neck under isoflurane anaesthesia 
(Forene®; Abott, Louvain-la-Neuve, Belgium). The attached polyurethane heparin-coated [10, 
30] catheter (Instech Solomon) was tunnelled into the abdominal cavity through the left flank. 
Antibiotics were provided to prevent peritonitis, as described earlier (oxacillin; 2.5 mg/day 
and gentamycin; 0.04 mg/day, Bristol-Myers Squibb, Brussels, Belgium) [10, 31]. In the first 
week after implantation, the catheter was flushed daily with 1 mL Earle’s Balanced Salt 
Solution at 37 °C (EBSS; Invitrogen, Merelbeke, Belgium) to allow wound healing. Then, the 
ports were punctured twice a day under sterile conditions to allow infusion of 10 mL 3.86% 
glucose peritoneal dialysate fluid (PDF) at 37 °C (Dianeal; Baxter SA, Lessines, Belgium). 
The area of the port was disinfected with ethanol 97% twenty seconds before puncture. 
Chapter 2: Peritoneal exposure to PD-fluids  
94 
Experimental design 
Three groups of experimental animals were studied.  
The animals of group Sul (n = 23) received peritoneal perfusion as described above. In 
addition, they received oral sulodexide (Biofer SpA, Medolla, Italy) mixed in powder form 
with their standard chew (rat and mice maintenance chow; Carfil, Oud Turnhout, Belgium) in 
a dose of 15 mg/kg/day. This dosage was based on those used in the clinical setting [29, 32] 
and animal studies [25, 33]. Before start of this study, food intake was monitored for 1 week. 
The lowest food intake weight was used to mix the sulodexide in. Rats in group Con (n = 20) 
received peritoneal perfusion, but no oral sulodexide and served as a positive control. The rats 
in group Sham (n = 6) were not surgically treated (no catheter and no peritoneal perfusion) 
and served as a negative control group.  
The weight of the rats was recorded weekly. Catheter patency and the integrity of the skin of 
the abdomen and around the port were evaluated twice a day. In the case of catheter 
obstruction, an attempt was made to infuse fluids under isoflurane anaesthesia. Rats in the 
Sham group were left uninstrumented during the 12 weeks. 
 
Peritoneal transport studies 
After 12 weeks of PDF exposure, a modified peritoneal equilibration test (PET) was used in 
all three groups to investigate peritoneal transport parameters. Briefly, rats were placed on a 
thermopad at 37 °C after anaesthesia with thiobutabarbital (Inactin®
For the PET test, plasma (P) and dialysate (D) samples were collected at time zero and after 
30, 60 and 240 min of dwell time for determination of creatinine (high-performance liquid 
chromatography), urea (urease), glucose (hexokinase), sodium (ion-selective electrodes 
calibrated for use in PDF), total protein (Biuret method) and VEGF [enzyme-linked 
immunosorbent assay (ELISA)] levels. 
 ; 100 mg/kg s.c.; Sigma, 
St Louis, MO). The trachea was intubated, the right jugular vein was cannulated for 
continuous saline infusion (0.9% NaCl, 3 mL/h), and the right carotid artery was cannulated 
for tension and blood sampling. A silicone catheter (Venflon, 18GA 1.77 IN; Becton-
Dickinson, Erembodegem, Belgium) was inserted into the peritoneal cavity 30 min after 
anaesthesia and 15 mL of 4% glucose PDF at 37 °C (BicaVera, Fresenius) was instilled (= 
time zero). 
At the end of all the PETs, PDF was recovered from the peritoneal cavity through the silicone 
catheter, after which the abdomen was opened by a midline incision to collect the remaining 
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dialysate and for tissue sampling. Net ultrafiltration was calculated and transport of low-
molecular weight solutes was evaluated by calculating the dialysate-to-plasma (D/P) ratios for 
creatinine, sodium and the D/D0
transport according to the method provided by Zweers et al. [34] to obtain an estimate of 
local production.  
 ratio for glucose at 0, 30, 60 and 240 min of dwell time. 
VEGF levels in the dialysate were quantified by ELISA (Quantikine, MMV00; R&D, 
Minneapolis, MN) according to the manufacturer’s instructions and corrected for diffusive 
Adequate attention was paid to maintain a hygienic environment and to prevent peritonitis. 
Furthermore, the tunnelled polyurethane catheter was removed in a sterile way and the tip 
was cultured. PDF samples were obtained for culture and white blood cell (WBC) counting in 
a Bürker chamber. Infection was arbitrarily defined as a positive dialysate culture with a 
dialysate WBC count >1000/mm3
from further analysis. 
 [35]. Rats positive for peritoneal infection were excluded 
 
Study of peritoneal morphology 
Parietal peritoneum (PP) and visceral peritoneum (VP) was carefully dissected in a 
standardized fashion in order to obtain the same anatomical region and to avoid mechanical 
trauma to mesothelial cells. The PP was collected at the contralateral side to the tip of the 
implanted catheter. Samples were immediately fixed in 4% neutral buffered formalin for 2 h 
at 4 °C, rinsed with phosphate-buffered saline and embedded in paraffin. Sections (5 µm) of 
the peritoneum were cut for histology with a Leica RM 2145 sliding microtome (Leica 
Microsystems, Nussloch, Germany).  
To determine the thickness of the PP, sections were sliced perpendicularly to the peritoneal 
surface and a classic Masson’s Trichome staining was performed. Double 
immunofluorescence stainings for alpha smooth muscle actin (α-SMA) and cytokeratin on VP 
sections were performed. These two stainings were executed as described previously [36].  
For visualization of blood vessels, adjacent VP sections were stained with monoclonal 
antibodies [anti-von Willebrand Factor (anti-vWF)] reactive with endothelial cells. Sections 
were deparaffinized, rehydrated and pretreated with Proteinase K (S3020-2; Dako, Heverlee, 
Belgium) for 7 min. Thereafter, sections were blocked for endogenous peroxidase for 30 min 
with 3% H2O2. After rinsing under running water, aqua dest (AD) and buffer [Tris-buffered 
solution (TBS) + Tween 0.05%], sections were incubated with UltraSense Block 
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(Immunologic kit, Klinipath, Olen, Belgium) for 10 min to avoid cross reactions. 
Subsequently, they were incubated with the primary antibody anti-FVIII (1/250, A0082, 
Dako) for 1 h, followed by incubation with the secondary antibody (Immunologic kit) for 10 
min and streptavidin peroxidase (Immunologic kit) for 10 min. 3,3’-diaminobenzidine (Dako) 
was used as the chromogenic substrate to visualize immunolabeling resulting in a brown 
precipitate. Finally, counterstaining was performed with Haematoxyline Mayer (Mallinckrodt 
Baker, Deventer, The Netherlands). Between every step, slides were rinsed in buffer solution. 
 
Morphometric analysis 
All slides were coded and blindly analysed by the same operator with an Olympus BX41 
microscope (Olympus, Aartselaar, Belgium). From each experimental animal, three peritoneal 
samples were analysed. For each sample of peritoneum, three sections were digitalized and 
quantified with a computerized image analysis system (CellD software; Olympus).  
The submesothelial thickness (micrometers) was measured using the Masson’s Trichome 
staining. Microvascular density of the vWF immunostainings was determined by counting the 
number of blood vessels (number per square millimeters) and by calculating the percentage of 
the stained area per section. The double a-SMA/cytokeratin staining was viewed with a 
fluorescence microscope (Axioscoop, Zeiss, Germany) and pictures were taken using CellF 
Software (Olympus Soft Imaging Solutions, Mu¨nster, Germany). A semiquantitative 
assessment was performed independently and blindly by two operators. Each section was 
screened to estimate the extent and distribution of colocalization of a-SMA and cytokeratin. 
Staining results were classified using a visual score: 0 = no co-localization at all, 1 = 
suggestive for co-localization, 2 = evidence of co-localization and 3 = clear colocalization 
and migration of mesothelial cells into the interstitium. The results were calculated as the 
mean of the individual scores of the two operators for each animal. 
 
Statistical analysis 
Data analysis was performed with SPPS version 15.0 (SPSS Inc,Chicago, IL). For all 
analyses, one-way analysis of variance for the three groups and post-hoc testing with Least 
Significant Difference was used. The results are expressed as mean ± SD. The significance 
level was set at P ≤ 0.05. 
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2.1.4. Results 
 
Technique survival  
During the experiment, the well-being of the animals was monitored daily and no apparent 
abnormalities were observed. Body weight was similar in the different experimental groups at 
all time points (data not shown). Technique survival was 100% in all groups.  
Two animals of group Sul were excluded because of positive dialysate culture (one 
streptococcus viridans, one with Bacteroides species), positive tip culture (Paecilomyces sp.) 
and increased dialysate leukocyte count. In the Con group, one dialysate culture yielded 
Corynebacterium species but without increased dialysate leukocyte count. 
 
Peritoneal transport studies 
Exposure to PDF (Sul and Con) reduced net ultrafiltration significantly after 240 min of dwell 
time as compared to Sham, but sulodexide did not have a protective effect (Figure 1A). 
In addition to the decrease of net ultrafiltration capacity, PDF in the Con group induced a 
significantly enhanced creatinine transport (Figure 1B) compared to Sham at every time point 
and compared to Sul group after 60 and 240 min. Addition of sulodexide partially prevented 
this enhancement of diffusive creatinine transport, because no significant differences in 
D/Pcreatinine
Glucose absorption was significantly increased in the Con compared to Sham group after 30 
and 60 min (Figure 1C).  
 were found between the Sul and Sham group.  
Sodium dip was less pronounced and earlier in the Con group versus the Sul and the Sham 
group (Figure 1D).  
Protein loss was significantly higher in the Con group versus the Sham and Sul group after 
240 min (Figure 1E). 
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Figure 1. Peritoneal Transport Parameters 
†P < 0.05 versus Sham, *P < 0.05 Con versus Sham; **P < 0.01 Con versus Sham, °°P < 0.01 Con versus Sul,  
°P < 0.05: Con versus Sul. Bars and line graphs represent mean ± SD. 
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Peritoneal morphology 
The Masson’s Trichrome staining showed a significant thickening of the submesothelial layer 
of the PP in the groups on peritoneal perfusion (Table 1 and Figure 2), with significant lower 
values in the Sul group compared to the Con group. Neo-angiogenesis was more expressed in 
the Con group as compared to the Sul group and the Sham group, without a difference 
between the latter two (Table 1 and Figure 3) and this both for the number of vessels per 
square millimeters as for the percentage surface stained with vWF. There was a higher score 
for epithelial-to-mesenchymal transition (EMT) in the Con versus Sul versus Sham group 
(Table 1 and Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Submesothelial thickness of parietal peritoneum 
(A) Significant differences were found between groups on 
peritoneal perfusion (Con: 19.9 ± 7.26 & Sul: 15.5 ± 4.86) and 
control group (Sham: 10.0 ± 1.57). *p<0.01 vs Sham,**p<0.05 vs 
Sham,°°p<0.05 vs Sul. Bars represent mean±SD. 
(B) Histological images of the Masson’s Trichome staining. 
(magnification, 400x) The submesothelial thickness of the parietal 
peritoneum was significant higher in the groups on peritoneal 
perfusion (Con & Sul), but with significant lower values for the Sul-
group, compared to the Con-group. 
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Figure 3. Vascularisation of the visceral peritoneum. 
Significantly less blood vessels (23.6±9.3 vs 31.8±12.6 vs 48.1±16.248.1±16.2) and % surface positive for 
vWF staining (0.28±0.17 vs 0.48±0.26 vs 1.05±0.64) were observed in the Sham vs Sul vs Con group. 
*p<0.01 vs Sham; °p<0.01 vs Sul; **p<0.01 vs Sham. Bars represent mean±SD.  
Pictures show representative Von Willebrand immunostainings of visceral peritoneum (magnification 
200x). 
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Figure 4. α-SMA, cytokeratin and a double staining for α-SMA and cytokeratin (+ DAPI nuclear 
staining) of the visceral peritoneum.  
Representative pictures are shown (magnification, 400x). Serial sections of the visceral peritoneum from 
Sham-rats (A-C), Sul-rats (D-F) and Con-rats (G-L) were stained for cytokeratin (A,D,G,J), α-SMA (B, E, 
H, K) and double stained for α-SMA  and cytokeratin (C, F, I, L). In the Sham-animals, only mesothelial 
cells stain for cytokeratin (A), only vascular smooth muscle cells stain for α-SMA (B) and virtually no α-
SMA/cytokeratin co-localization (C) occurs. In the peritoneal membrane of the Sul- and the Con-animals, 
α-SMA staining is found not only in the vascular smooth muscle layer of blood vessels, but also in 
submesothelial tissue (E, F & H, I resp.). In the Con-rats, cytokeratin staining is additionally found in the 
interstitial tissue (J,L). Co-localization of α-SMA and cytokeratin is pronounced in submesothelial tissue 
(I) and in the interstitial tissue (L).  
Arrows =co-localization. 
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Table 1. Histological and immunohistochemical analyses of the peritoneum. 
 
 
  
 
 
VEGF pathway 
VEGF levels in the dialysate were, after correction for diffusion, higher in the Con and Sul 
group as compared to the Sham group (9.3 ± 6.1 versus 7.8 ± 4.9 versus 1.5 ± 1.2, P = 0.02), 
but the difference between Con and Sul animals did not reach significance. 
 
Relationships 
Significant correlations were observed between the number of blood vessels and the 
functional PM parameters after 30 min of the PET: D/PCreatinine (r = 0.575, P < 0.01), 
D/D0glucose (r = - 0.525, P < 0.01) and D/Pprotein
No correlation was found between the vessel count and VEGF levels in the dialysate (r = 
0.381, P = 0.060), but after excluding the Sul group, a significant correlation was observed (r 
= 0.635, P < 0.050). VEGF correlated positively with the high transport rate of D/P
 (r = 0.598, P < 0.01).  
creatinine (r 
= 0.551, P < 0.01) and correlated negatively with D/D0glucose
  
 (r = - 0.420, P < 0.05) after 240 
min of PET. There was a weak correlation between the number of blood vessels and 
submesothelial thickness (r = 0.344, P < 0.05). EMT was not correlated with the number of 
blood vessels, but there was a correlation with submesothelial thickness (r = 0.405, P < 0.01). 
A weak negative correlation was detected between ultrafiltration and submesothelial 
thickness (r = - 0.393, P < 0.05). 
Sham Sul Con 
  / PD + Sulodexide PD 
vWF staining (% of surface) 0.276 ± 0.165 0.483 ± 0.263 1.05 ± 0.644
blood vessels (n/mm
a,b 
2 23.6 ± 9.27 ) 31.8 ± 12.6 48.1 ± 16.2
Submesothelial thickness (μm) 
b,c 
10.0 ± 1.57 15.5 ± 4.98 19.9 ± 7.26d 
EMT-score (0-3) 
a,e 
0.141 ± 0.185 0.704 ± 0.422 1.30 ± 0.628d 
 
b,c 
 
 aP < 0.01 versus Sham  
bP < 0.01 versus Sul  
cP < 0.001 versus Sham  
dP < 0.05 versus Sham  
eP < 0.05 versus Sul 
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2.1.5. Discussion  
In this study, an oral formulation of sulodexide was tested in a rat model for PD, based on 
previous observations of a beneficial impact of this GAG on the PM during PD, and in the 
hypothesis that sulodexide could inhibit the activity of VEGF in the PM [24, 25, 29, 37].  
We found a significantly worse peritoneal performance in the Con group by 12 weeks of 
exposure to PDFs, as evidenced by the increase of transport rate for creatinine, loss of 
ultrafiltration capacity and peritoneal tissue remodelling. Although no differences in net 
ultrafiltration were seen between the group with and without oral sulodexide administration, 
transport rates for creatinine and glucose and sodium sieving were better preserved in the 
sulodexide group. This functional improvement induced by sulodexide was associated with 
less neo-angiogenesis and reduced submesothelial thickening but not with a reduction of 
VEGF up-regulation in the dialysate.  
As we observed higher VEGF levels in the dialysate of animals treated with peritoneal 
perfusion versus Sham but no differences between the animals on peritoneal perfusion treated 
versus not treated with sulodexide, we hypothesize that sulodexide inhibits VEGF activity 
either by binding it or by inhibiting the interaction with its receptor. 
The role of VEGF in neo-angiogenesis during PD has been well established [34, 38]. Also in 
the current experiments, VEGF levels were higher in the animals submitted to peritoneal 
perfusion as compared to Sham animals. Structure–function relationship studies have shown 
that, both in rat models as in patients on long-term PD, loss of ultrafiltration capacity is 
associated with submesothelial thickening and the presence of neo-angiogenesis in the PM 
[39, 40]. For most people, exposure to glucose and especially glucose degradation products 
are the driving factors of the changes observed. However, also other factors can play a role 
[41]. Many additives and substances have been studied to counteract these alterations.  
In the present study, oral administration of sulodexide resulted in lower peritoneal transport 
rate of creatinine and glucose and more sodium sieving as compared to the control group, 
suggesting better preservation of the PM. This was in line with a lower microvascular density 
in the sulodexide group. Vessel count and functional membrane parameters were significantly 
correlated, which was also demonstrated by Vrtovsnik et al. [42]. 
Low-molecular weight heparin can inhibit the binding of different growth factors to their 
receptors, and hyaluronan, another GAG, is a known important regulator of growth and 
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migration of vascular endothelial cells and neoangiogenesis. Heparin fragments of < 18 
saccharides inhibit the activity of FGF and VEGF [13, 43, 44]. Pyda et al. [45] reported 
complexation of VEGF by heparin in patients presenting with acute myocardial infarction. In 
a rat model of oral administration of labelled sulodexide, fluorescent material was observed in 
the endothelium of veins and arteries [26, 46]. It can thus be hypothesized that oral 
sulodexide inhibits neo-angiogenesis by locally blocking the enhanced VEGF activity 
produced during PDF exposure. We observed that oral administration of sulodexide resulted 
in significantly lower neo-angiogenesis, but not in lower upregulation of VEGF at the protein 
level. These findings are compatible with the hypothesis that sulodexide interacts with the 
vascular effects of VEGF by either blocking the binding of VEGF to its receptor or by 
binding the VEGF molecule itself. This hypothesis is supported by our observation that 
VEGF levels and vessel count appeared to be significantly correlated, but only after 
excluding the sulodexide group. The data of the sulodexide group blur the correlation 
between VEGF and neo-angiogenesis, as the VEGF is present, but not active. Further 
experiments to explore the exact nature of this inhibition mechanism are warranted. 
Several authors have already tried to modify outcome of PD using GAGs, with conflicting 
results [24, 47–50]. Using a similar rat model of peritoneal perfusion as ours, Schilte et al. 
[51] failed to demonstrate a beneficial impact of heparin. However, Schilte et al. administered 
heparin intraperitoneally, while systemic activity of GAGs might be crucial to obtain the 
described pleiotropic effects. Indeed, the beneficial effects on PM damage after acute 
peritonitis were only observed when sulodexide was administered systemically by 
intramuscular injection and not when administered in the PDF [52]. Finally, the half-life of 
heparin is much shorter than that of sulodexide, so a once daily injection of heparin might be 
ineffective [19]. Sjoland et al. [53] demonstrated a reduction in D/Pcreatinine
 
, with an 
improvement in ultrafiltration capacity in a small human study of intraperitoneal heparin 
administration during 3 months. There was, however, a very high peritonitis rate in this study, 
making the results difficult to interpret. 
Oral administration of sulodexide did not result in differences in ultrafiltration capacity in the 
present study, despite a (beneficial) difference in angiogenesis and D/Pcreatinine. Breborowicz 
et al. [54] also found changes in transperitoneal permeability after intraperitoneal 
administration of hyaluronan, however, with an opposite pattern. Wang et al. [55] reported 
that intraperitoneal administration of hyaluronan reduced peritoneal fluid absorption without 
changing transperitoneal fluid transport in a rat model. All these observations raise the 
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suspicion that also changes in the physicochemical properties of the peritoneal interstitium 
take place when GAGs are administered and that the obtained effect depends upon the 
physicochemical properties of the substance used. Sulodexide is a negatively charged 
molecule, interstitial accumulation might hamper transport of water differently from that of 
non-polarized small solutes. It is, however, extremely difficult to visualize the presence of 
sulodexide in peritoneal tissue, as it is cleansed out during the normal processing of the tissue, 
so it was impossible to confirm this accumulation in our experiments. 
Breborowicz et al. demonstrated that hyaluronan had cytoprotective effects in an in vitro 
model of peritoneal mesothelial cells [54, 55]. Sulodexide also has anti-inflammatory 
properties. It is well-known that in animal models for PD, the presence of an indwelling 
catheter induces microtraumatization and inflammation [56]. It could thus be that sulodexide 
only inhibits this mechanical stress on the PM induced by the presence of the catheter. As we 
have no negative control group with an indwelling catheter, but without peritoneal perfusion, 
we cannot make any conclusion from our current study in that regard, however. 
We also observed a reduction of EMT indirectly, using a score for co-localization of α-SMA 
and cytokeratin and directly, by the lower degree of submesothelial thickening, itself a result 
of EMT. Although, for technical reasons, we were not able to further elaborate this, our 
observations fit with those of Breborowicz et al., who demonstrated a dose-dependent 
protective effect on healing of cultured monolayer cells after mechanical trauma, when 
sulodexide was added to the culture medium [57]. Others have demonstrated that certain 
GAGs inhibit Transforming Growth Factor (TGF)-β (over)expression at the transcription 
level, and it has been well established that up-regulation of TGF-β is one of the driving 
mechanisms of EMT and fibrosis [33, 58]. 
Although it can be seen as a limitation, we did not include a uraemic rat model in the current 
study. As uraemia per se can induce changes in peritoneal morphology [42, 51, 59] and, at 
least in our hands, a nephrectomy model can create large differences in states of uraemia, 
additional bias in the interpretation of the results would have resulted, which we wanted to 
avoid. It would be interesting to repeat the experiments in a uraemic model as described by 
Vrtovsnik et al.  
 
In conclusion, we have confirmed that PD induces significant damage to peritoneal tissues 
within 12 weeks, and in animals that received orally administered sulodexide, these changes 
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were less present. Neo-angiogenesis, submesothelial fibrosis and EMT were less pronounced 
in the group treated with oral sulodexide. Our data are compatible with the hypothesis that 
sulodexide inhibits VEGF activity at the local level and support further investigation of the 
longterm administration of sulodexide as a potential protective agent during chronic PD 
treatment. 
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3.1.1. Abstract 
Dietary salt intake has been linked to hypertension and cardiovascular disease through volume 
mediated effects. Accumulating evidence points to direct negative influence of salt intake 
independent of volume overload, such as cardiac and renal fibrosis, mediated through 
transforming growth factor beta (TGF-β). Epithelial-to-mesenchymal transition (EMT) has 
been implicated as a key process in chronic fibrotic diseases, such as chronic kidney disease 
or heart failure. The potential role of dietary salt intake on cell transdifferentiation has never 
been investigated.  
This study analysed the effect of dietary salt intake on EMT and fibrosis in the peritoneal 
membrane (PM) in a rat model. 
Twenty-eight Wistar rats were randomized to a normal salt (NS) or a high salt (HS) intake. 
NS and HS rats had free access to tap water or NaCl 2% as drinking water, respectively. After 
2 weeks, samples of peritoneum were taken, and TGF-β1
Dietary salt intake caused peritoneal fibrosis and thickening of the submesothelial layer and 
induced EMT as identified by colocalization of cytokeratin and α-SMA in cells present in the 
submesothelial layer. Peritoneal TGF-β
, Interleukin 6 (IL-6) and vascular 
endothelial growth factor (VEGF) mRNA expression were quantified with qRT–PCR. 
Fibrosis and submesothelial PM thickness were scored. EMT was evaluated using 
fluorescence staining with cytokeratin and alpha smooth muscle actin (α-SMA). 
1
High dietary salt intake induces EMT and peritoneal fibrosis, a process coinciding with 
upregulation of TGF-β
 and IL-6 mRNA expression were upregulated in the 
HS group. 
1
 
. 
3.1.2. Introduction 
Salt has been linked to hypertension for many years [1,2]. Initially, it was thought that the 
volume overload, induced by salt retention, was the main underlying mechanism and that this 
in turn was the driving factor for left ventricular hypertrophy. Recently, evidence has 
accumulated that dietary salt intake by itself, even without causing hypertension or volume 
overload, might be deleterious, resulting in cardiac remodelling, fibrosis and left ventricular 
hypertrophy [3,4]. Also in the kidney, it has been demonstrated that salt intake leads to 
enhanced glomerulosclerosis and deterioration of residual renal function [5–7]. It has been 
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postulated that upregulation of transforming growth factor beta 1 (TGF-β1) might be one of 
the underlying mechanisms. The effects of TGF-β1 seem to be diminished in the presence of 
nitric oxide (NO) [5], implying that salt mediated upregulation of TGF-β1
deleterious in subjects with NO deficiency [8], such as in uraemia [3].  
 might be even more 
TGF-β is a potent inducer of epithelial-to-mesenchymal transition (EMT) [9,10], a process 
which has recently been linked to chronic fibrotic diseases, such as chronic kidney disease, 
heart failure, lung and hepatic fibrosis [11–15]. In these diseases, EMT results in 
transdifferentiation of epithelial cells to myofibroblasts, which invade the interstitial space by 
transgression of the basal membrane and expand the extracellular matrix. The link between 
dietary salt intake and cellular transdifferentiation has, to our knowledge, never been 
investigated. 
In long-term peritoneal dialysis (PD) patients, both functional [16,17] and morphological 
[18,19] deterioration of the PM have been described. The morphological changes consist of 
neovascularisation, fibrosis [19] and EMT [20]. These negative effects have been related to 
exposure to glucose and glucose degradation products contained in the peritoneal dialysate, 
and to uraemia per se [16,21,22].  
TGF-β1 has been linked to glucose-induced enhanced senescence of mesothelial cells [23], 
peritoneal fibrosis and induction of EMT in the PM [24,25]. De Vriese et al. [21] have 
demonstrated that interaction of advanced glycation end products (AGE) with their cell 
surface receptor for AGE (AGE–RAGE interaction) in uraemia induces upregulation of TGF-
β1
The role of dietary sodium intake on the deterioration of the PM has however never been 
investigated. It is conceivable that patients who have a high dietary salt intake will also need 
more hypertonic glucose exchanges because they will drink more. Additionally, if high salt 
intake would lead to upregulation of TGF-β
, a process which they could also link to EMT.  
1
The present study has been undertaken to explore the effects of dietary salt loading on the PM 
in normal rats, with specific focus on EMT and fibrosis, and the role of TGF-β
 in the PM, in parallel to what has been shown 
for the heart and the kidneys, or an upregulation of vascular endothelial growth factor 
(VEGF), leading to neoangiogenesis as has been shown in the PM of PD patients, this would 
result in synergistic mechanisms leading to a rapid deterioration of the PM. 
1, VEGF and 
interleukin 6 (IL-6). 
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3.1.3. Materials and methods 
 
Laboratory animals 
Experiments were performed in 28 female Wistar rats (Iffa Credo, Brussels, Belgium), 
receiving care in accordance with the national guidelines for care and use of laboratory 
animals. The protocol was approved by the Ethical Committee of Experimental Animal 
Studies at the Faculty of Medicine and Health Sciences, Ghent University, Belgium. 
Study protocol 
The rats were randomly assigned to two groups: NS (normal salt intake) and HS (high salt 
intake). Each group was housed in separate cages. The NS group received normal rat chew 
(rat and mice maintenance chew, Carfil, Oud-Turnhout, Belgium) with a 0.1% salt content 
and free access to tap water. The HS group received the same rat chew, but had only free 
access to NaCl 2% as drinking water. Rats were weighed daily. After 2 weeks, rats were 
sacrificed. They were anaesthetized with thiobutabarbital (Inactin®
 
,100mg/kg s.c., Sigma, St. 
Louis, MO). The trachea was intubated to facilitate breathing, a carotid artery was cannulated 
for monitoring of arterial blood pressure and the abdomen was opened by a midline incision 
for tissue sampling. Samples of visceral peritoneum (VP) and parietal peritoneum (PP) were 
immediately fixed in a 4% phosphate buffered formaldehyde solution (pH = 7) (Klinipath, 
Olen, Belgium) and embedded in paraffin. The VP of the small and large bowel was entirely 
resected and together with biopsies of the PP, snapped frozen in liquid nitrogen and 
maintained at −80°C until analysis. 
(Immuno)histochemistry 
From all tissue samples, 5 μm sections were cut with a Leica RM 2145 sliding microtome 
(Leica Microsystems, Nussloch, Germany) for histology and immunohistochemistry.  
A Sirius Red staining (Klinipath, Geel, Belgium) was used to evaluate fibrosis in the VP. 
Sections of the VP were deparaffinized, rehydrated and stained with Giemsa. Subsequently, 
sections were washed and stained with 0.1% Sirius Red, resulting in a brick red staining of all 
fibrillary collagen.  
To determine the thickness of the PP, the sections were sliced perpendicularly to the 
peritoneal surface, and a classic Masson's trichrome staining was performed. Sections of the 
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PP were deparaffinized, rehydrated and stained with Haematoxylin Gill (Merck, Brussels, 
Belgium). Successively, sections went through a series of fluids [1% HCl (VWR, Leuven, 
Belgium), a ponceau (Sigma, Bornem, Belgium)-fuschin (VWR) mixture, phosphomolybdene 
acid and aniline blue (VWR)] to obtain the desired colour.  
Immunofluorescence stainings for alpha smooth muscle actin (α-SMA) and cytokeratin, as 
well as a double staining, were performed. Sections of VP were deparaffinized, rehydrated 
and pre-treated for antigen retrieval in Tris/EDTA (Tris[hydroxymethyl]aminomethane and 
[Ethylenedinitrilo]tetraacetic acid) (Acros Organics, Geel, Belgium) epitope retrieval solution 
(pH 9.0) at 96°C for 30 min. After cooling down, free aldehyde groups were blocked with 
NH4
Morphometric analysis 
Cl to block cross-linking of the antibodies (Ab) to inappropriate structures, and 1% 
BSA/TBS was used to block aspecific binding of the Ab. Subsequently, sections were 
incubated with the primary antibody: either a mouse monoclonal anti-human α-SMA Ab 
(M0851, Dako, Heverlee, Belgium) and/or a polyclonal rabbit anti-cow cytokeratin Ab 
(Z0622, Dako), followed respectively by a secondary goat anti-mouse Ab labelled with a 
green fluorescent dye (A-11017, Invitrogen, Merelbeke, Belgium) and/or a goat anti-rabbit 
Ab labelled with a red fluorescent dye (A-11072, Invitrogen). Sections were incubated shortly 
with a 4',6-diamidino-2-phenylindole (DAPI) nuclear stain (Invitrogen) and finally mounted 
with Vectashield mounting medium (Labconsult, Brussels, Belgium). 
Morphometric measurements of the stainings were made by a blinded operator with an 
Olympus BX41 microscope (Olympus, Aartselaar, Belgium) at magnification x400. From 
each experimental animal, three peritoneal samples were analysed. For each sample, three 
sections were analysed quantitatively with a computerized image analysis system (CellD 
software, Olympus). For the Sirius Red staining, the total amount of connective tissue (%) in 
the VP was determined. For the Masson's trichrome staining, the thickness of the PP was 
measured. The double α-SMA/cytokeratin staining was viewed with a fluorescence 
microscope (Axioscoop, Zeiss, Germany) and pictures were taken using CellF Software 
(Olympus Soft Imaging Solutions, Germany). A semi-quantitative assessment was performed 
independently by two blinded operators. Each section was screened to estimate the extent and 
distribution of colocalization of α-SMA and cytokeratin. Staining results were classified from 
0 to 3: 0 = no, 1 = mild-, 2 = moderate- and 3 = pronounced colocalization and migration of 
mesothelial cells into the interstititium. The results were calculated as the mean of the 
individual scores of the two operators for each sample. 
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IL-6/TGF-β1
Tissues were homogenized in TRI-Reagent (AB, Applied Biosystems, Foster City, CA, USA) 
on ice using a PowerGen 125 Tissue Homogenizer (Fisher Scientific). An aliquot of 
homogenate was separated into aqueous and organic phases by chloroform (Sigma) addition 
and centrifugation. RNA was precipitated from the aqueous phase by addition of isopropanol 
/VEGF mRNA determination 
(Sigma), washed with ethanol (MERCK) and solubilized. Concentration and purity of the 
extracted RNA were determined by spectrophotometry (UV-DU64 spectrophotometer, 
Beckman). Each sample was confirmed for integrity using the Agilent 2100 BioAnalyzer 
(Agilent Technologies, Santa Clara, CA, USA). Reverse transcription was performed by using 
the High Capacity cDNA Reverse Transcription kit (AB). Thermal cycling conditions were 
25°C (10′), 37°C (120′), 85°C (5″) and 4°C (∞). All cDNA samples were stored at −20°C 
until analysis.  
The expression of IL-6, TGF-β1 and VEGF mRNA was quantified by using the 7900HT Fast 
Real Time PCR System (AB). The thermal profile consisted of two hold steps, one at 50°C 
(2′) and one at 95°C (10′), followed by 40 cycles × [95°C (15″), 60°C (1′)]. RT–PCR 
efficiencies for each assay were calculated using the formula: Efficiency = [10(1/slope)] − 1. 
Samples and endogenous control were amplified in separate wells in a 96-well plate. The 
samples were run in triplicate and normalized to actin glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) levels, which was used as the endogenous control (reference gene). 
Pre-designed and labeled primer/probe sets were purchased from AB (TaqMan® Gene 
Expression Assays). The relative expression compares mRNA expression levels of the genes 
of interest (IL-6, TGF-β1
 
, VEGF) to the expression levels of the endogenous reference gene 
(Ref; GAPDH) according to the ΔΔCt method. In this method, the cycle in which the 
fluorescence level crosses a threshold value of fluorescence, during the exponential phase of 
amplification, is determined. As the fluorescence is directly correlated to the amount of 
double-stranded DNA present in each amplification cycle, the number of cycles needed to 
reach this level can therefore be used to calculate relative amounts of starting transcript 
mRNA. These values are expressed as relative values to an endogenous reference (= an 
internal control gene) to correct for differences in transcription rate and sample size between 
animals. Normalized relative quantity (NRQ) values were calculated using the following 
formula, as described previously by Pfaffl [26]: 
 sample)(control
refΔCt)ref(E
sample)(control
targetΔCt)target(E NRQ
−
−
=
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NRQ values from HS rats were compared to those from NS rats and expressed as relative 
increases (fold increase) between groups. 
 
Statistical analysis 
Data analysis was performed with SPSS version 15.0 (SPSS Inc., Chicago, USA). Normal 
distribution of data was tested using Kolmogorov–Smirnov testing. Data are accordingly 
presented as mean ± standard deviation (SD). Normally distributed data were compared with 
the Student's t-test for independent samples. P-values < 0.05 (two-tailed probability) were 
considered as significant.  
The increase in relative mRNA expression between NS and HS was calculated, and 95% 
confidence intervals (CI) were determined. Hereto, the natural log transformation of the NRQ 
was calculated, the difference of the mean between the test group and the control group was 
calculated, and this value was used as the exponent of 2, resulting in the fold increase with its 
corresponding 95% CI. For the NS group, data of the NS were used both for test and control, 
which theoretically should result in a mean difference of zero, and thus a 1-fold increase in 
mRNA expression. 
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3.1.4. Results 
 
General data of laboratory animals (Table 1) 
Mean body weight of the rats was 213 ± 7 g. After 2 weeks, rats of the HS group had a lower 
weight compared with the rats of the NS group. Blood pressure after 2 weeks was not 
different between the HS and NS groups. Haematocrit levels were significantly lower in the 
HS group after 2 weeks. Mean daily water intake in the HS group was 62.5 ml/rat, resulting in 
an extra dietary salt load of 1.25 g/day/rat. 
 
 
 
Peritoneal morphology 
Sirius Red staining of collagen was significantly more pronounced in the HS rats than in the 
NS rats. This was evident both in the submesothelial compact zone and in the interstitial 
tissue (18.8 ± 3.5 vs 24.7 ± 5.8% of total tissue in the NS vs HS group, respectively; P < 0.01) 
(Figures 1 and 2). The Masson's trichrome staining showed a significant thickening of the 
submesothelial layer of PP in the HS group (13.7 ± 3.2 vs 18.7 ± 3.7 μm in the NS vs HS 
group, respectively; P < 0.001) (Figures 3 and 4).  
Staining for the epithelial marker cytokeratin was confined to the mesothelial cell layer in all 
NS animals. In the HS animals, an extensive additional staining was observed in the 
submesothelial tissue. Staining for α-SMA was limited to the muscularis of the blood vessels 
in all the NS rats, but was also found in submesothelial areas in HS rats (Figure 5). Double α-
SMA/cytokeratin staining with fluorescence was virtually absent in all the NS animals, but 
was significantly prominent in HS animals (score 0.25 ± 0.25 vs 1.22 ± 0.32 in the NS vs HS 
group, respectively; P < 0.001) (Figure 6). 
  Normal Salt High Salt p-value 
  n = 14 n = 14 
 Initial Body Weight (g) 211.9 ± 9.1 214.0 ± 5.9 p = NS 
Body Weight (g) after two weeks 234.9 ± 19.1 217.2 ± 11.5 p < 0.01 
Blood Pressure after two weeks (mmHg) 140.4 ± 22.0 137.5 ± 15.3 p = NS 
Haematocrit level (%) 46.3 ± 1.7 44.2 ± 1.8 p < 0.01 
Table 1. Characteristics of experimental animals 
 
Chapter 3: Exposure to a forgotten uraemic toxin 
124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
Figure 1.  
Sirius Red Staining of collagen in the visceral peritoneal membrane (magnification x400). 
Prominent submesothelial and interstitial fibrosis was observed in the ‘high salt’ (C & D) 
animals, compared with the ‘normal salt’ animals (A & B).  
 
Figure 2.  
The amount of connective tissue in the visceral peritoneal 
membrane was significantly different between the ‘normal 
salt’ (18.8 ± 3.5%) group and the ‘high salt’ (24.7 ± 5.8%) 
group (*P < 0.01).  
Data are expressed as mean ± SD for groups of 14 rats.  
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Figure 3.  
Masson’s trichome staining of the parietal peritoneal membrane (magnification x400).  
The submesothelial thickness of the parietal peritoneum was increased in the ‘high salt’ (HS, panel B) 
group vs the ‘normal salt’ group (NS, panel A).  
 
Figure 4.  
Submesothelial thickness of the parietal peritoneal 
membrane was significantly different between the ‘normal 
salt’ (13.7 ± 3.2 µm) group and the ‘high salt’ (18.7 ± 3.7 
µm) group (P < 0.001).  
Data are expressed as mean ± SD for groups of 14 rats.  
Chapter 3: Exposure to a forgotten uraemic toxin 
126 
 
 
 
 
 
 
 
 
 
 
Figure 5.  
α-SMA-, Cytokeratin- and a double staining for α-SMA and Cytokeratin (magnification: x400). Serial sections of 
the visceral peritoneum from ‘normal salt’ (controls) rats (A-C) and ‘high salt’ rats (D-I) were stained for α-SMA 
(A,D,G), cytokeratin (B,E,H) and double stained for α-SMA and cytokeratin (C,F,I). In the control rats, only 
vascular smooth muscle cells stain for α-SMA (A), only mesothelial cells stain for cytokeratin (B) and no α-
SMA/cytokeratin colocalization (C) occurs. In the peritoneal membrane of the ‘high salt’ animals, α-SMA 
staining is found not only in the vascular smooth muscle layer of blood vessels, but also in submesothelial tissue 
G). Cytokeratin staining (E) is visible in the mesothelial cells and is additionally found in the interstitial tissue. 
Co-localization of α-SMA and cytokeratin (F,I) is pronounced in submesothelial tissue. Thick arrow, 
colocalizationn.  
 
Figure 6.  
Semi-quantitative scoring for colocalization of 
α-SMA and cytokeratin. Double α-
SMA/cytokeratin staining was virtually absent 
in the NS animals, but was significantly 
prominent in the HS animals (score 0.25 ± 
0.25 vs 1.22 ± 0.32, in the NS vs HS group 
respectively, P < 0.001). Scoring was done by 
two independent blinded observers for three 
samples of each experimental animal as 0, no 
colocalization; 1, mild colocalization; 2, 
moderate colocalization; 3, strong 
colocalization. 
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mRNA expression of IL-6, TGF-β1
Expression of IL-6 mRNA was upregulated 4.25 (95% CI 2.22–8.13) times in the HS versus 
the NS group in the VP, and 1.94 (95% CI 1.37–2.75) times in the PP. Expression of TGF-β
 and VEGF 
1
 
 
mRNA was upregulated 2.10 (95% CI 1.31–3.37) times in the HS vs the NS group in the VP, 
and 1.32 (95% CI 1.08–1.60) times in the PP. Expression of VEGF mRNA was not 
upregulated in the VP nor in the PP (Figure 7). 
 
 
 
 
 
 
3.1.5. Discussion 
This study demonstrates that dietary salt intake by itself induces EMT of mesothelial cells as 
identified by colocalization of cytokeratin and α-SMA in the submesothelial layer, fibrosis of 
the PM as documented by Sirius Red staining and a thickening of the submesothelial layer on 
Masson's trichrome staining. Concordant with this, peritoneal TGF-β1
dietary salt loading induces EMT and peritoneal fibrosis, potentially by upregulation of TGF-
β
 and IL-6 mRNA 
expression were increased, but not VEGF mRNA expression. These observations suggest that 
1
It is now progressively accepted that EMT underlies epithelial degeneration and fibrogenesis 
in some chronic degenerative, fibrotic disorders, in particular of the heart [15], the kidney 
[11], the lung [14] and the liver [13]. TGF-β
 and IL-6 mRNA. 
1 is able to induce all the basic steps of EMT: loss 
Figure 7.  
mRNA expression of IL-6, TGF-β1 and VEGF: fold change high salt (HS) versus normal salt (NS). ‘Normal salt’ 
group = control group, taken as a standard. Fold change of the NS group = 1. In the ‘high salt’ group, expression 
of IL-6 mRNA was 4.25 times [CI: (2.22, 8.13)HS vs (0.60, 1.65)NS] more upregulated in the visceral peritoneum 
(VP) and 1.94 times [CI: (1.37, 2.75)HS vs (0.71, 1.39)NS] more upregulated in the parietal peritoneum (PP). TGF-
β1 mRNA expression was 2.1 times (CI: [1.31, 3.37]HS vs [0.79, 1.26]NS) more upregulated in the VP and 1.32 
times [CI: (1.08, 1.60)HS vs (0.75, 1.31)NS] more upregulated in the PP. VEGF mRNA expression was 1.74 times 
[CI: (0.97, 3.12)HS vs (0.81, 1.22)NS] higher in the VP, but was not different between the two groups in the PP 
[CI: (0.84, 1.00)HS vs (0.83, 1.19)NS].  
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of epithelial adhesion properties, de novo α-SMA expression and actin reorganization, 
disruption of basement membrane and enhanced cell migration and invasion capacity [27]. 
Also in the PM, there are several lines of evidence that TGF-β1 plays a pivotal role in EMT 
and enhanced fibrosis. Margetts et al. used an adenoviral vector to increase TGF-β1 
expression in a rat model of PD [24]. By day 28, a substantial thickening of the PM was 
observed. Further experiments indicated that overproduction of TGF-β1 resulted in an 
increase in expression of genes associated with EMT and fibrosis, such as those regulating 
type I collagen A2, α-SMA and the zinc finger regulatory protein Snail [25]. Seven to 
fourteen days after exposure to TGF-β1
In our experiments, there was clear EMT of the peritoneal membrane in the rats fed with a 
high salt diet, as we observed colocalization of cytokeratin and α-SMA, as a hallmark of 
transdifferentiation of mesenchymal cells. In addition, these cells were localized in the 
submesothelial cell layer, as a sign of their transgression through the basal membrane with 
beginning invasion of the extracellular matrix. 
, appearance of epithelial cells in the submesothelial 
zone could be demonstrated. This phase was associated with disruption of the basement 
membrane and increased expression of matrix metalloproteinase 2. 
To our knowledge, this is the first observation of a link between dietary salt intake and EMT 
of the peritoneal membrane. 
So far, it is unclear how salt upregulates TGF-β1 expression. Ying and Sanders suggested that 
salt-induced shear stress in glomeruli activates tetraethylammonium-sensitive potassium 
channels, resulting in enhanced TGF-β1 production [7]. More recently, the same group 
demonstrated that dietary salt induces the activation of proline-rich tyrosine kinase-2 (Pyk2) 
and identified c-Src as an important binding partner of Pyk2 in dietary salt-mediated 
production of TGF-β1. Their data support the hypothesis that activation of Pyk2 recruits and 
activates c-Src and that this complex participates integrally in the vascular production of 
TGF-β1 in response to dietary salt in the rat [28]. Others have made a link with digitalis-like 
substances, such as marinobufagenin, which tend to be upregulated by salt loading [29,30] 
and result in enhanced formation of procollagen in the heart [31]. Digitalis-like substances 
block the Na/K-ATPase pumps, and thus increase the intracellular Ca2+
Angiotensin II stimulates extracellular matrix protein synthesis through induction of TGF-β in 
rat mesangial cells [32]. In addition, there is accumulating evidence that intracellular 
 concentration, which 
can activate calcium-dependent and downstream pro-fibrotic pathways.  
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angiotensin II plays an important role in renal cellular growth and fibrotic responses by 
activating NF-κB signalling, which is also on the final common pathway of the TGF-β1
Another potential mechanism is that the creation of local hyperosmolarity in the gut activates 
a tonicity-responsive enhancer binding protein (TonEBP)-mediated response. TonEBP 
activates osmoprotective genes to ensure cell function in hostile environments with increased 
interstitial tonicity, such as the renal medulla [37] and the lymphatic system [38]. A recent 
paper [39] showed that high salt intake increases protein expression of e.g. VEGF in 
macrophages in the subcutaneous tissue through activation of TonEBP. If such a 
hyperosmolarity-driven response would exist in the gut, it would be conceivable that this can 
be one of the mechanisms of EMT and the changing peritoneal morphology during long-term 
PD, where the peritoneum is exposed to hypertonic solutions.  
 
pathway [33]. Several studies have demonstrated that high salt intake decreases circulating 
levels of angiotensin II, but activates the tissue renin-angiotensinaldosterone system (RAAS) 
[34,35]. In salt-sensitive rats, a high salt intake resulted in increased intrarenal RAAS activity, 
associated with renal hypertrophy, fibrosis and damage [34]. Liang and Leenen demonstrated 
that fibrosis under these conditions of salt loading and high intrarenal RAAS activity could be 
prevented by angiotensin I converting enzyme (ACE)-inhibiting drugs [35]. This might 
explain why use of ACE inhibitors has a positive impact on PM morphology [36]. 
Further elaboration of this exciting hypothesis is certainly warranted, as it would imply that 
changing glucose for another hyperosmolar osmotic agent will not avoid the long-term 
peritoneal damage observed during PD.  
Next to TGF-β1
It is not clear how salt intake upregulates IL-6 expression. It might be that upregulation of 
TGF-β
, IL-6 expression is also linked to PM degeneration and fibrosis [40] and this 
was the case as well in the present study.  
1 leads to upregulation of IL-6. In vitro experiments already showed that TGF-β1 can 
induce IL-6 production in human myoblasts in a dose- and time-dependent manner [41]. This 
finding is in agreement with studies which report similar in vitro results in other cell types: 
TGF-β1 increases IL-6 mRNA levels in cultured thymus epithelial cells [42] and astrocytes 
[43] and IL-6 protein secretion in bone marrow stromal cells [44]. A recent paper by Leung et 
al. showed no clear association between upregulation of TGF-β and IL-6 in cultured human 
peritoneal mesothelial cells (HPMCs)[40]. However, the subtle and complex interplay of 
different cell types in vivo cannot be completely mimicked in vitro with one single cell type. 
In our experiments, there was a slight upregulation of VEGF mRNA in the visceral, but not in 
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the parietal membrane. This could point to a mechanism where the upregulation of TGF-β1
Adipocytes are ubiquitous in peritoneal tissue, and it is hypothesized that they can be an 
important source of cytokine secretion, including IL-6 and TGF-β [46,47]. In our study, salt 
intake induced a more pronounced upregulation of IL-6 and TGF-β
 
and IL-6 induces upregulation of VEGF, as in the study by Margetts et al., [45] rather than to 
a direct upregulation of VEGF by the enhanced dietary salt intake. Also here, upregulation of 
TonEBP, by creation of a hypertonic environment in the gut, might be involved [39]. 
1
Many experiments considering well-defined signaling pathways, e.g. in an in vitro setting, use 
purified stimulating factors in high concentrations, which do not represent the biological 
situation where a complex interplay of different pathways and cells is possible.  
 expression in the VP, 
where adipocytes are abundant, as compared to the PP, where less adipocytes are present. 
In our model, the only intervention was an increased dietary salt intake, but nevertheless, the 
resulting effects on EMT were still as impressive.  
Of course, the pathways leading to these observations need further elaboration. Potential 
interventions are the use of inhibitors of the renin-angiotensin system, of TGF-β1
needs further exploration. 
 and/or of 
TonEBP. Also the potential role of adipocytes and of macrophages infiltrating adipose tissue 
It is surprising that the effects of salt intake appeared so rapidly, after only 2 weeks of 
exposure. However, Ying and Sanders [7] also demonstrated enhanced renal fibrosis and 
glomerulosclerosis linked to upregulation of TGF-β after 15 days of salt loading in rats, and 
effects on the vasculature even after 4 days [48]. Machnik et al. [39] found important changes 
in the subcutaneous tissue after 2 weeks of salt loading in rats. All these experiments point out 
that effects of high salt intake seem to appear very rapidly. 
Finally, the question arises in how far our findings impact the application of PD which is a 
well-established renal replacement modality.  
Unfortunately, its longevity as a technique is restricted by functional and morphological 
deterioration of the PM over time [16,18,19,49]. It has always been puzzling why some 
patients do and others do not develop such morphological alterations. Although deterioration 
of the PM is mostly attributed to the exposure to PD fluids and peritonitis [16,50–52], large 
differences in PM structure and function can be found already at the start of PD, as is apparent 
both from morphological studies, such as the PD biopsy registry [19], and from functional 
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studies [16,53]. So far, this has been explained by differences in comorbidities such as 
diabetes, genetic background and/or uraemia [54–56].  
Hence, the changes over time of the PM in PD patients are not exclusively induced by the 
exposure to PD fluids and inflammation. Our study adds dietary salt intake to the underlying 
mechanisms, even without exposure to PD fluids. This finding becomes even more relevant in 
view of the need for more hypertonic glucose, which by itself is damaging to the PM, to 
counter volume overload in the case of high salt intake, thus initiating a synergistic pathway 
to a faster deterioration of the PM. This synergism needs further investigation.  
As such, our findings of peritoneal fibrosis and EMT of mesothelial cells induced by dietary 
salt intake are of direct clinical relevance for patients on PD. Dietary salt restriction is thus of 
importance in patients with chronic kidney disease, even during the pre-dialysis phase.  
In conclusion, dietary salt intake in non-uraemic rats induced EMT and peritoneal fibrosis. 
This was correlated with an upregulation of TGF-β1
 
 and IL-6 mRNA, which could be the link 
between dietary salt intake and EMT. 
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4.1.1. Abstract 
Although protein-bound uremic retention solutes are recognized as 1 of the 3 main categories 
of uremic retention solutes, they only recently have been submitted to thorough analysis. In 
vitro and ex vivo data link both p-cresyl sulfate and indoxyl sulfate, two of the main 
compounds of this solute group, to negative impact on the cardiovascular system and 
progression of kidney failure. Recent in vivo observational data also relate concentration of 
these compounds to survival outcome, inflammation, and vascular disease in different, even 
moderate, stages of chronic kidney disease.  
Removal by different dialysis strategies, even high-flux hemodialysis, is difficult, and only by 
applying convection, some improvement of removal has been obtained. The other strategy 
with the potential to decrease concentration is by influencing intestinal generation and/or 
absorption. The sorbent Kremezin (AST-120) has been shown in controlled studies to 
decrease protein-bound solute concentration. In pilot controlled studies, AST-120 has been 
shown to be superior on outcome parameters to placebo. Results from large randomized trials 
are awaited, before these data can be considered as solid enough to warrant the 
recommendation to use these compounds for overall therapeutic purposes. 
 
4.1.2. Introduction 
For reasons of convenience, uremic retention solutes are subdivided into 3 groups, depending 
on the physicochemical characteristics influencing their removal by dialysis1: (1) the small 
water-soluble compounds, with urea as a prototype; (2) the larger peptides (molecular weight 
> 500 Da), also named middle molecules, with β2
In this review,we will summarize the most important in vitro and in vivo data suggesting their 
toxicity; in the second part of this text, we will discuss therapeutic options for enhancing their 
removal and/or decreasing their concentration. 
-microglobulin as a prototype; (3) the 
proteinbound solutes, with the groups of indolic and phenolic compounds as prototypes. 
Among these, the protein-bound solutes have been the ones to receive the least attention until 
lately, possibly because strategies enhancing their removal were scanty and became identified 
only recently.  
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4.1.3. In Vitro and In Vivo Data 
A host of protein-bound retention solutes have been identified, mostly during recent years, 
and many of these interfere with essential biochemical functions (Table 1).2
 
 In this section, 
we will essentially focus on p-cresyl sulfate and indoxyl sulfate, the two protein-bound 
compounds that have recently received most attention. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.3.1. p-Cresyl Sulfate 
Until recently, studies on cresol and its derivatives had been focusing on p-cresol because it 
was believed to be the main compound of this family circulating in the body in uremia.3 A 
few years ago, it became apparent that the generation of p-cresol in uremic plasma was an 
artifact, due to hydrolysis of more complex conjugates as a consequence of sample 
acidification for deproteinization.4-6
In reality, conjugates were present, of which p-cresyl sulfate was the most important one. 
While p-cresol had been shown to be an immune inhibitor,
  
7 p-cresyl sulfate essentially 
activates leukocytes,8 pointing to the potential of this compound to contribute to vascular 
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damage. Further studies also revealed a role of p-cresyl sulfate in endothelial microparticle 
release, another indicator of vascular damage.9
Observational trials demonstrated a relationship between the concentration of p-cresol, in that 
setting acting as a surrogate for p-cresyl sulfate, and clinical outcomes.
  
10,11 Only recent 
studies showed a similar relationship with outcomes for the genuine compound, p-cresyl 
sulfate.12 A study byWang et al. also demonstrated a similar relation with coronary artery 
disease in patients with no or only moderate degrees of renal failure,13 suggesting that protein-
bound solutes might play a role as well in populations not suffering of advanced stages of 
chronic kidney disease.14
Interestingly, a recent study by Eloot et al. demonstrated an extremely poor correlation 
between the concentration of p-cresyl sulfate and estimated glomerular filtration rate (eGFR), 
pointing to the fact that concentration might be influenced not only by glomerular filtration 
rate but also by other, essentially metabolic, factors (see later text).
  
 
15 
4.1.3.2. Indoxyl Sulfate 
The indole indoxyl sulfate has been linked in vitro to almost every element at play in the 
generation of cardiovascular damage: the compound is proinflammatory16; increases 
osteoblastic resistance to parathyroid hormone,17 which might contribute to vascular 
calcification; increases endothelial microparticle release18; increases the adhesion of 
leukocytes to the endothelium19; enhances the proliferation of smooth muscle cells20; and 
increases cardiac fibrosis.21 Ex vivo, it increases vascular calcification per se in Dahl salt–
sensitive hypertensive rats.22 Indoxyl sulfate has also been related to kidney damage and 
progression of renal failure.16
Hence, these in vitro and ex vivo data point to an important impact of indoxyl sulfate on many 
aspects of cardiovascular disease. The question can be raised whether this is translated into 
clinical data in vivo. Remarkably enough, this aspect has been studied only recently. In a 
study by Barreto et al., indoxyl sulfate was related both to aortic calcification and mortality.
  
23 
Lee et al. demonstrated a correlation between indoxyl sulfate and interleukin-6.
 
24 
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4.1.4. Removal  
4.1.4.1. Dialysis and Related Strategies 
Up till recently, data on the removal of the protein-bound compounds have been deceiving. 
High-efficiency dialysis by high-flux membranes was not superior to standard low-flux 
dialysis,25 and long slow dialysis, which had a definite impact on the removal of so-called 
difficult-to-remove compounds, such as phosphate and β2-microglobulin,26 had no impact on 
protein-bound molecules.27 On the contrary, daily dialysis resulted in a long-term decrease of 
predialysis concentration.28 Only recently it was demonstrated that convective strategies under 
optimal conditions could remove more protein-bound compounds than conventional or high-
flux hemodialysis: compared with low-flux hemodialysis, predilution on-line hemofiltration 
was superior for decreasing the predialysis concentration of several protein-bound 
molecules29; in acute experiments, convective strategies were superior to high-flux 
hemodialysis with regard to intradialytic reduction rates30,31; postdilution hemodiafiltration 
was superior to predilution hemofiltration31; and in the long term, postdilution 
hemodiafiltration decreased predialysis concentration of protein-bound molecules, as 
compared with high-flux hemodialysis.32 Although most of these effects were significant, the 
long-term impact on concentration was only moderate,29,32
 
 leaving openings for alternative 
removal strategies. 
4.1.4.2. Absorption/Adsorption 
One aspect of protein-bound solute removal that has been assessed successfully during recent 
years has been related to methods pursuing elimination of these solutes through the 
intestine.33
In fact, both p-cresol and indole are generated in the intestine after metabolism of amino acids 
by the intestinal flora. Owing to changes in assimilation, generation of these mother 
compounds is even increasing as renal function regresses.
  
34 
Protein-bound solute concentration can be decreased through this intestinal process by dietary 
protein restriction, by changing metabolic capacity of intestinal flora after administration of 
probiotics or prebiotics, and by therapy with specific sorbents.  
They are then further conjugated 
in the intestinal wall and/or the liver to the currently known sulfates and glucuronides. 
Among these therapies, protein restriction has been shown to be efficient35; however, because 
of the risk of malnutrition, it is considered with care. More appealing approaches are 
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prebiotics and probiotics.36,37
However, the sorbent AST-120 (Kremezin, Kureha, Tokyo, Japan) not only impacts on the 
concentration of indoxyl sulfate
 All these approaches decrease the concentration of protein-
bound solutes, but none of them have been demonstrated to improve hard outcome 
parameters. 
38 and of other protein-bound solutes,39 but, more importantly, 
also was shown to postpone the start of dialysis,40 the progressive decline of eGFR,41 and 
survival outcomes after dialysis was started.42
Although most of these studies are of limited extent, and some of them may be flawed, they 
all point into the same direction; therefore, results of more extended controlled studies are 
anxiously awaited. 
  
It is conceivable that extracorporeal adsorptive strategies could also play an important role in 
this context. Pilot studies on fractionated plasma separation and adsorption (Prometheus 
[Fresenius Medical Care, Bad Homburg, Germany]—an artificial liver setup) in patients with 
chronic kidney disease showed a strong adsorptive impact on protein-bound uremic solutes by 
the resins involved in this strategy.43 However, this effect was jeopardized by a strong risk for 
thrombotic complications, probably due to simultaneous elimination of antithrombotic 
factors.
 
44 
4.1.4.3. Peritoneal Dialysis 
In peritoneal dialysis, absolute removal of protein-bound molecules such as indoxyl sulfate 
and p-cresyl sulfate is substantially lower than with hemodialysis.45,46 Nevertheless, plasma 
concentrations are the same (indoxyl sulfate)45 or even lower (p-cresyl sulfate),45,46 suggesting 
that elements other than dialysis removal are at play, such as intestinal or metabolic factors.
 
47 
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4.1.5. Conclusions 
More and more data suggest a cardinal role of protein-bound uremic toxins in uremic toxicity 
and especially in cardiovascular damage. Translating these in vitro and ex vivo findings into 
the clinical situation also provides more and more data suggesting an association between 
protein-bound solutes and outcome.  
Removal by dialysis strategies is limited but can be optimized by applying convection. 
Alternative options to be considered are altering intestinal metabolism and/or applying 
adsorption. Especially, controlled data obtained with the sorbent Kremezin suggest a positive 
impact of adsorption of protein-bound solutes on outcome parameters; therefore, results of 
more extended controlled trials are anxiously awaited. 
Metabolic factors play a remarkable role in influencing concentration, as also suggested by 
the highly different degrees of correlation between the concentration of these solutes and 
eGFR. 
 
4.1.6. Practical Application 
Identification of protein-bound uremic retention solutes and their pathophysiologic role has 
resulted in their classification according to importance. The next step is to evaluate whether 
improved removal of the most relevant solutes would result in better outcomes. 
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4.2.1. Abstract 
Both leukocyte activation and endothelial damage contribute to cardiovascular disease, the 
principal cause of morbidity and mortality in chronic kidney disease. In vitro and in vivo data 
link several protein-bound uremic retention solutes to cardiovascular damage. However, these 
models never took into account the complicated cross-talk between endothelium and 
leukocytes. This study evaluated the effects of acute exposure to indoxylsulfate (IS), p-
cresylsulfate (pCS) and p-cresylglucuronide (pCG) on the recruitment of circulating 
leukocytes in the rat peritoneal vascular bed, using intravital microscopy.  
The visceral peritoneum of rats was superfused by a physiological solution (HBSS) with or 
without a uremic toxin at concentrations in the high uremic range. Leukocyte recruitment and 
hemodynamic parameters were analyzed in postcapillary venules.  
IS induced very strong leukocyte adhesion and extravasation and interrupted blood flow. pCS 
caused an immediate increase in rolling. The combination of both pCS and pCG had no 
additive effect to pCS alone on leukocyte recruitment, but caused impaired blood flow and 
leakage of the vessels.  
These results provide for the first time clear in vivo evidence that IS, pCS and pCG exert 
proinflammatory effects that could contribute to vascular damage by stimulating cross-talk 
between leukocytes and vessels. In addition, IS and the combination of pCS and pCG induced 
unusual patterns of blood flow.  
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4.2.2. Introduction 
Cardiovascular disease (CVD) remains an important cause of death among patients with 
chronic kidney disease (CKD)1 and is associated with a baseline inflammatory status.2;3 
Atherosclerosis is highly prevalent and advances more rapidly in individuals with renal 
dysfunction compared to the general population.4-6 A key role in the development of 
atherosclerosis is played by leukocyte-endothelial interactions.2
CKD is characterized by the progressive retention of a host of solutes. A substantial number 
of these compounds is protein-bound.
 
7;8 The indole indoxylsulfate (IS) and the phenolic 
conjugates p-cresylsulfate (pCS) and p-cresylglucuronide (pCG) are prototype members of 
this group. In vitro and in vivo data link these solutes to several isolated molecular 
mechanisms associated with cardiovascular damage and progression of kidney failure.8-12 
Although for all three compounds two key mechanisms of vascular damage, leukocyte 
activation and endothelial dysfunction, have been demonstrated in separate in vitro models, 
they were to the best of our knowledge never directly assessed by evaluating the complicated 
cross-talk between endothelium and leukocytes in vivo. Intravital microscopy permits in vivo 
visualization of leukocyte recruitment in translucent tissues in real time. This technique was 
already applied successfully by our group to study harmful effects of peritoneal dialysis 
solutions on peritoneal membrane physiology.13
The present study evaluates the effects of an acute exposure to the protein-bound uremic 
compounds IS, pCS or pCG on the recruitment of circulating leukocytes in the rat peritoneal 
vascular bed, using this intravital microscopic method. 
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4.2.3. Results 
 
Leukocyte recruitment in response to lipopolysaccharides (LPS) 
Before observing leukocyte recruitment in response to uremic solutes, we first evaluated the 
effect of lipopolyscaccharide (LPS) as a positive control. As represented in figure 1, there 
were no differences in baseline values between the control-group and the LPS-group. 
Stimulation with LPS (n=8) dramatically and progressively increased the number of rolling 
leukocytes (A-1) compared to control (n=12), from 30 minutes on (36.6 ± 9.4 vs 14.6 ± 2.3, 
p<0.01), reaching a number of 90.4 ± 9.0 rolling leukocytes after 120 minutes exposure to 
LPS (p<0.01 vs control). The number of adhering leukocytes (B-1) was significantly higher 
versus control after 60 min (3.7 ± 0.8 vs 1.8 ± 0.3, p<0.05), reaching a number of 7.6 ± 1.4 
after 120 min exposure to LPS (p<0.05 vs control). The number of extravasating leukocytes 
(C-1) increased progressively from 30 min on (425 ± 59 vs 247 ± 36, p<0.05) resulting in a 
total number of 1574 ± 237 at 120 min (p<0.05 vs control).  
Figure 2 illustrates the increasing number of rolling, adhering and extravasated leukocytes 
after exposure to LPS at different time periods. 
 
Leukocyte recruitment in response to IS 
Baseline values were not different between the control-group and the IS-group, as represented 
in figure 1.  
Exposure to IS (n=9) provoked similar effects as with the LPS-induced recruitment, except 
for the number of rolling leukocytes (A-2). A progressive increase in the number of adhering 
leukocytes (B-2) was observed (9.9 ± 2.7 vs 3.5 ± 0.3 at 120 min, p<0.05). A pronounced and 
progressive effect of IS on the number of extravasating leukocytes (C-2) was observed, 
reaching significance after 30 min exposure (440 ± 79 vs 247 ± 36, p<0.05), and further 
increasing until 120 min (1120 ± 89 vs 655 ± 147, p<0.05).  
 
Leukocyte recruitment in response to pCS and the combination of pCS and pCG 
No difference in baseline values between the control group and the experimental groups was 
observed, as shown in figure 1 and illustrated in a representative experiment in figure 2. 
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Compared to control (n=12), superfusion with pCS (n=8) caused an almost immediate but 
moderate increase in the number of rolling leukocytes (A-3) after 10 min (25.5 ± 5.4 vs 13.2 ± 
2.6, p<0.05) with a maximal effect after 60 min exposure (44.3 ± 12.7 vs 14.3 ± 2.2, p<0.01); 
subsequently rolling stagnated. The combination of pCS and pCG (n=6) induced a similar 
effect on rolling, be it not significant; thus, no additive effect of combining the two 
compounds was observed. No effect was seen on the number of adhering leukocytes (B-3) in 
the presence of pCS, nor in the presence of the combination of pCS and pCG. Although a 
trend towards an increase in the number of extravasating leukocytes (C-3) in the presence of 
pCS and pCSpCG was observed, the increase was not significant.  
Figure 1: Leukocyte recruitment in response to LPS (1), IS (2) , pCS and pCSpCG (3) 
The number of rolling (A), adhering (B) and extravasated (C) leukocytes at different time points during 
superfusion by HBSS (■, full black line, n=12), HBSS with LPS (●, full grey line, n=8), HBSS with IS (♦, dotted 
line, n=9), HBSS with pCS (▲, broken line, n=8) and HBSS with pCS & pCG (▼, dotted line, n=6).  
*p<0.05; **p<0.01; ***p<0.001 versus HBSS. 
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Figure 2: Images of intravital microscopy 
Leukocyte rolling (black arrows), adhesion (white arrows) and extravasation (white circles) in response to LPS, 
pCS or the combination of pCS and pCG at baseline (t=0 min) and after 60 and 120 min of exposure. 
 
Remark: The amount of symbols is not representative for the exact number of leukocytes with corresponding 
characteristics present in the panels. Moreover, it is impossible to see the difference between rolling and 
adhering leukocytes on these static pictures. A short movie illustrating the different elements is posted online. 
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Figure 3: Evolution of red blood cell velocity (VRBC) in IS treated rats 
Panel A is representative for 4 rats with permanent stop of VRBC after 30-60 min. Panel B is representative for 2 rats 
with transient stop of VRBC, and return 30 min later. 
Leukocyte rolling (black arrows), adhesion (white arrows) and extravsation (white circles) in response to IS at baseline 
(t=0 min) and after 30, 60 and 120 min of exposure. 
The disappearance of a visible signal for the vessel corresponds to the disappearance of moving erythrocytes and thus 
for a defective (A) or temporary (B) stop of flow. 
Remark: The amount of symbols is not representative for the exact number of leukocytes with corresponding 
characteristics present in the panels. Moreover, it is impossible to see the difference between rolling and adhering 
leukocytes on these static pictures. A short movie illustrating the different elements is posted online. 
 
Effects on blood flow 
In 6 out of 9 IS treated rats, an interruption of blood flow was observed, as illustrated in figure 
3 and figure 4-A. In 4
A strong decrease in red blood cell velocity (V
 rats, flow stopped permanently after 30 - 60 min (figure 3-A).  
RBC
In addition, a strong blood flow decrease was also observed in 4 out of 6 pCSpCG rats (figure 
4-C). The combination of pCS and pCG caused a flow-stop in 1 of 4 rats after approximately 
60 min, but flow was restored again 30 min later. The flow in the 3 other rats showed a clear 
decline, but remained present.  
) was detected after 10-20 min in 2 out of 9 
rats. In one of these two, the blood flow disappeared completely but returned 30 min later 
(figure 3-B).  
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Figure 4: Impaired red blood cell velocity subsequent to IS and pCSpCG exposure 
In 6 out of 9 IS treated rats, an interruption of flow was observed in the period between the 30th and the 60th 
minute of exposure (A, red lines).  
In 4 rats, flow stopped permanently after 30-60 min (A, full red lines). A strong decrease in red blood cell 
velocity (VelRBC) was detected after 10-20 minutes in 2 other rats (A, dotted red lines). The remaining 3 animals 
showed less dramatic decreases of flow pattern (A, black lines).  
A strong blood flow decrease was observed in 4 out of 6 pCSpCG rats (C, dotted red lines).  
The combination of pCS and pCG caused a flow-stop in 1 rat after 60 min, but flow was restored. The remaining 
2 animals showed only minor declines of VRBC (C, black lines). Comparing the lowest detected values, both for 
IS (B) and pCSpCG (D) lower values were found compared to control lowest values. *p<0.05 vs controls 
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Capillary leakage 
Capillary leakage was significantly higher compared to control in both the LPS-group and 
pCSpCG-group (p<0.05). (figure 5) 
 
 
 
 
 
Hemodynamic parameters 
Hemodynamic parameters are shown in table 1.  
Although baseline venular diameters of the pCSpCG group were significantly lower 
compared to the pCS group, they remained stable throughout the evaluation period. No 
difference was observed with the control group.  
Figure 5: Capillary leakage 
Mean leakage of the fluorescent isothiocyanate labeled albumin is significantly higher in the LPS-group 
and in the pCSpCG-group, compared to controls. Representative pictures are shown (magnification 100x);  
* p<0.05 versus controls. 
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Unexpectedly, the flow problems observed after exposure to IS and pCSpCG were not 
reflected by significant changes in VRBC if the analysis was performed per time point. 
However, comparing the lowest detected values per animal for VRBC independently 
Like for V
of time, 
for both IS (figure 4-B) and pCSpCG (figure 4-D) lower values were found than for the nadir 
of controls (resp. 0.5 ± 0.25 and 0.5 ± 0.17 vs 1.1 ± 0.11, p<0.05).  
RBC
 
, a decreasing trend in venular wall shear rate (VWSR) was observed in the IS 
and pCSpCG rats, but the effect was not significant. 
 
 
 
 
 
 
 
 
 
Evaluation of IS for vasoactive effects 
Because detectable changes in vessel diameter were absent throughout the experiments with 
IS, vasoconstrictive properties of IS were tested in vitro by a wire myograph in segments of 
both aorta and femoral artery. IS did not elicit a contractile effect even when present for 2 
hours.  
 
Circulating leukocytes and hematocrit 
Total number of leukocytes and hematocrit values were not significantly different between the 
groups at any of the experimental time points. (data not shown) 
 
Blood Pressure (mmHg), Venular Diameter (µm), Red Blood Cell Velocity (mm/s), Venular Wall Shear Rate (s-1), are shown as means ± SEM. 
Controls (n=12), IS (n=9), pCS (n=8), pCSpCG (n=6). 
ap<0.05 versus control group, bp<0.05 versus pCS-group  
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Quantification of uremic solute concentrations in HBSS solutions and sera by HPLC 
The concentrations of the uremic toxins in the HBSS solutions conformed with those 
observed in CKD patients.  
IS-HBSS solutions had a mean IS level of 232 ± 4.4 mg/l, the pCS-HBSS solutions contained 
a mean pCS level of 100 ± 2.3 mg/l and the pCSpCG-HBSS solutions a pCS level of 85 ± 1.5 
mg/l and a pCG level of 26 ± 0.33 mg/l. The plasma levels, which were low (total) to 
undetectable (free) at the start of the experiment, steadily increased, but never exceeded 15 % 
of the HBSS concentration. (table 2) 
 
 
Chemotaxis experiments  
In comparison to control, pCS and pCG (alone or in combination) and IS had no effect on the 
fMLP induced chemotaxis of polymorphonuclear leukocytes (PMNL); neither had they a 
chemotactic potential on their own in this assay.  
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4.2.4. Discussion 
In this study, the effects of the protein-bound uremic solutes indoxylsulfate (IS), p-
cresylsulfate (pCS) and p-cresylglucuronide (pCG) on leukocyte recruitment were evaluated 
for the first time in an in vivo rat model, using intravital microscopy. 
IS caused an immediate firm adhesion and extravasation of the circulating leukocytes (figure 
1). In addition, IS had a dramatic effect on blood flow, resulting in an interruption or even a 
complete flow stop (figure 3 & 4). On the other hand, pCS induced a moderate activation only 
resulting in an increased number of rolling leukocytes (figure 1). The combination of both 
pCS and pCG had no additive effect to pCS alone on leukocyte recruitment. However, the 
addition of pCG to pCS caused an impaired blood flow and leakage of albumin (figure 4 & 5). 
Until now, experimental effects of IS, pCS and pCG have mainly been evaluated in an in vitro 
setting. IS plays a role in inflammation-related processes by inducing ROS production in 
endothelial cells14;15, increasing endothelial microparticle release16, enhancing the 
proliferation of vascular smooth muscle cells17 and inhibiting endothelial cell repair.18 IS 
increases cardiac fibrosis19 and osteoblastic resistance to parathyroid hormone20 which might 
contribute to vascular calcification. Also pCS was shown to have an immune stimulating 
effect due to the increase of leukocyte free radical production.21 In addition, a synergistic 
effect of pCS and pCG was demonstrated.22 Vascular damage of pCS is suggested by 
demonstration of endothelial microparticle release.23
Clinical studies already showed a relation between p-cresol (acting as a surrogate for pCS) 
and clinical outcomes.
 
24;25 Recent studies confirmed that pCS levels were predictive for 
mortality at different stages of CKD26 and for cardiovascular and all-cause mortality in 
hemodialysis patients.27 The relation between pCS and coronary artery disease in patients 
with no or only moderate degrees of CKD28 extends the association of this compound with 
cardiovascular outcomes beyond the scope of pronounced uremia.29 IS was linked to mortality 
and aortic calcification.30 In addition, a correlation between IS and plasma levels of 
interleukin-6 was demonstrated.31
In clinical studies, it is difficult to determine whether a given uremic toxin intrinsically has 
deleterious effects or is merely an inert biomarker for the degree of renal function. The 
present in vivo approach enables us to evaluate the effects of specific uremic compounds on 
the cross-talk between the major cell types involved in vascular damage: the leukocytes and 
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the endothelium. Intravital microscopy permits direct in vivo visualization. Different 
parameters can be studied concomitantly in the same animal. This technique was already used 
by our group to study effects of peritoneal dialysis solutions on peritoneal membrane 
physiology.13
The present in vivo data demonstrate a pro-inflammatory effect of pCS, as was already 
suggested in vitro.
 
21;22
In comparison to the p-cresyl conjugates, the effect of IS on recruitment was more 
pronounced, resulting in an immediate and strong adhesion and extravasation. The in vivo 
data strengthen previous in vitro findings demonstrating that IS influences expression of 
endothelial adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1)
 Increased production of free radicals by leukocytes can contribute to 
endothelial damage. The additive effect of pCG and pCS as demonstrated by Meert et al in 
vitro for leukocytes could not be confirmed in the present recruitment studies. However, 
addition of pCG to pCS induced leakage through the vessel wall and a drop in blood flow 
which was not observed in the presence of pCS alone. 
32 and E-
selectin.33 In addition, Ito et al showed IS-induced leukocyte adhesion to the femoral artery 
after administering IS in the drinking water of nephrectomized mice for 10 days33, which was 
significantly reduced by anti-E-selectin antibody treatment. The firm arrest of leukocytes, 
which was seen in our study after exposure to indoxylsulfate has already been observed for 
another tryptophan metabolite, kynurenic acid, beit in an in vitro model.34
The present study also demonstrated a clear effect on blood flow in the presence of pCSpCG 
and an even more substantial impact in the presence of IS. The underlying mechanism of this 
disturbed blood flow is not clear. Since a hemodynamic effect could not be demonstrated 
neither by direct observation of vessel wall diameters, nor by wire myograph on thoracic and 
femoral arteries, a possible role of the coagulation cascade in this phenomenon might be an 
interesting line of thought. Low and oscillatory shear stress is well known to cause endothelial 
activation
 
35-37, which can shift the thromboresistant surface of the endothelium towards a 
prothrombotic state.38 This can result in the expression of tissue factor (TF), the main stimulus 
for thrombin generation. Gondouin et al demonstrated the ability of IS and indole acetic acid 
(IAA) to modulate TF production, via the aryl hydrocarbon receptor pathway.39 IS and IAA 
increased TF protein expression, which was associated with increased procoagulant activity. 
This might be an explanation for the strong decrease and even disappearance of blood flow 
after IS superfusion in our study. Furthermore, soluble tissue factor (sTF) is elevated in CKD 
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patients40 and several uremic solutes raise TF production in different cell types: asymmetric 
dimethyl arginine (ADMA) increases monocyte TF antigen41, and also kynurenin, which like 
IS belongs to the large group of the indoles, is associated with increased sTF levels and 
hypercoagulability in CKD patients.42 Moreover, endothelial microparticles (EMPs), 
considered as markers of endothelial dysfunction, are shed upon endothelial activation and are 
involved in the regulation of coagulation by activating the tissue factor pathway.43 Both IS 
and pCS have been shown to elicit EMPs release in vitro.16;23
An attempt to explain the leukocyte recruitment characteristics of the tested uremic solutes 
was made by evaluating their chemotactic properties. Since these compounds did not affect 
the chemotaxis process, nor were chemotactic by themselves, this suggest a possible direct 
role on the expression of leukocyte or endothelial surface molecules or an indirect role by 
inducing the release of substances from other cell types like the mesothelial cells, which on 
their turn could have an influence on leukocyte recruitment. 
 
The present in vivo data support the hypothesis that protein-bound uremic toxins are not only 
involved in the progression of CKD, but also in the promotion of cardiovascular disease. 
Although pCS, pCG and IS all are protein bound molecules, they seem to exert divergent 
effects. The large group of protein-bound uremic solutes cannot be considered as a 
homogenous entity since pathophysiology, degree and strength of protein binding, protein-
binding sites, retention pattern, and even the nature of the binding protein(s) are unlikely to be 
the same for all of them.  
In conclusion, the present study provides in vivo evidence that IS, pCS, and pCG exert 
proinflammatory effects that could contribute to vascular damage by stimulating cross-talk 
between leukocytes and vessels. In addition, IS and the combination of pCSpCG induced 
unusual blood flow patterns. A possible role of the coagulation cascade in this phenomenon 
should be considered and further evaluated. The next step would be to set up infusion studies 
in animals, examining biological effects of one single toxin over a prolonged period of time. 
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4.2.5. Concise methods 
 
Laboratory animals  
The study was performed in 43 healthy female Wistar rats (Charles River Laboratories, 
L'Abresle, France). They were handled in accordance to the NIH guide for the care and use of 
laboratory animals, avoiding the influence of environmental stress. The ethical committee for 
animal experiments at the Faculty of Medicine and Health Sciences, Ghent University, 
Belgium, approved the protocol. 
 
Intravital microscopy 
Rats were anesthetized subcutaneously in the neck with thiobutabarbital (Inactin® 100mg/kg, 
Sigma, St. Louis, MO, USA). After intubation of the trachea (polyethylene (PE) 240 catheter; 
Becton Dickinson (BD), Erembodegem, Belgium) to ensure open airways throughout the 
experiment, a jugular vein was cannulated (PE50, BD) for continuous infusion of isotonic 
saline (3ml/h), and a carotid artery was cannulated (PE50, BD) for continuous monitoring of 
arterial blood pressure and blood sampling. Cromoglycate (Cromolyn®
In each experimental animal, a single unbranched venule with a diameter of 15–25 μm and a 
length of 150-200 μm was selected for investigation. After completion of surgery and 
exposure of the venule, the preparation was allowed to stabilize for 30 minutes. The exposed 
intestine was moistened with sterile soaked gauze to prevent tissue dehydration. 
, 10mg/kg, 
intravenously (IV), Sigma, St. Louis, MO, USA) was administered 15 min before surgery to 
block degranulation of mast cells induced by surgical manipulation. Body temperature was 
kept at 37°C during the whole experiment by a heating pad with feedback control. A small 
midline abdominal incision was made and a short segment of the small bowel was 
exteriorized. Carefully avoiding stretching, the visceral peritoneum was spread over a glass 
plate and superfused continuously with Hank’s Balanced Salt Solution (HBSS; Gibco, Life 
Technologies Europe B.V., Gent, Belgium) maintained at 37 °C.  
Observations were made with an Axiotech Vario 100 HD microscope (Zeiss, Jena, Germany) 
using water immersion objectives (Achroplan 10X, 40X). The microscopic stage was operated 
by using a joystick (Lang, Hüttenberg, Germany). The tissue was transilluminated via a fiber-
optic using a light source (KL 1500, Schott, Wiesbaden, Germany) equipped with a 150 W 
halogen lamp. The resulting image was displayed on a television monitor by a TK-1281 
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camera (Victor Company of Japan LTD-JVC, Tokyo, Japan) or a high-speed video camera 
(Kodak Motioncorder Analyzer, Eastman Kodak Company, San Diego, CA,USA) and video 
recorded (S-VHS Panasonic AG-7350, Matsushita, Japan) for off-line analysis with an image 
analysis software program (Cap-Image®, Ingenieurbüro Zeintl, Heidelberg, Germany), as 
previously described by De Vriese et al13;44
 
. At the end of the experiment, the animal was 
euthanized by an overdose of anaesthetic. If hemodynamic instability occurred, the 
experiment was ended prematurely. 
Study of leukocyte recruitment 
Rolling leukocytes were assessed by counting the number of rollers per minute crossing an 
imaginary line perpendicular to the axis of the vessel. They were defined as those cells 
moving at lower velocity than red blood cells and being in contact with the endothelial 
surface. Adhering leukocytes were defined as white cells not moving during a 30 second 
period; they were counted as the number per 100 µm vessel length. Extravasated leukocytes 
were determined as the number counted within a predefined area of perivenular tissue. 
Preactivation of the tissue was minimized by considering for further analysis only vessels in 
which baseline leukocyte rolling was < 30 cells/min and baseline adhesion was < 3 cells/100 
µm of vascular endothelium. A short video fragment with the different steps of leukocyte 
recruitment is posted online as supplemental material.  
 
Experimental protocol: LPS-induced or uremic toxin-induced leukocyte recruitment 
a. Inflammatory stimulus 
As a positive control for leukocyte stimulation, 1 µg/ml lipopolysaccharide (LPS) derived 
from E. coli (Escherichia coli serotype 0127:B8; Phenol extracted, L3129, Sigma, Bornem, 
Belgium) was used.45-47
b. Uremic toxins 
 
The uremic toxins were tested at concentrations in the uremic range, as applied in preceeding 
in vitro experiments: 236 mg/l for IS7, 100 mg/l for pCS21 and 24 mg/l for pCG.22 pCS was 
synthesized according to Feigenbaum and Neuberg as a potassium salt.48 pCG was 
synthesized from protected glucuronyl-trichloroacetimidate and p-cresol using a protocol 
similar to the one described by Van der Eycken et al.49 Indoxylsulfate was purchased from 
Sigma-Aldrich (Bornem, Belgium). Because recent in vitro findings pointed out synergistic 
Chapter 4: Peritoneal exposure to uraemic toxins 
168 
effects of pCS and the other conjugate of p-cresol, p-cresylglucuronide22
c. Endotoxin concentration 
, also this 
combination was tested. 
All experimental solutions were checked for endotoxin contamination, by means of the 
Limulus Amebocyte Lysate (LAL) QCL-1000-test®
d. Study design 
, a quantitative kinetic and chromogenic 
assay (Cambrex Bio Science, Walkersville, MD, USA). All HBSS solutions with and without 
uremic toxins were endotoxin free (<0.003 EU/ml).  
After a 30 min stabilization period, the peritoneal membrane was superfused with either the 
control solution (HBSS, alone), or with (a) LPS (positive control) or (b) one or two uremic 
solutes dissolved in HBSS. After establishing baseline levels (0 min), measurements were 
repeated after 2, 10, 20, 30, 60, 90 and 120 min exposure to HBSS with or without solved 
LPS or uremic solute(s). The number of rolling, adhering and extravasated leukocytes, 
leukocyte rolling velocity, red blood cell velocity (VRBC), and vessel diameter (D) were 
measured three times at each time point. Venular wall shear rate (γw) was calculated as γw = 8 
x VRBC
 
/D.  
Capillary leakage 
FITC-labeled albumin (Sigma-Aldrich) was injected (200 mg/kg, IV) at the end of each 
experiment to check for capillary leakage. A visual score was allocated (0: no leakage at all, 
1: suggestive for weak leakage at a few spots, 2: evidence of leakage at many spots, 3: heavy 
leakage covering the whole area). 
 
Studies of vasoactive effect of indoxyl sulfate (IS) in vitro  
Because of the unusual flow-patterns seen during the IS-superfusion experiments, 
vasocontractile effect of IS on the vessel was studied by using a wire myograph, as described 
by Nimmegeers et al.50
Briefly, three female Wistar rats were used. After cervical dislocation, the thoracic aorta and 
femoral artery were carefully removed from each animal and transferred to cooled Krebs-
Ringer bicarbonate (KRB) solution. Ring segments of the isolated arteries were mounted in a 
small-vessel myograph with a tissue chamber filled with 10 ml of KRB solution and were 
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cleansed from adhering tissue. Two stainless steel wires were guided through the lumen of the 
segments. One was fixed to a force transducer, the other was connected to a micrometer. After 
mounting, the preparations were allowed to equilibrate for 30 min in the KRB solution 
bubbled with 95% O2-5% CO2 (pH 7.4) at 37 °C. After applying the optimal resting tension, 
preparations were contracted 3 times with a KRB solution containing 30 mmol/L K+ and 10-6 
M norepinephrine (NOR), washed and allowed to relax to basal tension. To evaluate 
endothelial integrity, precontraction was elicited with 10-6 M NOR and when a stable 
contraction plateau was obtained the relaxing influence of adding 10-6 M acetylcholine (Ach) 
was evaluated. After washing the ring segments so that they were again at optimal basal 
tension, cumulative concentrations of IS were added to the KRB solution (10-7-10-3
 
M). The 
latter concentration (concentration tested in the intravital experiment) was left in contact with 
the preparations for 2 hours. 
Circulating leukocytes and hematocrit 
Arterial blood samples were taken at baseline and after 1 and 2 hours. Twenty-five µl blood 
was added to 475 µl 2% orthophosphoric acid (VWR International, Leuven, Belgium) to lyse 
the red blood cells. Peripheral leukocytes were counted in a Bürker chamber and expressed as 
number/mm3
 
. To estimate the hydration status of the rats, micro hematocrit capillaries (Brand, 
Wertheim, Germany) were used.  
Quantification of uremic toxins in HBSS solutions and sera by HPLC 
The solute (pCS, pCG and IS) concentrations in the experimental solutions and in serum at 
different time points was checked by HPLC analysis, as previously described.51
 
 A detection 
limit of 0.25 mg/l was applied for pCS and pCG and 0.15 mg/L for IS. 
Chemotaxis 
Polymorphonuclear leukocyte (PMNL) chemotaxis was determined by the under-agarose 
method.52 formyl-Methionine-Leucine-Phenylalanine (fMLP, Sigma Aldrich) dissolved in 
PBS at a final concentration of 4x10-7 M was used as chemoattractant. Five x 105 PMNLs 
were suspended in 10 µl control or an experimental solution (containing pCS, pCS+pCG or IS 
at the above mentioned concentrations). After a 2 h incubation period at 37 °C, the cells were 
fixed with methanol and paraformaldehyde and stained with Giemsa (Merck, Darmstadt, 
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Germany). The distance migrated under the agarose was measured under the microscope. In 
addition, the chemotactic capacity of the uremic solutes by themselves was also tested by 
using them in the assay instead of fMLP.  
 
Statistical Analyses  
Data analysis was performed with SPSS Statistics version 19 (IBM, Armonk, New York, US), 
using the non parametric Mann Whitney U test or Kruskall Wallis test for comparison 
between 2 or more groups. Post hoc analysis was performed using Dunn’s multiple 
comparison test. The results are expressed as mean ± standard error of the mean (SEM). A p-
value < 0.05 was considered statistically significant. 
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4.3.1. Abstract 
 
Rationale 
Asymmetric dimethylarginine (ADMA) and its structural counterpart symmetric 
dimethylarginine (SDMA) are elevated in patients with chronic kidney disease (CKD). 
ADMA is considered a mediator of vascular damage through inhibition of endothelial nitric 
oxide synthase (eNOS) irrespective of kidney function. SDMA has been linked to 
proinflammatory leukocyte effects. However, the complicated in vivo cross-talk between 
endothelium and leukocytes was never directly assessed for these two compounds.  
Objective 
The present intravital microscopy study evaluated the effects of acute exposure to ADMA or 
SDMA on the recruitment of circulating leukocytes in the rat peritoneal vascular bed. 
Methods and Results 
The visceral peritoneum of rats was superfused by a physiological solution (HBSS = control), 
HBSS with ADMA or SDMA  at concentrations in the CKD range or HBSS with LPS as a 
positive control. Leukocyte recruitment, capillary leakage and hemodynamic parameters were 
analyzed.  
Rolling of leukocytes was activated by ADMA (54.2 ± 8.9 vs 20.2 ± 3.9 at 90 min, p<0.05) 
and even more by SDMA (80.2 ± 20.5 vs 14.3 ± 2.2 at 60 min, p<0.001), compared to 
controls. This activation was similar to the reaction elicited by 1 µg/ml LPS (36.6 ± 9.4 vs 
14.6 ± 2.3 at 30 min, p<0.01). Leakage scores were significantly higher (p<0.05) after 
ADMA-, SDMA-, and LPS-superfusion, compared to the control group, revealing endothelial 
damage.  
Conclusions 
In conclusion, the present study indicates for the first time directly in vivo that both ADMA 
and SDMA are important simultaneous inducers of leukocyte activation, interaction of 
leukocytes with endothelium and severe vascular leakage.  
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4.3.2. Introduction 
Endothelium-derived nitric oxide (NO) plays a critical role in endothelial cell relaxation.1 
Endothelial dysfunction caused by reduced availability of NO is an early step in the course of 
atherosclerotic vascular disease. Inhibition of NO synthesis by endogenous inhibitors of the 
NO synthase (NOS) pathway is causally involved in this process.2 Next to endothelial 
dysfunction, also leukocyte activation and the interaction between activated leukocytes and 
endothelial cells has been stressed to play a role in atherosclerosis.3-5
In 1992, Vallance et al first reported markedly elevated levels of asymmetric 
dimethylarginine (ADMA) and its structural counterpart symmetric dimethylarginine 
(SDMA) in patients with chronic kidney disease (CKD) and demonstrated inhibition of NO 
production by ADMA in vitro and in vivo.
  
6 More recently, also SDMA was shown to inhibit 
NO synthesis by competing with the transport of L-arginine, the substrate of NOS.7
Nowadays, ADMA is accepted as a general marker for endothelial dysfunction and a strong 
predictor of cardiovascular disease (CVD) in the general population.
  
8-12 ADMA correlates 
well with established clinical markers of cardiovascular burden such as intima-media 
thickness of the carotid artery in the general population13 or left ventricular mass in 
hemodialysis patients.14 ADMA is demonstrated in vitro to affect vascular structure as well as 
vascular reactivity.15-17
SDMA, for a long time considered to be inert, was recently shown in vitro to enhance the 
production of reactive oxygen species (ROS) in monocytes by a mechanistic pathway 
involving Ca
 Of note, the majority of observations allocate the biological activity of 
ADMA to endothelial effects, whereas the role of leukocytes has been barely explored. 
2+ influx.18 Additionally, activation of NF-κB resulting in the enhanced 
expression of IL-6 and TNF-α by monocytes was demonstrated, next to a strong correlation of 
SDMA with IL-6 and TNF-α in patients at different CKD-stages.19 In the case of SDMA, the 
only study considering the endothelial aspect showed an increased ROS production together 
with an inhibited NO synthesis in endothelial cells.7
Hence, the role of ADMA in endothelial dysfunction and of SDMA in leukocyte activation 
has been studied, but to the best of our knowledge, no studies assessed the complex cross-talk 
between endothelium and leukocytes in vivo as a basic mechanism of vascular damage with 
these two compounds. Intravital microscopy permits real time in vivo visualization of 
leukocyte recruitment in translucent tissues.
  
20  
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The present study evaluated for the first time the in vivo effects of acute exposure to ADMA 
or SDMA on the recruitment of circulating leukocytes in the rat peritoneal vascular bed, using 
an intravital microscopic model.  
 
4.3.3. Materials and methods 
 
Laboratory animals  
The study was performed in 33 healthy female Wistar rats (Charles River Laboratories, 
L'Abresle, France). They were treated in accordance to the NIH guide for the care and use of 
laboratory animals, avoiding the influence of environmental stress. The ethical committee for 
animal experiments at the Faculty of Medicine and Health Sciences, Ghent University, 
Belgium, approved the protocol. 
 
Intravital microscopy 
Rats were anesthetized subcutaneously in the neck with thiobutabarbital (Inactin® 100mg/kg, 
Sigma, St. Louis, MO, USA). After intubation of the trachea (polyethylene (PE) 240 catheter; 
Becton Dickinson (BD), Erembodegem, Belgium) to ensure open airways throughout the 
experiment, a jugular vein was cannulated (PE50, BD) for continuous infusion of isotonic 
saline (3ml/h), as well as a carotid artery was cannulated (PE50, BD) for continuous 
monitoring of arterial blood pressure and blood sampling. Cromoglycate (Cromolyn®
In each experimental animal, a single unbranched venule with a diameter of 15–25 μm and a 
length of 150-200 μm was selected for investigation. After completion of surgery and 
exposure of the venule, the preparation was allowed to stabilize for 30 minutes. The exposed 
intestine was moistened with sterile gauze soaked in HBSS to prevent tissue dehydration. 
, 
10mg/kg, intravenously (IV), Sigma, St. Louis, MO, USA) was administered 15 min before 
surgery to block degranulation of mast cells induced by surgical manipulation. Body 
temperature was kept at 37°C during the whole experiment by a heating pad with feedback 
control. A small midline abdominal incision was made and a short segment of the small bowel 
was exteriorized. Carefully avoiding stretching, the visceral peritoneum was spread over a 
glass plate and superfused continuously with Hank’s Balanced Salt Solution (HBSS; Gibco, 
Life Technologies Europe B.V., Gent, Belgium) maintained at 37 °C. (Figure 1)  
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Observations were made with an Axiotech Vario 100 HD microscope (Zeiss, Jena, Germany), 
using water immersion objectives (Achroplan 10X, 40X). The microscope stage was operated 
by using a joystick (Lang, Hüttenberg, Germany). The tissue was transilluminated via a fiber-
optic using a light source (KL 1500, Schott, Wiesbaden, Germany) equipped with a 150 W 
halogen lamp. The resulting image was displayed on a television monitor by a TK-1281 
camera (Victor Company of Japan LTD-JVC, Tokyo, Japan) or a high-speed video camera 
(Kodak Motioncorder Analyzer, Eastman Kodak Company, San Diego, CA,USA) and 
recorded by a video recorder (S-VHS Panasonic AG-7350, Matsushita, Japan) for off-line 
analysis with an image analysis software program (Cap-Image ®, Ingenieurbüro Zeintl, 
Heidelberg, Germany), as previously described by De Vriese et al.20, 21
 
 At the end of the 
experiment, the animal was euthanized by an overdose of anaesthetic. If hemodynamic 
instability occurred, the experiment was ended prematurely. 
Study of leukocyte recruitment 
Rolling leukocytes were assessed by counting the number of rollers per minute crossing an 
imaginary line perpendicular to the axis of the venule. They were defined as those cells 
moving at lower velocity than red blood cells and being in contact with the endothelial 
surface. Adhering leukocytes were defined as white cells not moving during a 30-s period; 
they were counted as the number per 100 µm length of venule. Extravasated leukocytes were 
determined as the number counted within a predefined area of perivenular tissue. 
Preactivation of the tissue was minimized by considering for further analysis only vessels in 
which baseline leukocyte rolling was < 30 cells/min and baseline adhesion was < 3 cells/100 
µm of vascular endothelium.  
 
Experimental protocol: dimethylarginine- or LPS-induced leukocyte recruitment 
a. Dimethylarginines 
SDMA and ADMA were purchased from Merck (Darmstadt, Germany). Separate stock 
solutions were prepared in HBSS (Gibco) and stored at -20°C. Just before starting the 
experiment, they were diluted in HBSS resulting in a concentration of 36.0 µmol/l ADMA or 
6.1 µmol/l SDMA 22
HBSS per se was used as control condition. 
, corresponding to the values observed in CKD.  
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b. Inflammatory stimulus 
As a positive control for leukocyte stimulation, 1 µg/ml lipopolysaccharide (LPS) derived 
from E. coli (Escherichia coli serotype 0127:B8; Phenol extracted, L3129, Sigma, Bornem, 
Belgium) was used23-25
c. Endotoxin concentration 
.  
All experimental solutions were checked for endotoxin contamination, by means of the 
Limulus Amebocyte Lysate (LAL) QCL-1000-test®
d. Study design 
, a quantitative kinetic and chromogenic 
assay (Cambrex Bio Science, Walkersville, MD, USA). All HBSS solutions with and without 
dimethylarginines were endotoxin free (<0.003 EU/ml).  
After a 30 min stabilization period, the peritoneal membrane was superfused with either the 
control solution (HBSS, alone), or with (a) ADMA or SDMA or (b) LPS (positive control) 
dissolved in HBSS. After establishing baseline levels (0 min), measurements were repeated 
after 2, 10, 20, 30, 60, 90 and 120 min exposure to HBSS with or without dissolved LPS or 
dimethylarginines. The number of rolling, adhering and extravasated leukocytes, leukocyte 
rolling velocity, red blood cell velocity (VRBC), and venular diameter (D) were measured three 
times at each time point. Venular wall shear rate (VWSR) was calculated as VWSR = 8 x 
VRBC
 
/D.  
Capillary leakage 
FITC-labeled albumin (Sigma-Aldrich) was injected (200 mg/kg, IV) at the end of each 
experiment to check for capillary leakage. A visual score was allocated (0: no leakage at all, 
1: suggestive for weak leakage at a few spots, 2: evidence of leakage at many spots, 3: heavy 
leakage covering the whole area).  
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Circulating leukocytes and hematocrit 
Arterial blood samples were taken at baseline, after 1 and 2 hours. Twenty-five µl blood was 
added to 475 µl 2% orthophosphoric acid (VWR International, Leuven, Belgium) to lyse the 
red blood cells. Peripheral leukocytes were counted in a Bürker chamber and expressed as 
number/mm3
 
. To estimate the hydration status of the rats, micro hematocrit capillaries (Brand, 
Wertheim, Germany) were used.  
Statistical Analyses  
Data analysis was performed with SPSS Statistics version 19 (IBM, Armonk, New York, US), 
using the non parametric Mann Whitney U test or Kruskall Wallis test for comparison 
between respectively 2 or more groups. Post hoc analysis was performed using Dunn’s 
multiple comparison test. The results are expressed as mean ± standard error of the mean 
(SEM). A p-value<0.05 was considered statistically significant. 
 
 
 
 
 
 
Figure 1: Intravital Microsocopy 
A segment of the small bowel is exteriorized, spread over a glass plate, and superfused with Hank’s Balanced Salt 
Solution (HBSS), HBSS mixed with LPS or HBSS mixed with ADMA or SDMA, which allows the study of 
leukocyte recruitment in postcapillary venules. 
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4.3.4. Results 
 
Leukocyte recruitment 
Leukocyte recruitment in response to ADMA and SDMA was assessed with LPS as a positive 
control. At baseline, no differences were found between the control group and the 
experimental groups. Figure 2-A shows images from representative experiments at different 
time periods. Illustrative movies can be found online as supplemental material.  
a. Rolling leukocytes 
As shown in figure 2-B, ADMA activated rolling with significantly higher numbers compared 
to the control group from 90 min on (54.2 ± 8.9 vs 20.2 ± 3.9, p<0.05).  
Superfusion with SDMA caused an even stronger activation of rolling. The number of rolling 
leukocytes tended to increase from 30 min on (28.8±4.7 vs 14.6±2.3, p=NS), and then further 
increased to reach a plateau at 60 min (80.2 ± 20.5 vs 14.3±2.2, p<0.001 vs control). 
Stimulation with LPS induced a strong increase, similar to that of SDMA, in the number of 
rolling leukocytes from 30 minutes on (36.6 ± 9.4 vs 14.6 ± 2.3, p<0.01 vs control), reaching 
a number of 90.4 ± 9.0 rolling leukocytes after 120 minutes exposure (p<0.01 vs control).  
b. Adhering and extravasated leukocytes 
No effect on adhesion and extravasation was seen in the presence of ADMA or SDMA, in 
contrast to LPS which was associated with a higher number of adhering leukocytes versus 
control after 60 (3.7 ± 0.8 vs 1.8 ± 0.3, p<0.05) and 120 min exposure (7.6 ± 1.4 vs 3.5 ± 0.3; 
p<0.05 vs control), and with an increased number of extravasating leukocytes from 30 min on 
(425 ± 59 vs 247 ± 36, p<0.05). 
 
Hemodynamic parameters  
Hemodynamic parameters are shown in table 1. Blood pressure, venular diameter and red 
blood cell velocity were not different between the groups.  
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Figure 2: Representative pictures (A) 
of intravital microscopy. Rolling 
leukocytes in response to ADMA, 
SDMA or LPS (B).  
A: Leukocyte rolling (arrows) in 
response to ADMA, SDMA or LPS, at 
baseline (t=0 min), after 60 and 120 
min of exposure. 
B: The number of rolling leukocytes at 
different time points during 
superfusion by HBSS (=controls) (■, 
n=12), ADMA (▼, n=6), SDMA (▲, 
n=7) or LPS (●, n=8).  
*p<0.05; **p<0.01; ***p<0.001 versus 
HBSS. 
 
 
 
 
 
 
 
4.3. Vascular damage by ADMA and SDMA 
187 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Peritoneal Exposure to uraemic toxins 
188 
Capillary leakage 
Capillary leakage, as demonstrated in figure 3, was more pronounced in the presence of 
ADMA and SDMA compared to control, and the leakage score was comparable to that caused 
by LPS (p<0.05). Leakage was observed in 3/12 (25%) rats in the control group, 6/8 (75%) 
rats in the LPS group, 6/7 (86%) rats in the SDMA group and 5/6 (83%) rats in the ADMA 
group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Capillary leakage 
Mean leakage scores of the fluorescent isothiocyanate labeled albumin at the end 
of the experiments, expressed as means ± SEM. Representative pictures are 
shown (A: 400x, B: 100x). 
*p<0.05 versus controls 
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Circulating leukocytes and hematocrit 
The total number of leukocytes and hematocrit values were not significantly different between 
the groups at any of the experimental time points. (data not shown) 
 
4.3.5. Discussion  
The present study investigates for the first time the effects of the dimethylarginines ADMA 
and SDMA on leukocyte recruitment, a critical step for inflammation and atherosclerosis, in 
an in vivo rat model, using intravital microscopy. 
The main findings were as follows: (1) rolling was activated by ADMA, (2) SDMA induced 
even earlier a more pronounced increase in rolling of the circulating leukocytes, similar to the 
reaction elicited by 1 µg/ml LPS; (3) both ADMA and SDMA caused strong leakage through 
the vessel wall.  
Until now, biological effects of ADMA have only been evaluated in an in vitro setting and 
mainly in cultured endothelial cells. Exposure to ADMA reduces endothelial NO synthesis, 
increases endothelial superoxide generation and increases adhesiveness of endothelial cells 
for monocytes by upregulation of MCP-1 and an increased endothelial NF-κB activity. 15 In 
addition, angiotensin II induces endothelial inflammatory reactions via the NF-κB pathway by 
stimulation of ADMA production.17 Monocytes become hyperadhesive when co-cultured with 
endothelial cells that have been exposed to ADMA.26 While the above-mentioned in vitro 
studies demonstrated endothelial effects of ADMA, only few focused on direct effects on 
leukocytes, and if so they reported contradictory results. Zhang et al demonstrated the ability 
of ADMA to increase intracellular monocytic TNF-α in a cultured THP-1 cell line, 
concomitantly with activation of NF-κB and intracellular reactive oxygen species (ROS) 
production.27  Schepers et al could only confirm the increase of ROS production but not the 
effect on NF-κB.19, 28
Our data on the other hand, definitely and directly underscore the involvement of leukocytes 
in the vascular impact of ADMA in vivo.  
  
While the impact on leukocytes has largely been neglected previously for ADMA, a reverse 
situation is seen for SDMA, where in vitro focus has been laid on leukocytes, overlooking a 
potential interference  with the endothelium. SDMA stimulates ROS production in monocytes 
through a mechanistic pathway involving Ca2+ influx 18. Stimulated ROS production is related 
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to oxidative stress, which is generally considered as one of the key factors causing vascular 
damage.29 Furthermore, SDMA has been shown to activate NF-κB in monocytes, resulting in 
an increased intracellular expression of TNF-α and IL-6.19 This was confirmed by a highly 
significant correlation between SDMA on one hand and IL-6 and TNF-α on the other in a 
clinical study in patients with different stages of CKD.19 SDMA also increases ROS 
production and inhibits NO synthesis in endothelial cells7, but the latter effect is probably due 
to the fact that SDMA causes a decreasing availability of L-arginine to NOS. In contrast to 
ADMA, which inhibits NO production by directly interfering with eNOS, SDMA acts as a 
competitor for the uptake of L-arginine, the substrate for eNOS, into the cells by inhibition of 
the γ+ class of cationic amino acid transporters.30
Our data show that both leukocytes and the endothelium interfere in the presence of SDMA, 
and that this effect is even more pronounced than in the presence of ADMA, which in general 
is considered as the more vasoactive compound of the two dimethylarginines. To the best of 
our knowledge, no previous studies have considered the cross-talk between the major cell 
types involved in vascular damage: leukocytes and endothelial cells, in the presence of 
ADMA and SDMA. Intravital microscopy by direct in vivo visualization enables to study and 
quantify these effects. This technique was already used by our group to study effects of 
peritoneal dialysis solutions on leukocyte recruitment.
 
20
Activation of circulating leukocytes is an early event in the inflammatory process. By 
releasing ROS, they have the potential to damage the endothelium.
  
31, 32 For a long time, 
leukocyte adhesion has been implicated as a prerequisite for leukocyte induced endothelial 
injury.33, 34 However, other studies evidenced that sites of albumin leakage are often different 
from those of leukocyte adhesion and migration, suggesting that other mechanisms are critical 
in the regulation of vascular leakage and barrier dysfunction during inflammation.35-38 More 
recently, activated leukocytes have been shown to increase vascular permeability in the 
absence of adhesion.39 In addition, the release of respiratory burst products upon leukocyte 
activation was found to increase microvessel permeability and endothelial intracellular 
calcium, independently from leukocyte adhesion and the migration process.32 This could 
explain the fact that rolling in the absence of adhesion or extravasation of leukocytes, as 
observed in the presence of ADMA and SDMA, is associated with distinct vascular leakage. 
These data then show that both rolling and leakage independently of adhesion can be linked to 
vascular damage.  
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Increased capillary permeability is a hallmark of functional microangiopathy and is associated 
with local interstitial edema in specific organs, such as the heart and the kidney, in arterial 
hypertension and diabetes mellitus.40 It is likely that alteration in the interstitial matrix 
composition contributes to organ damage.41 Leakage induced by the dimethylarginines was 
suggested earlier in vitro for ADMA42-44 and in vivo for SDMA45
It is conceivable that induction of rolling is linked to altered expression of adhesion 
molecules. However, the information on the effects of ADMA and SDMA on surface 
molecules is scanty. An in vitro study showed that both ADMA and SDMA decrease CD62L 
expression on granulocytes, a leukocyte selectin that mediates rolling.
, be it at higher 
concentrations than in the present study, respectively more than two-fold for ADMA and even 
more than 10-fold for SDMA. 
28 This could be caused 
by a downregulation of L-selectin by proteolytical shedding in response to cell activation, as 
previously demonstrated by Kansas et al 46. In addition, SDMA was shown to upregulate 
expression of the adhesion molecues CD11a and CD11b on monocytes.28
In conclusion, the present study indicates for the first time in vivo that both ADMA and 
SDMA are important inducers of leukocyte activation and their recruitment towards the 
endothelium, and that they can cause severe vascular leakage, comparable to leakage induced 
by LPS. These findings might have important pathophysiologic consequences, necessitating 
focus on leukocytes next to endothelium in the search for neutralization of the activity of 
ADMA on the vessels. In addition, conform clinical and experimental data from our group
 To the best of our 
knowledge, there are no data on the effects on endothelial adhesion molecules. 
18, 
19, 28
 
, the role of SDMA was at least as important as that of ADMA, stressing that among the 
dimethylarginines next to ADMA, also SDMA should as such be taken into account when 
assessing cardiovascular damage or risk.  
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Peritoneal dialysis (PD) is a life saving renal replacement therapy1 with several advantages 
compared to haemodialysis (HD) such as an increased flexibility and a better survival in the 
first years of application. Moreover, it is more cost-effective compared to predominantly 
hospital based HD.2 The most important limiting factor for its long-term use is the progressive 
decline of dialytic efficacy, especially ultrafiltration, as a result of progressive degradation of 
peritoneal membrane structure and function.3-5
This deterioration of the quality of the peritoneal membrane in patients on peritoneal dialysis 
has been described as a combination of neoangiogenesis and fibrosis, the latter especially due 
to an increase in submesothelial thickness.
 
6;7
The presence of glucose and glucose degradation products (GDPs) in the dialysate fluid
 
8
Although these solutions perform clearly better in terms of biocompatibility in an in vitro 
setting
, and 
the unphysiological low pH of the dialysate solution have attracted most attention as culprits 
in these processes, finally leading to the development of solutions low in GDPs and with a 
physiological pH.  
9-12 and in animal models13-17
This discrepancy can be explained by the fact that, besides GDPs and low pH, many other 
factors impact on the properties of the peritoneal membrane. These factors are often neglected 
in clinical studies, potentially leading to unnoticed differences in case-mix and blurring of the 
potential impact of the novel solutions. On the other hand, many of these factors are 
modifiable, and attention should be paid to them also in everyday clinical practice to maintain 
peritoneal membrane integrity. 
, their benefit in clinical conditions on preservation of 
peritoneal membrane integrity so far remains unproven.  
The present thesis focused on factors potentially influencing peritoneal membrane integrity, 
with exclusion of those associated to the PD fluid (PDF) itself. In the first part, we assessed 
the effect of potentially protective interventions to slow down deterioration of the peritoneal 
membrane. In the second part, we investigated the impact of individual uraemic retention 
solutes on the behaviour of leukocytes in vivo to unravel the association between uraemia, 
inflammation and cardiovascular damage at vascular level. 
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In chapter 2, it was demonstrated that an oral formulation of sulodexide (Biofer SpA, 
Medolla, Italy)
Sulodexide is a highly purified mixture of glycosaminoglycans (GAGs) containing 80% low-
molecular weight heparin and 20% dermatan sulphate.
 preserved the peritoneal membrane integrity in a chronic rat PDF perfusion 
model. 
18-20
It has the advantage that it is available as an oral preparation, in contrast to e.g. hyaluronan 
and low-molecular weight heparins. Sulodexide has been approved for human use.  
  
Of interest, peritoneal membrane changes during long-term PD are similar to those observed 
in diabetes21 and both conditions have been related to the presence of high glucose 
concentrations.22;23 Sulodexide has been investigated as an oral drug for prevention of diabetic 
nephropathy, and the preliminary investigations were promising.24 However, in a recent large 
randomized controlled trial in diabetics with micro-albuminuria, oral sulodexide did not result 
in any difference in evolution of either albuminuria or serum creatinine.25 In an accompanying 
editorial, a warning was given that, although surrogate endpoints were not changed, one 
should be careful not to miss harder endpoints, such as morphology.26
Although in our study no difference in net ultrafiltration between the PD-groups with and 
without sulodexide was seen, peritoneal transport rates for creatinine and glucose, sodium 
sieving and protein loss were better preserved in the sulodexide treated PD-group. This 
functional improvement was associated with less neoangiogenesis and reduced submesothelial 
thickening and epithelial-to-mesenchymal transition (EMT). However, no reduction of VEGF 
in the dialysate was observed. We hypothesize that sulodexide inhibits VEGF activity either 
by binding it or by inhibiting the interaction with its receptor.  
 In addition, the authors 
raised the point that sulodexide could potentially be protective through mechanisms not 
related to albuminuria. 
These data at least support further investigation of oral sulodexide administration as a 
potentially interesting strategy in PD patients. 
As we did not use diabetic rats in our model, it could be interesting to repeat the experiments 
to see whether the effect of sulodexide is reproducible in diabetic animals.  
Furthermore, it could be interesting to evaluate the effect of chronic oral sulodexide 
administration on capillary leakage, using intravital microscopy. 
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We also believe it could be of interest to investigate renal morphology of diabetic rats treated 
with oral sulodexide, to investigate the effects on neoangiogenesis under these conditions in 
the kidney. 
Additional experiments with longer study periods, testing different doses of sulodexide is 
necessary before performing clinical trials. Until today, no large clinical trial to examine 
potential positive effects of sulodexide on peritoneal membrane morphology and function has 
been executed. However, sulodexide has already been extensively investigated as a drug for 
prevention of diabetic nephropathy, as described above. The reason for this is practical rather 
than scientific. The pharmaceutical market for diabetic nephropathy is larger than that for 
peritoneal dialysis, which makes it unfortunately more difficult to start such large clinical 
trials in the field of PD.  
 
In Chapter 3, we focused on the potentially harmful effects of dietary salt intake on the 
peritoneal membrane. There is abundant evidence about deleterious effects of high salt intake 
in the general population, ranging from hypertension to inflammatory events.27 Increased salt 
intake is related to extracellular fluid expansion, resulting in an increased blood pressure and 
left ventricular hypertrophy. Furthermore, increased salt intake by itself is directly associated 
to cardiovascular complications, even without volume overload.28
End-stage renal disease 
  
patients are particularly susceptible to the negative consequences of 
sodium loading. While individuals with normal kidney function are able to regulate their 
sodium balance through adaptation of the renal sodium excretion, dialysis patients have to 
rely virtually entirely on the dialysis procedure for the elimination of their dietary sodium. For 
PD-patients, high salt intake and subsequent higher fluid intake are detrimental because of the 
need to use more hypertonic dialysate solutions to maintain volume balance, which by itself is 
a cause of deterioration of the peritoneal membrane.
Our animal study demonstrated that dietary salt intake by itself induces EMT of the peritoneal 
membrane, as identified by co-localization of cytokeratin and alpha-smooth muscle actin (α-
SMA), together with an increase in interstitial fibrosis and thickening of the submesothelial 
layer.  
  
Concordant with this, peritoneal Transforming Growth Factor beta 1 (TGF-β1) and 
interleukin-6 (IL-6) mRNA expression were increased, suggesting that dietary salt loading 
induces EMT and peritoneal fibrosis, by upregulation of TGF-β1 and IL-6.  
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It is surprising that the effects of salt intake appeared so rapidly, after only 2 weeks of 
exposure. However, previous experiments of salt loading from other groups already pointed 
out that effects of high salt intake seem to appear very rapidly.29-31
The underlying mechanisms leading to these observations need further elaboration.  
  
Interesting ways to unravel the pathways could be to block TGF-β1 using anti-TGF-β1 
antibodies or using ACE inhibitors to block angiotensin II, which is able to activate TGF-β.32 
The latter mechanism explains why use of ACE-inhibitors has a positive impact on peritoneal 
membrane morphology.33 The activation of TGF-β through angiotensin hypothetically could 
even explain the discordant results found in studies on the detrimental effects of sodium 
restriction in diabetic patients34 In patients with type 2 diabetes, lower 24-h urinary sodium 
excretion was paradoxically associated with increased all-cause and cardiovascular 
mortality.35;36
The possible role of the hyperosmolar environment created in the gut by the ingestion of 
dietary salt could be also interesting to investigate. It has been demonstrated that local 
hyperosmolarity leads to osmotic stress and upregulation of tonicity-responsive enhancer 
binding protein (TonEBP). TonEBP activates osmoprotective genes to ensure cell function in 
hostile environments with increased interstitial tonicity,
 An association between reduced sodium intake and an activation of metabolic 
and neurohormonal pathways, including the renin-angiotensin-aldosterone (RAAS) system 
has been reported, so it could be hypothesized that sodium restriction leads to upregulation of 
RAAS, and sodium loading can thus give an effect comparable to that of ACE-inhibition. 
37;38 but also stimulates macrophages 
and upregulates VEGF production.31
Another interesting pathway is to investigate the adipocytes, which are ubiquitous in 
peritoneal tissue. It is hypothesized that they can be an important source of cytokine secretion, 
including IL-6 and TGF-β
 
1.39-41 In our study, salt intake induces more pronounced 
upregulation of IL-6 and TGF-β1
Finally, it would be interesting to know if peritoneal changes induced by high sodium diet are 
reversible.  
 expression in the visceral peritoneal membrane, where 
adipocytes are abundant as compared to the parietal peritoneal membrane, where they are 
rather scarce. Again, it could be that the local hyperosmolarity induced by peroral salt intake 
leads to irritation of the adipocytes. 
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In chapter 4, we analysed the impact of the uraemic milieu itself on the integrity of the 
endothelium of the venules in the peritoneal membrane. 
When kidney function is lost and renal failure develops, a host of compounds which under 
normal conditions are excreted into the urine by the healthy kidneys, accumulate in the body. 
These compounds cause a gradual state of endogenous intoxication, named uraemia, after the 
most abundant, but relatively inert compound urea. This uraemic intoxication results in the 
malfunctioning of most body organs and organ systems. One of the most worrying problems 
is the accelerated vascular damage, which is partially a result of the increased inflammation in 
uraemia.  
The last decade, an increasing number of uraemic solutes with direct vasotoxic effects are 
identified42, and a lot of uraemic solutes can be held responsible for the micro-inflammation 
in the uraemic patient. Besides cardiovascular disease, another important cause of death in 
chronic kidney disease patients is infection.43-45
On the one hand, leukocytes at baseline are chronically activated in an uraemic milieu. This 
results in chronic inflammation, on itself one of the underlying reasons of cardiovascular 
disease and malnutrition, a syndrome coined as “malnutrition inflammation arteriosclerosis” 
(MIA) syndrome.
 It has been postulated that disturbances in 
leukocyte function due to accumulation of uraemic retention solutes are the common pathway 
of these two processes.  
46-48 On the other hand, they do not respond adequately upon stimulation, 
resulting in an impaired immune response and increased risk of (bacterial) infection. Chronic 
infection in its turn has been associated with enhanced cardiovascular risk.49
Chronic inflammation of the peritoneal membrane leads to fibrosis, neoangiogenesis, and 
EMT.
 Thus, these two 
apparently conflicting phenomena can explain the chronic inflammation as well as the 
defective immune response causing an increased susceptibility for infection, observed in 
uraemia. 
50 The prevention of leukocyte activation caused by pro-inflammatory uraemic toxins, 
could thus be an interesting pathway to prevent damage of the peritoneum. For example, it has 
been demonstrated that administration of inhibitors of the prostaglandin synthase pathway can 
result in an improved preservation of the peritoneal membrane.51
Our laboratory has done extensive research on the in vitro impact of individual uraemic 
retention products. Such an in vitro setting has the major advantage that all known and 
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unknown factors involved can be well controlled. However, the interaction between different 
factors and the responsible mechanisms can better be evaluated in an in vivo system. 
As described in chapter 4.2. and chapter 4.3., we used an intravital video microscopy model to 
evaluate leukocyte function in postcapillary venules of the peritoneal membrane under 
exposure to representatives of 2 major subgroups of uraemic retention solutes: 1) the protein-
bound compounds (indoxylsulfate, p-cresylsulfate and p-cresylglucuronide) and 2) the water-
soluble compounds (ADMA and SDMA).  
The major advantage of intravital microscopy is the possibility to evaluate leukocytes in their 
normal environment. In this model, we could easily add well defined doses of individual 
uraemic toxins to the superfusion solution, to explore the impact of this addition on the 
behaviour of the leukocytes.  
In vitro and ex vivo data link both p-cresylsulfate and indoxylsulfate to negative impact on the 
vascular system. Recent in vivo observational data also relate serum concentrations of these 
compounds to mortality, inflammation, vascular disease and progression of renal disease in 
different, even moderate stages of chronic kidney disease.52-58
As described in chapter 4.2., indoxylsulfate caused an immediate firm adhesion and 
extravasation of the circulating leukocytes and had a dramatic effect on blood flow, resulting 
in an interruption, or even a complete stop of the flow. P-cresylsulfate induced a moderate 
activation, resulting in an increased number of rolling leukocytes. The combination of both p-
cresylsulfate and p-cresylglucuronide had no additive effect to p-cresylsulfate alone on 
leukocyte recruitment. On the other hand, the addition of both compounds caused an impaired 
blood flow and enhanced capillary leakage.  
  
Although all three compounds investigated in this study are protein-bound molecules, they 
seem to exert divergent effects, but all are proinflammatory in a way that they could 
contribute to vascular damage by stimulating cross-talk between leukocytes and vessels. In 
addition, indoxylsulfate and the combination of p-cresylsulfate and p-cresylglcuronide 
induced unusual blood flow patterns.  
Next to the group of the protein-bound compounds, the effects of the water-soluble 
compounds asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) 
are described in chapter 4.3., ADMA and SDMA appeared to be important inducers of 
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leukocyte rolling and were able to cause severe vascular leakage, in a degree comparable to 
the vascular damage induced by LPS.  
This is, to our knowledge, the first time that the association between ADMA and 
inflammation through activiation of leukocytes has been demonstrated in an in vivo setting. 
Neutralizing ADMA will thus not only have beneficial effects on the endothelium directly 
through NO mediated vasodilation, but also indirectly through its impact on leukocyte activity 
and thus inflammation. In addition, the role of SDMA was at least as important, stressing that 
next to ADMA, SDMA should also be taken into account when assessing cardiovascular 
damage or risk, and especially when developing removal or neutralization strategies.  
 
Future work will be conducted to elucidate the underlying mechanism responsible for blood 
flow interruption after exposure to indoxylsulfate. It might be interesting to investigate the 
impact of these uraemic toxins on the coagulation pathway, more especially the role of tissue 
factor, and certainly to evaluate cross-links between coagulation and the inflammatory 
pathways. 
It is also of interest to analyze the effects of individual uraemic toxins on leukocyte function 
in a more chronic setting. For this goal, chronic infusion studies with individual uraemic 
toxins can be set up in healthy animals. Alternatively, acute and chronic infusion of these 
toxins could be performed in uraemic animals, to explore the impact of the individual 
compounds on top of the uraemic state. These type of experiments could shed light in the 
question whether selective removal of individual uraemic retention solutes could result in 
improved outcomes. Finally, we think it would be also useful to investigate the effects of 
different solutes simultaneously. 
At the moment, technology for direct adsorption from blood by haemoperfusion with bead 
columns is available for β2-microglubulin59 and interleukin-1β60, and systems for protein-
bound solutes61
To unravel the underlying pathways by which uraemic toxins exert their effects, specific 
blockers can be used. In the case of SDMA for example, in vitro experiments from our group 
showed that N-acetyl-cysteine (NAC) and the ACE-inhibitor captopril are able to inhibit 
respectively the SDMA-induced NF-κB activation
 are under development.  
62 and the SDMA-enhanced ROS 
production63 Also the in vivo effect of such substances could be analyzed. 
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Although we agree that using a uraemic rat model would be extremely interesting, we did not 
use it in the studies included in this doctoral thesis, because of different reasons:  
1) We wanted to investigate the impact on peritoneal membrane morphology and 
function of the different compounds (salt, sulodexide, uremic toxins,…) per se and in isolated 
fashion. Inducing uraemia would cause more interfering factors, as it has been well described 
that uraemia per se can cause changes in peritoneal morphology.64-66
2) A problem of the nephrectomy rat model is that it creates large differences in 
degrees of uraemia obtained, at least in our hands, but also in other reported models. This 
would create additional bias in the interpretation of the results, as then the different degrees of 
baseline uraemia would be a major confounder, potentially blurring effects. We wanted to 
first establish the separate effect of individual components.  
  
3) The initial mortality rate of a peritoneal dialysate exposure model in uraemic 
animals is high. This creates a problem of “selection bias” (survival of the fittest), and most 
likely also of survival of those animals who have the lowest degree of uraemia. Again, this 
would severely hamper the interpretation of the results. 
4) In the case of the salt study, we asked ourselves the question why some uraemic 
patients do and others do not develop morphological and functional alterations of the 
peritoneal membrane, already before the start of peritoneal dialysis. Of course, these 
differences are partially explained by differences in comorbidities such as diabetes, genetic 
background and/or uraemia. However, salt intake on itself has already been shown to induce 
cardiac fibrosis67 and glomerulosclerosis in the kidney.29
5) For the intravital microscopy experiments, we prefered to evaluate the acute effects of 
one single toxin, excluding the effect of the whole uraemic milieu. For clinical use, a 
classification of uraemic solutes according to their unique biological effect is needed to permit 
a clinically and economically justified choice of target molecules in set-ups of selective toxin 
removal. 
 Because we hypothesized salt intake 
could induce similar effects on the peritoneal membrane, we used healthy Witstar rats. 
However, in the future, it would indeed be interesting to perform the same experiments in 
uraemic and/or PD rats.  
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In summary, the main conclusions of the studies performed in this thesis are: 
1) Excessive salt administration induces peritoneal membrane changes, even without the 
presence of glucose-containing dialysis fluids. Therefore, dietary salt restriction in the 
diet of CKD patients should be advocated already in pre-dialysis patients.  
2) The glycosaminoglycan sulodexide in its oral formulation is a good candidate for the 
protection of the peritoneal membrane during peritoneal dialysis. 
3) In vivo, indoxylsulfate, p-cresylsulfate and p-cresylglucuronide exerted pro-
inflammatory effects through activation of leukocytes, while indoxylsulfate and the 
combination of p-cresylsulfate and p-cresylglucuronide induced a dramatic decrease of 
blood flow. 
4) In vivo data show that both ADMA and SDMA are important inducers of leukocyte 
activation, thereby causing severe vascular damage. 
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Peritoneale dialyse (PD) is een levensreddende, nierfunctievervangende therapie1 met 
verscheidene voordelen ten opzichte van hemodialyse (HD) zoals een grotere flexibiliteit en 
een betere overleving gedurende de eerste jaren. Bovendien is ze goedkoper, vergeleken met 
HD die overwegend in het ziekenhuis wordt uitgevoerd.2 De belangrijkste limiterende factor 
voor het langdurig gebruik van PD is de progressieve achteruitgang van de doeltreffendheid 
van de dialyse, voornamelijk wat betreft de ultrafiltratie, als gevolg van progressieve 
achteruitgang van de structuur en functionaliteit van de peritoneale membraan.3-5
Deze achteruitgang van de kwaliteit van de peritoneale membraan bij PD-patiënten bestaat uit 
een combinatie van neovascularisatie en fibrose, meer in het bijzonder een toename van de 
submesotheliale zone.
 
6;7
De aanwezigheid van glucose en glucose degradatieproducten (GDPs) in het dialysevocht
 
8
Ondanks het feit dat deze oplossingen het beter doen op vlak van 
, en 
de onfysiologisch lage pH van het dialysevocht hebben tot nog toe steeds het meest de 
aandacht getrokken als oorzaken voor deze processen, wat uiteindelijk geleid heeft tot de 
ontwikkeling van dialysaatoplossingen met lage GDP concentraties en een fysiologische pH. 
biocompatibiliteit in een in 
vitro setting9-12 en in dierenmodellen13-17
De tegenstrijdige resultaten bekomen met deze nieuwe dialysaatoplossingen kunnen verklaard 
worden door het feit dat, behalve GDPs en een lage pH, ook vele andere factoren een impact 
hebben op de eigenschappen van de peritoneale membraan. Deze factoren worden vaak over 
het hoofd gezien in klinische studies, wat kan leiden tot onopgemerkte verschillen tussen de 
studiepopulaties die de mogelijke impact van nieuwe oplossingen kunnen doen vervagen. Aan 
de andere kant zijn vele van deze factoren modificeerbaar en zou er rekening mee moeten 
gehouden worden in de klinische praktijk om de integriteit van de peritoneale membraan te 
behouden. 
, is hun voordeel qua behoud van de integriteit van de 
peritoneale membraan tot nog toe nog niet bewezen in klinische omstandigheden. 
Deze thesis heeft zich toegelegd op factoren die mogelijk de integriteit van de peritoneale 
membraan beïnvloeden, met uitsluiting van componenten aanwezig in het dialysaatvocht zelf. 
In het eerste deel hebben we de gevolgen nagekeken van interventies die de achteruitgang van 
de peritoneale membraanfunctie zouden kunnen vertragen. In het tweede deel onderzochten 
we de impact van individuele uremische retentiestoffen op het gedrag van leukocyten in vivo 
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om het verband tussen uremie, inflammatie en cardiovasculaire schade te ontrafelen op 
vasculair niveau. 
In hoofdstuk 2 werd in een chronisch ratmodel met perfusie van peritoneale 
dialysaatvloeistoffen aangetoond dat de integriteit van de peritoneale membraan beschermd 
kan worden door orale toediening van sulodexide (Biofer
Sulodexide is een zuivere mengeling van glycosaminoglycanen (GAGs) bestaande uit 80% 
laag-moleculair heparine en 20% dermatan sulfaat.
 SpA, Medolla, Italië).  
18-20
Veranderingen in de peritoneale membraan tijdens lange-termijn toepassing van PD zijn 
dezelfde als bij diabetes
 Het heeft als groot voordeel 
beschikbaar te zijn in een orale vorm, in tegenstelling tot bijvoorbeeld hyaluronan en laag-
moleculair gewicht heparines. Sulodexide werd goedgekeurd voor humaan gebruik.  
21 terwijl beide condities aan mekaar verwant zijn door de 
aanwezigheid van hoge glucose concentraties.22;23 In zijn orale vorm is sulodexide al 
onderzocht in het kader van preventie van diabetische nefropathie met veelbelovende 
preliminaire resultaten.24 In een recente grote gerandomiseerde gecontroleerde studie in 
diabetici met micro-albuminurie kon daarentegen geen effect van orale sulodexide in de 
evolutie van albuminurie of serum creatinine aangetoond worden.25
In een bijhorend editoriaal werd er op gewezen dat, hoewel geen veranderingen in surrogaat 
eindpunten werden gevonden, de resultaten toch met omzichtigheid moesten worden 
geïnterpreteerd. Inderdaad werden geen harde eindpunten zoals bijvoorbeeld morfologie 
onderzocht in deze studie.
  
26
Alhoewel we in onze rattenstudie geen verschil zagen in ultrafiltratie tussen de groepen met 
en zonder sulodexide, werden het peritoneaal transport voor creatinine en glucose, de ‘sodium 
sieving’ (sodium dip) en het eiwitverlies wel beter bewaard in de sulodexide groep. Deze 
functionele verbetering was geassocieerd met minder neovascularisatie, minder epitheliale 
naar mesenchymale transitie van de mesotheelcellen (EMT) en een mildere toename van de 
submesotheliale zone. Merkwaardigerwijs werd echter geen daling van ‘Vascular Endothelial 
Growth Factor’ (VEGF) in het dialysaat geobserveerd, zodat we kunnen veronderstellen dat 
sulodexide de VEGF activiteit kan inhiberen door ofwel VEGF te binden, ofwel door de 
interactie van VEGF met zijn receptor te beletten. 
 Het is daarom niet uit te sluiten dat een positief effect van 
sulodexide in deze studie werd gemist indien de beschermende werking niet via een reductie 
van albuminurie zou gaan.  
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Deze gegevens zijn een stimulans om verder onderzoek te doen naar orale sulodexide 
toediening als een potentieel interessante strategie in PD patiënten. 
Aangezien we geen diabetische ratten in ons model hebben gebruikt, zou het interessant 
kunnen zijn deze experimenten te herhalen om te kijken of het effect van sulodexide 
reproduceerbaar is in dieren met diabetes. 
Bovendien kan het interessant zijn om het effect van chronisch orale sulodexide toediening op 
capillaire lekkage te bekijken, gebruik makende van intravitaalmicroscopie. 
We geloven ook dat het van belang kan zijn om de morfologie van de nieren van diabetische 
ratten, behandeld met sulodexide, te bestuderen om de vorming van nieuwe bloedvaten in de 
nier te onderzoeken. 
Extra dierexperimenten, met een langere studieduur, en waarbij verschillende dosissen van 
sulodexide worden getest, zijn noodzakelijk vooraleer er kan worden overgegaan naar 
klinische studies. Tot op vandaag zijn er geen klinische studies waarbij potentieel positieve 
effecten van sulodexide op de morfologie en functie van de peritoneale membraan zijn 
bestudeerd. Sulodexide is wel reeds uitgebreid geëvalueerd als medicijn voor de preventie van 
diabetische nefropathie, zoals hierboven beschreven. Uiteraard dient hierbij in rekening te 
worden gebracht dat de farmaceutische markt voor diabetische nefropathie veel groter is dan 
die voor peritoneale dialyse, wat het minder waarschijnlijk maakt dat dergelijke grootschalige 
gerandomiseerde klinische studies in een populatie onder behandeling met PD effectief zullen 
plaatsgrijpen.  
 
In hoofdstuk 3 richtten we ons op de mogelijke nadelige effecten van zoutinname op de 
peritoneale membraan. Er is al heel wat gekend over de schadelijke effecten van een hoge 
zoutinname in de algemene populatie, gaande van hypertensie tot inflammatie.27 Een 
verhoogde zoutinname is gerelateerd aan een toename van het extracellulaire volume, 
resulterend in een verhoging van de bloeddruk en linkerventrikelhypertrofie. Verder is 
verhoogde zoutinname op zich rechtstreeks geassocieerd aan cardiovasculaire aandoeningen, 
zelfs zonder dat er sprake is van volume overbelasting (pleiotrope effecten).28
Patiënten met eindstadium nierfalen zijn bijzonder vatbaar voor de negatieve gevolgen van 
een te hoge inname van natriumchloride. In tegenstelling tot mensen met een normale 
nierfunctie, die in staat zijn om hun natriumbalans te regelen door aanpassing van de renale 
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natrium excretie, hangen dialysepatiënten zo goed als volledig af van de dialyseprocedure om 
hun natrium dat aanwezig is in hun dieet te elimineren. Voor PD patiënten is een hogere 
zoutinname en een daaruit volgende hogere vloeistofinname extra nadelig omdat er dan meer 
hypertone dialysaatoplossingen nodig zijn om de volumebalans in stand te houden, wat op 
zichzelf dan weer beschadiging kan veroorzaken aan de peritoneale membraan. 
Ons proefdieronderzoek toonde aan dat een verhoogde zoutinname via het voedsel interstitiële 
fibrose in het interstitium veroorzaakt, en een verdikking van de submesotheliale zone. We 
observeerden ook EMT van de peritoneale membraan, aangetoond door colokalisatie van 
cytokeratine en ‘alpha-smooth muscle actin’ (α-SMA). We vonden ook een toegenomen 
expressie van peritoneaal ‘Transforming Growth Factor beta 1’ (TGF-β1) en interleukine-6 
(IL-6) mRNA, wat zou kunnen wijzen op het feit dat zoutinname fibrose en EMT in het 
peritoneum induceert via opregulatie van TGF-β1
Het is opmerkelijk dat de effecten van zoutinname zo snel optraden, na slechts 2 weken 
blootstelling. Echter, voorgaande experimenten van andere onderzoeksgroepen met 
zoutinname wezen ook uit dat effecten van een hoge zoutinname zeer snel optraden.
 en IL-6. 
29-31
De onderliggende mechanismen verantwoordelijk voor deze veranderingen moeten nog 
verder worden onderzocht. Het zou interessant zijn deze te ontrafelen door TGFβ
  
1 te 
blokkeren door middel van hetzij anti-TGFβ1 antilichamen, hetzij ‘Angiotensin Converting 
Enzyme’ inhibitoren (ACEI), die de productie remmen van angiotensine II, een TGF-β 
activator.32 Het laatste mechanisme zou kunnen verklaren waarom het gebruik van ACE-
inhibitoren een positieve invloed heeft op de morfologie van de peritoneale membraan.33 
Hypothetisch gezien kan het zelfs de tegenstrijdige resultaten, gevonden in studies omtrent 
schadelijke effecten van zoutrestrictie in diabetespatiënten, verklaren.34 In patiënten met 
diabetes type II is een lagere 24-uurs urinaire natrium excretie paradoxaal geassocieerd met 
een toegenomen mortaliteit.35;36
De invloed van de hyperosmolaire omgeving die in de darm gecreëerd wordt door de inname 
van zout via de voeding, is ook interessant om te bestuderen. Het is namelijk al aangetoond 
dat hyperosmolariteit leidt tot osmotische stress en opregulering van het ‘tonicity-responsive 
 Het is aangetoond dat een gereduceerde zoutinname 
geassocieerd is met een activatie van metabole en neurohormonale assen, inclusief het renine-
angiotensine-aldosterone systeem (RAAS); het zou dus kunnen dat zoutrestrictie bij 
diabetespatiënten leidt tot een opregulatie van het RAAS, en zoutinname in dat geval dus een 
effect vergelijkbaar met dat van ACE-inhibitie kan hebben. 
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enhancer binding protein’ (TonEBP). TonEBP activeert osmoprotectieve genen die de 
celfunctie in een vijandige omgeving met een toegenomen interstitiële toniciteit 
verzekeren37;38, maar stimuleert ook macrofagen en VEGF productie.31
Een ander interessant aspect om te onderzoeken, is de rol van de adipocyten, welke veelvuldig 
aanwezig zijn in het peritoneale weefsel. Zij vormen een belangrijke bron van cytokine 
secretie, inclusief IL-6 en TGF-β
  
1.39-41 In onze studie zagen we dat zoutinname een meer 
uitgesproken opregulering van IL-6 en TGF-β1
Tenslotte zou het interessant zijn om te weten of de veranderingen in de peritoneale 
membraan veroorzaakt door een verhoogd zoutdieet, reversibel zijn. 
 expressie gaf in het visceraal peritoneum, 
waar adipocyten overvloedig aanwezig zijn in vergelijking met het pariëtaal peritoneum, waar 
adipocyten eerder schaars zijn. Het is ook mogelijk dat de lokale hyperosmolariteit, 
geïnduceerd door orale zoutinname, leidt tot irritatie van de adipocyten. 
 
In hoofstuk 4 analyseerden we de impact van het uremisch milieu op de integriteit van het 
endotheel van de venules in de peritoneale membraan. 
Wanneer de nierfunctie achteruit gaat en nierfalen ontstaat, accumuleren een groot aantal 
stoffen in het lichaam welke normaal gezien door de nieren uitgescheiden worden in de urine. 
Deze stoffen veroorzaken een geleidelijke staat van endogene vergiftiging, uremie genaamd, 
wat resulteert in een dysfunctie van de meeste organen en orgaansystemen. Eén van de meest 
zorgwekkende problemen is de versnelde ontwikkeling van vaatschade die deels een gevolg is 
van de toegenomen inflammatie in uremie. 
Het voorbije decennium werd er een groot aantal uremische retentiestoffen met directe 
vasotoxische effecten geïdentificeerd42, waarvan een aanzienlijk deel ook in verband kon 
worden gebracht met de micro-inflammatie in de uremische patiënten. Naast cardiovasculaire 
ziekten is infectie een andere grote oorzaak van sterfte in patiënten met nierfalen.43-45
Accumulatie van uremische toxines resulteert in een verstoring van de functies van de witte 
bloedcellen, die zowel in cardiovasculaire ziekten als in infectie een rol speelt. 
  
Enerzijds worden witte bloedcellen chronisch basaal geactiveerd in een uremisch milieu. Dit 
resulteert in chronische inflammatie, op zichzelf één van de onderliggende redenen van 
cardiovasculaire ziekte en malnutritie, een syndroom benoemd als het “malnutritie 
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inflammatie arteriosclerose” (MIA) syndroom.46-48 Anderzijds reageren de witte bloedcellen 
van uremische patiënten niet adequaat op stimulatie, wat resulteert in een verzwakte 
immuunrespons en een toegenomen risico op (bacteriële) infectie. Chronische infectie is op 
zijn beurt geassocieerd met een groter cardiovasculair risico.49
Chronische inflammatie van de peritoneale membraan leidt tot fibrose, neovascularisatie en 
EMT.
 Op deze manier kunnen in 
uremie zowel de chronische inflammatie als de defectieve immuunrespons met verhoogde 
vatbaarheid voor infectie tot gevolg, worden verklaard. 
50 Het afremmen van de pro-inflammatoire eigenschappen van de uremische toxines die 
een activatie van de witte bloedcellen veroorzaken, zou dus een interessante manier kunnen 
zijn om de peritoneale membraan te beschermen. Het is bijvoorbeeld al aangetoond dat 
toediening van inhibitoren van de prostaglandine synthese resulteert in een beter behoud van 
de peritoneale membraan.51
Ons laboratorium heeft reeds uitgebreid onderzoek verricht naar de in vitro impact van 
individuele uremische retentieproducten op witte bloedcellen. In vitro proeven hebben het 
grote voordeel dat alle betrokken gekende en ongekende (geteste) factoren goed gecontroleerd 
kunnen worden. Niettemin worden de interactie tussen verschillende factoren en de 
verantwoordelijke mechanismen beter bestudeerd in een in vivo opstelling. 
 
Zoals beschreven in hoofdstuk 4.2. en hoofdstuk 4.3., maakten we in dit werk gebruik van 
een intravitaal videomicroscopie model om de functie van de witte bloedcellen te bestuderen 
in postcapillaire venules van de peritoneale membraan. We stelden in dit model de witte 
bloedcellen bloot aan representatieve vertegenwoordigers van twee grote subgroepen 
uremische retentiestoffen: 1) de eiwitgebonden stoffen (nl. indoxylsulfaat, p-cresylsulfaat en 
p-cresylglucuronide) en 2) de water-oplosbare stoffen (nl. ADMA en SDMA). 
Het grote voordeel van intravitaalmicroscopie is de mogelijkheid om witte bloedcellen te 
observeren in hun normale omgeving. Met dit model konden we relatief eenvoudig goed 
gedefinieerde concentraties van individuele uremische toxines toevoegen aan de superfusie 
oplossing, om zo de impact van deze toxines op het gedrag van de witte bloedcellen te 
bestuderen. 
In vitro en ex vivo gegevens tonen aan dat zowel p-cresylsulfaat als indoxylsulfaat een 
negatieve vasculaire impact kunnen hebben. Recente in vivo observationele gegevens 
associëren serum concentraties van deze componenten met mortaliteit, inflammatie, 
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vaatziekten en de progressie van nierziekte in verschillende, zelfs milde stadia van chronisch 
nierfalen.52-58
In hoofdstuk 4.2. beschrijven we de sterke adhesie en extravasatie van de circulerende witte 
bloedcellen die uitgelokt wordt door indoxylsulfaat, met een dramatisch effect op de 
bloeddoorstroming in de capillairen, zelfs resulterend in een onderbreking van de flow. P-
cresylsulfaat veroorzaakte een matige activatie van de witte bloedcellen, hetgeen resulteerde 
in een toegenomen aantal rollende witte bloedcellen. De combinatie p-cresylsulfaat en p-
cresylglucuronide veroorzaakte geen additief effect op de recrutering van witte bloedcellen in 
vergelijking met p-cresylsulfaat alleen, maar veroorzaakte daarentegen wel een verzwakte 
doorbloeding en toegenomen capillaire lekkage.  
 
De drie eiwitgebonden moleculen die werden onderzocht in deze studie zijn allemaal pro-
inflammatoir, maar lijken ook uiteenlopende effecten te kunnen veroorzaken. Ze kunnen 
bijdragen tot vaatschade door de interferentie tussen witte bloedcellen en bloedvaten te 
stimuleren. Daarenboven veroorzaakten indoxylsulfaat en de combinatie van p-cresylsulfaat 
en p-cresylglucronide ook nog eens ongewone patronen van capillaire doorbloeding. 
De effecten van de wateroplosbare stoffen asymmetrisch dimethylarginine (ADMA) en 
symmetrisch dimethylarginine (SDMA) staan beschreven in hoofdstuk 4.3. 
ADMA en SDMA bleken de witte bloedcellen sterk te activeren en veroorzaakten ernstige 
vaatschade, waarvan de mate vergelijkbaar is met de vaatschade veroorzaakt door LPS.  
Het is voor zover we weten de eerste keer dat er een associatie is aangetoond tussen ADMA 
en inflammatie door activatie van witte bloedcellen in een in vivo opstelling. Het neutraliseren 
van ADMA zou dus niet enkel een rechtsreeks voordelig effect hebben op het endotheel door 
beter in stand houden van NO gemedieerde vasodilatatie, maar ook onrechtstreeks door het 
bestrijden van de impact van ADMA op witte bloedcel activatie en dus inflammatie. 
Daarnaast blijkt SDMA een minstens even belangrijke rol te spelen. Naast ADMA moet dus 
ook met SDMA rekening worden gehouden wanneer men cardiovasculaire schade of risico 
gaat inschatten, en vooral wanneer men selectieve strategieën voor verwijdering- of 
neutralisatie wenst te ontwikkelen. 
In de toekomst zullen er experimenten worden opgezet om de mechanismen op te helderen 
die verantwoordelijk zijn voor de onderbreking van de bloedstroom na blootstelling aan 
indoxylsulfaat. Het kan interessant zijn om het effect van dit uremisch toxine op de 
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stollingscascade te bestuderen, en dan meer specifiek de rol van tissue factor, en om 
verbanden tussen stolling en ontsteking op te helderen.  
 
Het is ook van belang om de effecten van de individuele toxines op witte bloedcel functie te 
bestuderen in een chronisch experiment. Om dit doel te bereiken zullen chronische infusie-
experimenten met individuele toxines in gezonde dieren worden opgezet. Bijkomend zouden 
ook acute en chronische infusie-experimenten met deze toxines moeten worden uitgevoerd in 
uremische dieren, om op die manier de impact van een individuele component bovenop het 
volledig uremisch milieu te bekijken. Deze experimenten zouden een licht kunnen werpen op 
de vraag of selectieve verwijdering van een individueel uremisch toxine kan resulteren in een 
verbeterde ‘outcome’. Ten slotte denken we dat het ook nuttig zou zijn om het effect van 
verschillende stoffen simultaan te bestuderen. 
Hemoperfusietechnologie voor directe adsorptie van retentiestoffen uit het bloed met 
kolommen die gevuld zijn met korrels, is momenteel al beschikbaar voor β2-microglubuline59 
en interleukine-1β60. Systemen voor eiwitgebonden stoffen zijn in ontwikkeling.61
Om de onderliggende elementen waardoor de uremische toxins hun effect uitoefenen, te 
ontrafelen, kunnen specifieke blockers worden gebruikt. In het geval van SDMA 
bijvoorbeeld, hebben in vitro experimenten uitgevoerd door onze onderzoeksgroep 
aangetoond dat N-acetyl-cysteine (NAC) en de ACE-inhibitor captopril respectievelijk de 
SDMA-geïnduceerde NF-κB activatie
 Het zou 
interessant zijn om dergelijke technieken uit te testen voor een eventueel gunstig effect op de 
pathologische mechanismen die we nu hebben geobserveerd. 
62 en de SDMA-verhoogde ROS productie63 kunnen 
inhiberen. Ook het in vivo effect van dergelijke stoffen zou kunnen worden geanalyseerd. 
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Alhoewel het zeer interessant zou zijn om een uremisch rattenmodel te gebruiken, hebben we 
dit niet gedaan in de studies beschreven in deze doctoraatsthesis, omwille van verschillende 
redenen: 
1) We wilden de impact van de verschillende componenten (zout, sulodexide, 
uremische toxines,…) per se op de morfologie en functie van de peritoneale membraan 
onderzoeken. Een uremische status zou hiermee sterk kunnen interfereren aangezien het goed 
beschreven is dat uremie op zichzelf veranderingen kan veroorzaken in de peritoneale 
morfologie.64-66
2) Volgens onze eigen ervaring, maar ook volgens andere gerapporteerde modellen is 
het belangrijkste nadeel bij een rattenmodel de variabele graad van uremie die met 
nefrectomie wordt bekomen. Dit kan een extra bias creëren in de interpretatie van de 
resultaten. De gradatie in uremie wordt dan een grote confounder, die mogelijks andere 
effecten kan doen vervagen. Daarom wilden we eerst de individuele effecten van de 
verschillende componenten aantonen. 
  
3) Het sterftecijfer van een peritoneaal dialyse model bij uremische ratten is zeer hoog. 
Dit creëert een “selectie-bias” ( survival of the fittest), en waarschijnlijk ook overleving van 
die dieren met de laagste graad van uremie. Ook dit kan de interpretatie van de resultaten 
sterk beïnvloeden.   
4) In het geval van de zoutstudie vroegen we ons af waarom sommige uremische 
patiënten wel en andere geen morfologische en functionele veranderingen van de peritoneale 
membraan ontwikkelen, reeds vóór de start van peritoneale dialyse. Deze verschillen zijn 
natuurlijk gedeeltelijk te verklaren door verschillen in comorbiditeit zoals diabetes, genetische 
achtergrond en/of uremie. Zoutinname kan echter ook op zichzelf cardiale fibrose67 en 
glomerulosclerose in de nier induceren.29
5) Voor de experimenten met de intravitaalmicroscoop, verkozen we om de acute 
effecten van één enkel toxine te evalueren, zonder rekening te houden met het volledige 
uremisch milieu. Bij het klinische gebruik van selectieve bloedzuiveringstechnieken is het 
 Omdat we dachten dat zoutinname op zichzelf 
gelijkaardige effecten zou kunnen veroorzaken in de peritoneale membraan, gebruikten we 
gezonde Wistar ratten, om de onafhankelijke impact te evalueren. Niettemin zou het 
interessant zijn om in de toekomst dezelfde experimenten te herhalen in uremische ratten 
en/of ratten behandeld met peritoneale dialyse. 
Algemene conclusies & toekomstperspectieven 
226 
nodig de uremische retentiestoffen te klasseren volgens hun biologisch effect, zodat de keuze 
van de doelmolecules klinisch en economisch verantwoord is.  
 
 
 
 
 
Samenvattend zijn de belangrijkste conclusies van de studies die uitgevoerd zijn in het kader 
van deze thesis:  
1) Overdadig zoutverbruik veroorzaakt veranderingen in de peritoneale membraan, zelfs 
in afwezigheid van glucose-bevattende dialysaatvloeistoffen. Daarom is zoutrestrictie 
in het dieet van patiënten met CKD aangewezen, zelfs nog voor de start van dialyse en 
in patiënten die andere nierfunctie vervanging ondergaan dan PD. 
2) Het glycosaminoglycan sulodexide is in de orale vorm een goede kandidaat om verder 
onderzocht te worden om na te gaan of het bescherming biedt voor de peritoneale 
membraan tijdens peritoneale dialyse 
3) In vivo onderzoek toont aan dat indoxylsulfaat, p-cresylsulfaat en p-cresylglucuronide 
een pro-inflammatoir effect hebben door activering van witte bloedcellen, terwijl 
indoxylsulfaat en de combinatie van p-cresylsulfaat en p-cresylglucuronide een 
dramatische daling in bloedstroom veroorzaken. 
4) In vivo data tonen aan dat zowel ADMA als SDMA belangrijke activatoren zijn van 
witte bloedcellen, waarbij ze ook sterke vaatschade veroorzaken.  
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If we knew what it was we were doing, it would not be called research, would it 
-Albert Einstein- 
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dingen. Mijn doctoraat is nu eindelijk af, hopelijk kunnen we samen wat meer rustmomenten 
in-‘bouwen’! Binnenkort beginnen we alvast aan een volgend hoofdstuk, ik kijk er naar uit! 
Bedankt voor je steun en je liefde… 
 
Anneleen 
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